第111回日本泌尿器科学会総会 JUA Abstracts

松井秀彰{まついひであきMATSUIHIDEAKI}____武田正之{たけだまさゆきTAKEDAMASAYUKI}________特別講演 1【日本語セッション】脳神経科学最先端・アルツハイマー、パーキンソン病研究の新展開____－

SL1

特別講演 1【日本語セッション】
脳神経科学最先端・アルツハイマー、パーキンソン病研究の新展開

廣田有紀{ひろたゆきHIROTAYUKI}|山倉和彦{やまくらかずひこYAMAKURAKAZUHIKO}|江田佳子{えだよしこEDAYOSHIKO}____吉野能{よしのやすしYOSHINOYASUSHI}________特別講演 2【日本語セッション】トレーニング、コンディショニングそしてコーチング・アスリートからのメッセージ____－

SL2

特別講演 2【日本語セッション】
トレーニング、コンディショニングそしてコーチング・アスリートからのメッセージ

伊藤聡子{いとうさとこITOSATOKO}|野々村芳和{ののむらよしかずNONOMURAYOSHIKAZU}____－________特別講演 3【日本語セッション】グローカルな視点から地方創生を考える____－

SL3

特別講演 3【日本語セッション】
グローカルな視点から地方創生を考える

HiroshiOnishi{ONISHIHIROSHI}|YukinoriMatsuo{MATSUOYUKINORI}|TakashiShuto{SHUTOTAKASHI}|NaokiNakamura{NAKAMURANAOKI}____IsaoHara{HARAISAO}|HidefumiKinoshita{KINOSHITAHIDEFUMI}________Panel Discussion 1【他診療科・多職種連携セッション】Role of radiotherapy in RCC treatment____Stereotactic body radiation therapy for renal cancer腎癌に対する定位放射線治療|Stereotactic Body Radiotherapy for Oligometastatic Renal Cell Carcinoma腎細胞癌オリゴ転移に対する体幹部定位放射線治療(SBRT)|Stereotactic radiotherapy for metastatic brain tumors from renal cell carcinoma腎がん脳転移に対する定位放射線治療|Palliative high-precision radiotherapy for metastatic renal cell carcinoma腎癌の転移巣に対する緩和照射における高精度照射の役割

PD1

Panel Discussion 1【他診療科・多職種連携セッション】
Role of radiotherapy in RCC treatment

HiromichiIwamura{IWAMURAHIROMICHI}|KotaroYoshida{YOSHIDAKOTARO}|TadashiWatabe{WATABETADASHI}|KentaMiki{MIKIKENTA}|SoichiroYoshida{YOSHIDASOICHIRO}____TakahiroKimura{KIMURATAKAHIRO}|ToshitakaShin{SHINTOSHITAKA}____YukiKohada{KOHADAYUKI}|JunIto{ITOJUN}|GoAnan{ANANGO}|MakotoSato{SATOMAKOTO}|YasuhiroKaiho{KAIHOYASUHIRO}|HidetoshiKuruma{KURUMAHIDETOSHI}____Symposium 1【他診療科・多職種連携セッション】Current status and future perspectives of novel imaging modalities in prostate cancer____The Significance of Whole-body MRI in Prostate Cancer Treatment前立腺がん治療におけるWhole-body MRIの意義|Whole-body MRI; how to introduce and use in high-volume centers and university hospitals前立腺がん治療におけるWhole-body MRIの現状と今後の課題|Utility of PSMA-PET to revolutionize the treatment of prostate cancer前立腺がん治療におけるPSMA-PETの革新的有用性|Initial experience of PSMA radioligand therapy for Japanese CRPC patients.日本人の去勢抵抗性前立腺癌患者に対するPSMA標的内用療法の治療経験|The Impact of Next Generation Imaging Modalities on Prostate Cancer Treatment新規画像モダリティが前立腺がん治療に与える影響

SY1

Symposium 1【他診療科・多職種連携セッション】
Current status and future perspectives of novel imaging modalities in prostate cancer

TakanobuUtsumi{UTSUMITAKANOBU}|NaokiTerada{TERADANAOKI}|RihitoAizawa{AIZAWARIHITO}|SoichiroYoshida{YOSHIDASOICHIRO}____ToshiyukiKamoto{KAMOTOTOSHIYUKI}|HiroyoshiSuzuki{SUZUKIHIROYOSHI}____MioInui{INUIMIO}|TaroOkazaki{OKAZAKITARO}|NaokiIshitsuka{ISHITSUKANAOKI}|YutaSuzuki{SUZUKIYUTA}|TakahideNoro{NOROTAKAHIDE}|IijimaShota{SHOTAIIJIMA}|YukaSugizaki{SUGIZAKIYUKA}|TakatoshiSomoto{SOMOTOTAKATOSHI}|RyoOka{OKARYO}|TakumiEndo{ENDOTAKUMI}|NaotoKamiya{KAMIYANAOTO}|HiroyoshiSuzuki{SUZUKIHIROYOSHI}|TakashiKobayashi{KOBAYASHITAKASHI}|YujiNakamoto{NAKAMOTOYUJI}|TakashiMizowaki{MIZOWAKITAKASHI}____Panel Discussion 2【他診療科・多職種連携セッション】Local and metastasis-directed therapy for patients with metastatic prostate cancer____Local and metastasis-directed therapy for patients with metastatic prostate cancer: Global trends from the report of the APCCC原発巣・転移巣への局所治療:APCCCからみたグローバルトレンド|Local therapy and metastasis directed therapy for patients with metastatic prostate cancer; present outcomes and future perspectives in Japan原発巣・転移巣への局所治療:日本でのエビデンスと今後|Local and metastasis-directed radiation therapy for metastatic prostate cancer転移性前立腺癌への局所および転移巣への放射線治療|Local therapy for primary and metastatic lesions in metastatic prostate cancer: treatment strategies and case discussions from a urologist's perspective転移性前立腺がんにおける原発巣・転移巣への局所療法: 泌尿器科医の立場からの実際の治療戦略と症例ディスカッション

PD2

Panel Discussion 2【他診療科・多職種連携セッション】
Local and metastasis-directed therapy for patients with metastatic prostate cancer

TakeoKosaka{KOSAKATAKEO}|TakahiroInoue{INOUETAKAHIRO}|MasakiShiota{SHIOTAMASAKI}|TakumaKatou{KATOUTAKUMA}____MikioSugimoto{SUGIMOTOMIKIO}|HiroshiKitamura{KITAMURAHIROSHI}________Symposium 2Has upfront doublet/triplet therapy changed the treatment strategy for metastatic prostate cancer?____How to use chemotherapy after doublet/triplet treatmentdoublet triplet/Triplet治療後の化学療法の使い方|To whom and when do we apply the cancer genome precision medicine for mCRPC after upfront hormonal therapy (doublet/triplet therapy)?Upfront時代におけるmCRPCに対してゲノム医療はいつ、誰に行うべきか?|New Treatment Development and Future Prospects after Doublet/Triplet TreatmentDoublet/Triplet治療後の新規治療開発と将来展望|Initial treatment strategy for mCSPC in anticipation of future mCRPC treatment将来のmCRPC治療を見越したmCSPCに対する初期治療戦略

SY2

Symposium 2
Has upfront doublet/triplet therapy changed the treatment strategy for metastatic prostate cancer?

TaketoKawai{KAWAITAKETO}|HideoFukuhara{FUKUHARAHIDEO}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|MakitoMiyake{MIYAKEMAKITO}|AtsushiIkeda{IKEDAATSUSHI}____KiyohideFujimoto{FUJIMOTOKIYOHIDE}|TetsuyaFujimura{FUJIMURATETSUYA}____TohruNakagawa{NAKAGAWATOHRU}|KeijiInoue{INOUEKEIJI}|NobutakaNishimura{NISHIMURANOBUTAKA}|TatsukiMiyamoto{MIYAMOTOTATSUKI}|KiyohideFujimoto{FUJIMOTOKIYOHIDE}|HirokazuNosato{NOSATOHIROKAZU}|HiroyukiNishiyama{NISHIYAMAHIROYUKI}____Symposium 3Optimal treatment for intermediate-risk NMIBC____The overarching issues of intermediate-risk NMIBC中リスクNMIBCの総論的課題|TUBRT for intermediate risk NMIBC中リスクNMIBCのTURBT|Intravesical Chemotherapy for Intermediate-Risk NMIBC中リスクNMIBCに対する抗がん薬膀注療法|Is intravesical instillation of BCG overtreatment for intermediate-risk non-muscle invasive bladder cancer?: Optimal strategy for the tricky population.中リスク NMIBC って BCG 膀胱注入療法まで必要? ～曲者集団に対する治療戦略～|Follow-up for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer中リスクNMIBCの経過観察

SY3

Symposium 3
Optimal treatment for intermediate-risk NMIBC

RyuuichiMizuno{MIZUNORYUUICHI}|SatoshiMorita{MORITASATOSHI}|ToyohikoWatanabe{WATANABETOYOHIKO}____HirotsuguUemura{UEMURAHIROTSUGU}|MototsuguOya{OYAMOTOTSUGU}____HiroyukiYamamoto{YAMAMOTOHIROYUKI}|MasayukiTakahashi{TAKAHASHIMASAYUKI}|TakashiKobayashi{KOBAYASHITAKASHI}|ShingoHatakeyama{HATAKEYAMASHINGO}|ShinichiSakamoto{SAKAMOTOSHINICHI}|HayakawaNozomi{NOZOMIHAYAKAWA}|EijiKikuchi{KIKUCHIEIJI}|TakahiroYasui{YASUITAKAHIRO}|ToshiyukiKamoto{KAMOTOTOSHIYUKI}____Symposium 4【専門医制度対応講習単位認定プログラム（泌尿器科領域講習）】【他診療科・多職種連携セッション】Clinical research in GU oncology: significance and creation of Realworld data (including how to use NCD).____Cancer Clinical Research: Significance and Generation of Real-World Data, Including Utilization of National Clinical Database (NCD)がん臨床研究: Real world dataの意義と創出 (NCD活用法)|Statistical aspects of real world data analysisリアルワールドデータの統計解析|Clinical research and leadership talent required in healthcare organizations from a management perspective経営学的視点からみた今後求められる医療組織における臨床研究とリーダーシップ人材

SY4

Symposium 4【専門医制度対応講習単位認定プログラム（泌尿器科領域講習）】【他診療科・多職種連携セッション】
Clinical research in GU oncology: significance and creation of Realworld data (including how to use NCD).

*専門医制度対応講習単位認定プログラム（泌尿器科領域講習）

片山聡{かたやまさとしKATAYAMASATOSHI}|中島裕理{なかじまひろみちNAKAJIMAHIROMICHI}|泉浩二{いずみこうじIZUMIKOUJI}|成田伸太郎{なりたしんたろうNARITASHINTAROU}|武内務{たけうちつとむTAKEUCHITSUTOMU}____深貝隆志{ふかがいたかしFUKAGAITAKASHI}|溝上敦{みぞかみあつしMIZOKAMIATSUSHI}____小林泰之{こばやしやすゆきKOBAYASHIYASUYUKI}|荒木元朗{あらきもとおARAKIMOTOO}____Panel Discussion 3【日本語セッション】【患者連携セッション】mCSPC治療〜escalationは正義か？〜____今こそmCSPCにおけるVintage治療の価値を明らかにする ～個別化治療に向けて～Time to shed light on the value of androgen deprivation therapy in mCSPC Toward personalized medicine|必要十分を目指すmCSPC治療Less is More: mCSPC treatment|リアルワールドから見えてくるmCSPC治療におけるvingateと2G-ARSIの実相The real-world data-based mCSPC treatment; vintage vs 2G ARSI|Upfront ARSIの適応と限界～積極的にupfront ARSIを行ってきた立場から～Indications and Limitations of Upfront ARSI in mCSPC: A Statement Based on Real-World Outcomes in the Japanese Population|mCSPC患者個々の病態と患者の生活信条に見合った薬物療法をProvide medications appropriate to the disease state and lifestyle beliefs of each mCSPC patient

PD3

Panel Discussion 3【日本語セッション】【患者連携セッション】
mCSPC治療〜escalationは正義か？〜

太田雅也{おおたまさやOOTAMASAYA}|山本由利子{やまもとゆりこYAMAMOTOYURIKO}|森武男{もりたけおMORITAKEO}|VaughanDarrell{DARRELLVAUGHAN}____朝倉博孝{あさくらひろたかASAKURAHIROTAKA}|関戸哲利{せきどのりとしSEKIDONORITOSHI}________総会校企画 1【指導医教育コース認定プログラム】【日本語セッション】【多職種セッション】介護と医療　排尿管理____尿路ストーマや尿路カテーテルの管理に関する課題と泌尿器科訪問診療医の果たす役割Management and issues of urinary stomas and urinary catheters, and role of urologists providing home care medicine.|尿路ストーマ・尿道カテーテルを有する患者のケア上の問題点と在宅の皮膚・排泄ケア認定看護師の果たす役割|生活期リハビリテーションの排尿管理Urinary incontinence with rehabilitation|交通事故による尿道損傷のための恥骨上留置カテーテルの経験

SP1

総会校企画 1【指導医教育コース認定プログラム】【日本語セッション】【多職種セッション】
介護と医療　排尿管理

*指導医教育コース認定プログラム

SunaoShoji{SHOJISUNAO}|YuOkabe{OKABEYU}|NaotakaGunge{GUNGENAOTAKA}|JunMutaguchi{MUTAGUCHIJUN}|YuutaYamada{YAMADAYUUTA}|YuichiroKonnai{KONNAIYUICHIRO}|SatoshiWashino{WASHINOSATOSHI}|AtsukoFujihara{FUJIHARAATSUKO}____MasatsuguIwamura{IWAMURAMASATSUGU}____JunNaruse{NARUSEJUN}|MoekoTazawa{TAZAWAMOEKO}|KazuyaOda{ODAKAZUYA}|TakatoUchida{UCHIDATAKATO}|SochiroYuzuriha{YUZURIHASOCHIRO}|KanoTatsuo{TATSUOKANO}|SatoshiKuroda{KURODASATOSHI}|TatsuyaUmemoto{UMEMOTOTATSUYA}|NobuyukiNakajima{NAKAJIMANOBUYUKI}|MasahiroNitta{NITTAMASAHIRO}|MasanoriHasegawa{HASEGAWAMASANORI}|AkiraMiyajima{MIYAJIMAAKIRA}|FumihiroYamazaki{YAMAZAKIFUMIHIRO}|ChizuruNakagawa{NAKAGAWACHIZURU}|MasahiroTachibana{TACHIBANAMASAHIRO}|YuichiroFukuhara{FUKUHARAYUICHIRO}|KosukeTominaga{TOMINAGAKOSUKE}|GungeNaotaka{NAOTAKAGUNGE}|TakeshiMiyazaki{MIYAZAKITAKESHI}|KazunaTsubouchi{TSUBOUCHIKAZUNA}|HiroshiMatsuzaki{MATSUZAKIHIROSHI}|NobuyukiNakamura{NAKAMURANOBUYUKI}|NobuhiroHaga{HAGANOBUHIRO}|FumihiroYamasaki{YAMASAKIFUMIHIRO}|YuuichirouFukuhara{FUKUHARAYUUICHIROU}|KousukeTominaga{TOMINAGAKOUSUKE}|MiyazakiTakeshi{TAKESHIMIYAZAKI}|YuOkabe{OKABEYU}|ChikaoAoyagi{AOYAGICHIKAO}|MasahiroOda{ODAMASAHIRO}|ShunsukeGoto{GOTOSHUNSUKE}|SatoshiKobayashi{KOBAYASHISATOSHI}|TakashiMatsumoto{MATSUMOTOTAKASHI}|MasakiShiota{SHIOTAMASAKI}|InokuchiJunichi{JUNICHIINOKUCHI}|KensakuMori{MORIKENSAKU}|MasatoshiEto{ETOMASATOSHI}|SatoruTaguchi{TAGUCHISATORU}|YoichiFujii{FUJIIYOICHI}|JunKamei{KAMEIJUN}|YoshiyukiAkiyama{AKIYAMAYOSHIYUKI}|DaisukeYamada{YAMADADAISUKE}|KumeHaruki{HARUKIKUME}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|MasashiTakeuchi{TAKEUCHIMASASHI}|MioTanigawa{TANIGAWAMIO}|ReiTakeuchi{TAKEUCHIREI}|YotaYasumizu{YASUMIZUYOTA}|TanakaNobuyuki{NOBUYUKITANAKA}|ToshikazuTakeda{TAKEDATOSHIKAZU}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|TakeoKosaka{KOSAKATAKEO}|HirofumiKawakubo{KAWAKUBOHIROFUMI}|YukoKitagawa{KITAGAWAYUKO}|MototsuguOya{OYAMOTOTSUGU}|KimitoshiSaito{SAITOKIMITOSHI}|KaiYazaki{YAZAKIKAI}|KouheiMito{MITOKOUHEI}|KousukeKazashi{KAZASHIKOUSUKE}|TomoakiMiyagawa{MIYAGAWATOMOAKI}|TakumiShiraishi{SHIRAISHITAKUMI}|TakashiUeda{UEDATAKASHI}|YutaInoue{INOUEYUTA}|HidetoTaga{TAGAHIDETO}|NaruhiroKayukawa{KAYUKAWANARUHIRO}|MiyashitaMasatsugu{MASATSUGUMIYASHITA}|TakeshiYamada{YAMADATAKESHI}|MasayoshiOkumi{OKUMIMASAYOSHI}|FumiyaHongo{HONGOFUMIYA}|OsamuUkimura{UKIMURAOSAMU}____総会賞ビデオ 01前立腺・膀胱____Focal therapy with high-intensity focused ultrasound for the patients with localized prostate cancer: a multi-institutional prospective study in Japan限局性前立腺癌に対する高密度焦点式超音波療法を用いたFocal Therapy: 多施設共同前向き研究|Risk factors of major adverse events in transurethral resection of bladder tumor following oral administration of 5-aminolevulinic acid5-アミノレブリン酸の経口内服下での経尿道的膀胱腫瘍切除術における主要有害事象のリスク因子|Development of Nerve-Sparing Surgical Technique Using ICG Fluorescence Navigation System in Robot-Assisted Radical Prostatectomyロボット支援前立腺全摘除術におけるICG蛍光ナビゲーションシステムを用いた神経温存手術法の開発|Accuracy Comparison of Object Detection System in NBI Cystoscopic ImagesNBI膀胱鏡画像における物体検出システムの精度比較|Targeted pelvic lymph node dissection using tumor-targeted Indocyanine green injection assisted by Magnetic Resonance Imaging - Ultrasonography fusion techniqueMRI-US 融合技術とインドシアニングリーン蛍光法を応用したターゲット骨盤リンパ節郭清|Automated surgical process recognition using artificial Intelligence and external validity verification in robot-assisted radical prostatectomyAIを用いたロボット支援前立腺全摘除術における工程認識及び外的妥当性の検証|Novel anterior approach is associated with favorable continence recovery and less postoperative inguinal hernia compared to conventional approach in RARPRARPにおける新しい膀胱前腔展開方法ー良好な尿禁制と鼠径ヘルニアの低減ー|Clinical workflow of lesion targeted focal therapy for localized prostate cancer限局性前立腺癌に対するLesion targeted focal therapy実施における臨床ワークフロー

AVP-01

総会賞ビデオ 01
前立腺・膀胱

HideakiMiyake{MIYAKEHIDEAKI}|KenichiTabata{TABATAKENICHI}|MasashiTakenaka{TAKENAKAMASASHI}|JunMiki{MIKIJUN}____MasatsuguIwamura{IWAMURAMASATSUGU}|RyoichiShiroki{SHIROKIRYOICHI}____MasatoFujisawa{FUJISAWAMASATO}|MakiyaOyake{OYAKEMAKIYA}|NatsuhoFujita{FUJITANATSUHO}|ShougoMaeda{MAEDASHOUGO}|TomonariMotonaga{MOTONAGATOMONARI}|WataruNakamura{NAKAMURAWATARU}|SarutaMasanobu{MASANOBUSARUTA}|TakuhisaNukaya{NUKAYATAKUHISA}|KenjiZennami{ZENNAMIKENJI}|ManabuIchino{ICHINOMANABU}|KiyoshiTakahara{TAKAHARAKIYOSHI}|HitomiSasaki{SASAKIHITOMI}|RyoichiShiroki{SHIROKIRYOICHI}|KosukeIwatani{IWATANIKOSUKE}|ShunSaito{SAITOSHUN}|ShotaKawano{KAWANOSHOTA}|TakayukiSano{SANOTAKAYUKI}|KeiFujio{FUJIOKEI}|NishiharaTeruyuki{TERUYUKINISHIHARA}|KotaroTadano{TADANOKOTARO}|KenjiKawashima{KAWASHIMAKENJI}|TakahiroKimura{KIMURATAKAHIRO}____Symposium 5Surgical Robots in New generation ; Pros & Cons____Early experience with the use of domestic surgical robot system, hinotori国産手術支援ロボットhinotoriの初期使用経験|Clinical outcomes and features of the Hugo RAS systemHugo RAS システムの特徴と臨床成績|Da vinci SP robotic platform in urology泌尿器科領域におけるda Vinci SPについて|Initial clinical experience of urological surgery utilizing the tactile sensation-enabled surgical robot "Saroa"触覚を有した手術ロボット「サロア」を用いた泌尿器手術の初期経験

SY5

Symposium 5
Surgical Robots in New generation ; Pros & Cons

KouichirouWada{WADAKOUICHIROU}|AtsushiFujikawa{FUJIKAWAATSUSHI}|NobuyukiHinata{HINATANOBUYUKI}|TsunenoriKondou{KONDOUTSUNENORI}____TsunenoriKondo{KONDOTSUNENORI}|KazuhideMakiyama{MAKIYAMAKAZUHIDE}____KoheiOgawa{OGAWAKOHEI}|KazutakaMitani{MITANIKAZUTAKA}|GenTanaka{TANAKAGEN}|SaoriYoshioka{YOSHIOKASAORI}|TakafumiHara{HARATAKAFUMI}|TsuboiIchiro{ICHIROTSUBOI}|YusukeKobayashi{KOBAYASHIYUSUKE}|HirochikaNakajima{NAKAJIMAHIROCHIKA}|TaichiNagami{NAGAMITAICHI}|ChiakiKoike{KOIKECHIAKI}|SatoshiHonda{HONDASATOSHI}|HiroakiShiina{SHIINAHIROAKI}____Symposium 6The latest minimally invasive surgery for renal pelvic and ureteral cancer: Robot-assisted laparoscopic nephroureterectomy and renal preservation therapy using URS____Management for upper tract urothelial carcinoma (UTUC) by ureterorenoscopy (URS): indication, procedures and outcomeURSによるUTUCのマネジメント ～適応・手技・成績について～|Trans-ureteral Surgery for Upper Urinary Tract Tumors: Practical Applications in General Hospitals and Potential for Advancement低リスク上部尿路腫瘍に対する経尿管手術:一般病院での実践とその発展の可能性|Establishment of a reproducible robot-assisted radical nephroureterectomy再現性の高いロボット支援根治的腎尿管全摘除術の確立|Robotic radical nephroureterectomy with lymphadenectomy - Being a standard procedure for advanced upper tract urothelial carcinoma? -ロボット腎尿管全摘に伴うリンパ節郭清ー上部尿路上皮癌患者に対する標準治療となるか?ー

SY6

Symposium 6
The latest minimally invasive surgery for renal pelvic and ureteral cancer: Robot-assisted laparoscopic nephroureterectomy and renal preservation therapy using URS

MitsuhiroTambo{TAMBOMITSUHIRO}|ShimpeiYamashita{YAMASHITASHIMPEI}|DaisukeKudou{KUDOUDAISUKE}|ShuzoHamamoto{HAMAMOTOSHUZO}____TakahiroYasui{YASUITAKAHIRO}|IsaoHara{HARAISAO}____YasuoKohjimoto{KOHJIMOTOYASUO}|IsaoHara{HARAISAO}|KazumiTaguchi{TAGUCHIKAZUMI}|KengoKawase{KAWASEKENGO}|ReiUnno{UNNOREI}|AtsushiOkada{OKADAATSUSHI}|TakahiroYasui{YASUITAKAHIRO}____Symposium 7Cutting Edge of Stone Surgery____Selection of surgical treatment for urinary stones according to the revised guidelines改訂ガイドラインにみる尿路結石手術治療の選択|Tips and tricks of ureteroscopy for preventing postoperative infection due to elevation of intrapelvic pressure腎盂内圧上昇による術後感染症を予防するためのURSのポイント|The advent of TFL in Japan: Beyond the Ho:YAGツリウムファイバーレーザ(TFL)の本邦への導入～Ho:YAGの先へ|The management of ureteral stricture following ureteresocpic lithotripsy: robot-assisted uretero-ureterostomy術後尿管狭窄に対するロボット支援尿管形成術

SY7

Symposium 7
Cutting Edge of Stone Surgery

KeitaNakane{NAKANEKEITA}|NobuhiroHaga{HAGANOBUHIRO}|KimitoshiSaito{SAITOKIMITOSHI}|KosukeKitamura{KITAMURAKOSUKE}____SatoruMuto{MUTOSATORU}|TakuyaKoie{KOIETAKUYA}____HiroyukiIto{ITOHIROYUKI}|KazumasaMurase{MURASEKAZUMASA}|FumiyaSugino{SUGINOFUMIYA}|SanaeNamiki{NAMIKISANAE}|NaotakaKumada{KUMADANAOTAKA}|KawaseMakoto{MAKOTOKAWASE}|DaikiKato{KATODAIKI}|ManabuTakai{TAKAIMANABU}|KojiIinuma{IINUMAKOJI}|YukiTobisawa{TOBISAWAYUKI}|TakuyaKoie{KOIETAKUYA}|YuOkabe{OKABEYU}|TakeshiMiyazaki{MIYAZAKITAKESHI}|FumihiroYamazaki{YAMAZAKIFUMIHIRO}|ChizuruNakagawa{NAKAGAWACHIZURU}|MasahiroTachibana{TACHIBANAMASAHIRO}|TsubouchiKazuna{KAZUNATSUBOUCHI}|YuichiroFukuhara{FUKUHARAYUICHIRO}|KosukeTominaga{TOMINAGAKOSUKE}|NaotakaGunge{GUNGENAOTAKA}|HiroshiMatsuzaki{MATSUZAKIHIROSHI}|NobuyukiNakamura{NAKAMURANOBUYUKI}|SatoshiWashino{WASHINOSATOSHI}|NaokiHuzisawa{HUZISAWANAOKI}|SumireTakeuchi{TAKEUCHISUMIRE}|KousukeKazashi{KAZASHIKOUSUKE}|KouheiMito{MITOKOUHEI}|YazakiKai{KAIYAZAKI}|TomoakiMiyagawa{MIYAGAWATOMOAKI}|YutoMiyoshi{MIYOSHIYUTO}|FumitakaShimizu{SHIMIZUFUMITAKA}|SatoruMuto{MUTOSATORU}|ShigeoHorie{HORIESHIGEO}____Panel Discussion 4Challenges in standardization and education of robot-assisted intracorporeal diversion in low-volume hospitals____Changes in Surgical Techniques for ICUD EfficiencyICUD効率化のための手術手技の変遷|Innovations in urinary diversion for robot-assisted radical cystectomy - standardization of technique, education and troubleshooting in a low volume facilityロボット支援膀胱全摘除の尿路変向の工夫 ーLow Volume施設における術式標準化、教育、トラブルシューテイングー|Our tips and encountered adverse events in intracorporeal urinary diversion当院で行っているICUDの工夫と経験した有害事象|What is needed to make robot-assisted radical cystectomy with intracorporeal urinary diversion (ICUD) a safe procedureICUDを新規導入するために必要な事

PD4

Panel Discussion 4
Challenges in standardization and education of robot-assisted intracorporeal diversion in low-volume hospitals

YutaroTanaka{TANAKAYUTARO}|TeruakiSugino{SUGINOTERUAKI}|KyoheiKurose{KUROSEKYOHEI}|KazumiTaguchi{TAGUCHIKAZUMI}|AtsunariKawashima{KAWASHIMAATSUNARI}|ToshikazuTakeda{TAKEDATOSHIKAZU}|KazukiTakekawa{TAKEKAWAKAZUKI}|ToshitakaUematsu{UEMATSUTOSHITAKA}|TakeshiYamasaki{YAMASAKITAKESHI}|YasuoKohjimoto{KOHJIMOTOYASUO}____RyoichiShiroki{SHIROKIRYOICHI}____YudaiYoshimura{YOSHIMURAYUDAI}|ShuzoHamamoto{HAMAMOTOSHUZO}|RieTajiri{TAJIRIRIE}|KazufumiTakano{TAKANOKAZUFUMI}|MasashiYoshimura{YOSHIMURAMASASHI}|OkadaAtsushi{ATSUSHIOKADA}|KenjiroKohri{KOHRIKENJIRO}|TakahiroYasui{YASUITAKAHIRO}|YusukeMori{MORIYUSUKE}|HiroshiYoshikawa{YOSHIKAWAHIROSHI}|MihokoMaruyama{MARUYAMAMIHOKO}|KazumiTaguchi{TAGUCHIKAZUMI}|KoeiTorii{TORIIKOEI}|TatsuyaHattori{HATTORITATSUYA}|RyusukeDeguchi{DEGUCHIRYUSUKE}|ReiUnno{UNNOREI}|YamashitaShimpei{SHIMPEIYAMASHITA}|RyosukeAndo{ANDORYOSUKE}|AtsushiOkada{OKADAATSUSHI}|IsaoHara{HARAISAO}|HiroshiSadamori{SADAMORIHIROSHI}|KeisukeAsahara{ASAHARAKEISUKE}|YusukeOkamoto{OKAMOTOYUSUKE}|ShujiMiyake{MIYAKESHUJI}|AtsushiTakamoto{TAKAMOTOATSUSHI}|IwasakiToshimitsu{TOSHIMITSUIWASAKI}|TadashiMurata{MURATATADASHI}|TomohiroHayashida{HAYASHIDATOMOHIRO}|TakanoriSuezawa{SUEZAWATAKANORI}|KengoKawase{KAWASEKENGO}|RyosukeChaya{CHAYARYOSUKE}|TeruakiSugino{SUGINOTERUAKI}|KentaroMizuno{MIZUNOKENTARO}|TetsujiMaruyama{MARUYAMATETSUJI}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|NorichikaUeda{UEDANORICHIKA}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KentaroTakezawa{TAKEZAWAKENTARO}|YamanakaKazuaki{KAZUAKIYAMANAKA}|TaigoKato{KATOTAIGO}|KojiHatano{HATANOKOJI}|YoichiKakuta{KAKUTAYOICHI}|ShinichiroFukuhara{FUKUHARASHINICHIRO}|NorioNonomura{NONOMURANORIO}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|YotaYasumizu{YASUMIZUYOTA}|NobuyukiTanaka{TANAKANOBUYUKI}|ShinyaMorita{MORITASHINYA}|KosakaTakeo{TAKEOKOSAKA}|RyuichiMizuno{MIZUNORYUICHI}|HiroshiAsanuma{ASANUMAHIROSHI}|MototsuguOya{OYAMOTOTSUGU}|AkioHoriguchi{HORIGUCHIAKIO}|MasayukiShinchi{SHINCHIMASAYUKI}|KenichiroOjima{OJIMAKENICHIRO}|YusukeHirano{HIRANOYUSUKE}|EijiTakahashi{TAKAHASHIEIJI}|AsakumaJunichi{JUNICHIASAKUMA}|FumihiroKimura{KIMURAFUMIHIRO}|YoshiyukiFurukawa{FURUKAWAYOSHIYUKI}|KeiichiIto{ITOKEIICHI}|KeikoIguchi{IGUCHIKEIKO}|NaoYukimatsu{YUKIMATSUNAO}|TaiyouOtoshi{OTOSHITAIYOU}|MinoruKato{KATOMINORU}|JunjiUchida{UCHIDAJUNJI}____総会賞ビデオ 02副腎・腎・尿管・その他____"No thermal injury in endoscopic surgery" a new surgical technology with femtosecond lasersフェムト秒レーザーによる新規テクノロジー「熱損傷のない内視鏡的治療」の開発|Robot-assisted renal puncture vs. ultrasound-guided renal puncture: a multi-center prospective benchtop studyロボット支援下腎穿刺vs超音波ガイド下腎穿刺:多施設共同前向きベンチトップ研究|Innovative Patch Formation Using the Hepatic Round Ligament Technique for Managing Inferior Vena Cava Invasion in Right Renal Cell Carcinoma: A Case Study血行再建の新たな選択肢:右腎細胞癌の下大静脈浸潤に対して肝円索を用いたパッチ形成が有用であった一例|Efficacy of a ureteral illuminating catheter in robot-assisted ureteral reconstructionロボット支援尿管形成術における蛍光尿管カテーテルの有用性の調査|Establishment of surgical procedure and evaluation of lymph node dissection in retroperitoneal robot-assisted radical nephroureterectomy上部尿路上皮癌に対する後腹膜鏡下ロボット支援腎尿管全摘除術の術式確立とリンパ節郭清の評価|Preoperative planning for laparoscopic partial adrenalectomy using 3D models腹腔鏡下副腎部分切除術の術前プランにおける3Dモデルの有用性|One-stage transperineal dorsolateral onlay urethroplasy for pan-anterior urethral stricture前部尿道全長狭窄に対する経会陰的一期的 dorsolateral onlay法|Successful surgery for renal cell carcinoma with tumor thrombus invading the inferior vena cava in a patient with situs inversus totalis: a case report完全内臓逆位の下大静脈腫瘍栓を伴う腎細胞がん:症例報告|Initial experience of robot-assisted IVC tumor thrombectomy (RA-IVCT) for level 1-4 IVC tumor thrombusLevel1-4下大静脈腫瘍塞栓に対するロボット支援腎摘除術の初期経験|Intraoperative conversion from robot-assisted partial nephrectomy to open surgery or radical nephrectomyロボット支援腎部分切除術から開腹手術あるいは腎摘除術へのconversionについての検討

AVP-02

総会賞ビデオ 02
副腎・腎・尿管・その他

横山みなと{よこやまみなとYOKOYAMAMINATO}|寺島雅典{てらしままさのりTERASHIMAMASANORI}|小路直{しょうじすなおSHOJISUNAO}|宋成浩{そうしげひろSOUSHIGEHIRO}____市川智彦{いちかわともひこICHIKAWATOMOHIKO}|山口健哉{やまぐちけんやYAMAGUCHIKENYA}____深川剛生{ふかがわたけおFUKAGAWATAKEO}|藤井靖久{ふじいやすひさFUJIIYASUHISA}|齋藤忠則{さいとうただのりSAITOTADANORI}|山口健哉{やまぐちけんやYAMAGUCHIKENYA}|横山みなと{よこやまみなとYOKOYAMAMINATO}|高橋悟{たかはしさとるTAKAHASHISATORU}|深貝隆志{ふかがいたかしTAKASHIFUKAGAI}____Panel Discussion 5【日本語セッション】【他診療科・多職種連携セッション】医療技術提案の実際____ロボット支援膀胱全摘除・副腎摘除の施設基準緩和の提案Proposal for alleviation of facility standards of robot-assisted radical cystectomy and adrenalectomy|ロボット支援胃癌手術増点Approval of additional cost for robotic gastrectomy|医療技術提案の実際:MRI撮影および超音波検査融合画像に基づく前立腺針生検法Roadmap for coverage of magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate target biopsy by the National Health Insurance in Japan|小児泌尿器科領域における取り組みOur experience in the field of pediatric urology

PD5

Panel Discussion 5【日本語セッション】【他診療科・多職種連携セッション】
医療技術提案の実際

橋本翔{はしもとしょうHASHIMOTOSHO}|岡田充生{おかだみつをOKADAMITSUO}|中村祐基{なかむらゆうきNAKAMURAYUKI}|北村浩二{きたむらこうじKITAMURAKOJI}____近藤幸尋{こんどうゆきひろKONDOYUKIHIRO}|津島知靖{つしまともやすTSUSHIMATOMOYASU}|上原慎也{うえはらしんやUEHARASHINYA}____大橋和記{おおはしかずきOHASHIKAZUKI}|大澤美優{おおさわみゆうOSAWAMIYUU}|荒川滋行{あらかわしげゆきARAKAWASHIGEYUKI}|中原健{なかはらけんNAKAHARAKEN}|大日方大亮{おびなただいすけOBINATADAISUKE}|吉澤剛{よしざわつよしTSUYOSHIYOSHIZAWA}|持田淳一{もちだじゅんいちMOCHIDAJUNNICHI}|山口健哉{やまぐちけんやYAMAGUCHIKENNYA}|髙橋悟{たかはしさとるTAKAHASHISATORU}|早稲田悠馬{わせだゆうまWASEDAYUMA}|藤井靖久{ふじいやすひさFUJIIYASUHISA}____Panel Discussion 6【日本語セッション】保険診療～若手の疑問、エキスパートの答え～____本邦における外来保険診療に関連する疑問点Questions regarding of medical insurance system in japan|保険診療 若手の疑問 ～DPC 入院中の高額な薬剤の使用について～Insured medical treatment, young urologist's question -DPC Use of expensive drugs during hospitalization-|処方日数の制限、症状詳記についての保険診療の疑問Questions about health insurance treatment: prescription day limits and insurance audit|総括Summary Remarks

PD6

Panel Discussion 6【日本語セッション】
保険診療～若手の疑問、エキスパートの答え～

SandhuJaspreet{JASPREETSANDHU}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|StephenA.boorjian{A.BOORJIANSTEPHEN}|TakashiKobayashi{KOBAYASHITAKASHI}|StephenA.Boorjian{BOORJIANSTEPHENA.}|SeijiArai{ARAISEIJI}|YujiroNagata{NAGATAYUJIRO}|ShoSekito{SEKITOSHO}____AseemR.Shukla{SHUKLAASEEMR.}|TakahikoMitsui{MITSUITAKAHIKO}________JUA/AUA Joint Symposium【指導医教育コース認定プログラム】【英語セッション】____Management of Urinary Incontinence after Radical Prostatectomy|Targeting homologous recombination repair pathway in prostate cancer|Contemporary Management of Renal Cell Carcinoma with IVC Tumor Thrombus|Panel Discussion Theme: Bladder cancer (RARC urinary tract diversion)

JUA_AUA

JUA/AUA Joint Symposium【指導医教育コース認定プログラム】【英語セッション】

*指導医教育コース認定プログラム

AseemR.shukla{R.SHUKLAASEEM}____TakahikoMitsui{MITSUITAKAHIKO}________AUA Lecture 1【英語セッション】The lower tract approach to pediatric robotic surgery?Myths vs. Reality____The lower tract approach to pediatric robotic surgery?Myths vs. Reality

AUA1

AUA Lecture 1【英語セッション】
The lower tract approach to pediatric robotic surgery?Myths vs. Reality

JaspreetSandhu{SANDHUJASPREET}____TakahikoMitsui{MITSUITAKAHIKO}________AUA Lecture 2【英語セッション】Management of Refractory Overactive Bladder____Management of Refractory Overactive Bladder

AUA2

AUA Lecture 2【英語セッション】
Management of Refractory Overactive Bladder

KevinKoo{KOOKEVIN}|NirmishSingla{SINGLANIRMISH}|JuanLuisVásquez{VÁSQUEZJUANLUIS}|FilipKowalski{KOWALSKIFILIP}____TakahikoMitsui{MITSUITAKAHIKO}|HideakiMiyake{MIYAKEHIDEAKI}____JulieGehl{GEHLJULIE}____Scholarship Forum【英語セッション】____Medical Management of Kidney Stones: A Practical Approach for Urologists|MicroRNAs: Turning the Tide in Testicular Cancer|Calcium Electroporation for Bladder Tumor Treatment: A Study Proposal|Endoscopic treatment of ureteral strictures with use of self-expanding stents

SC

Scholarship Forum【英語セッション】

KatsuhiroIto{ITOKATSUHIRO}|KenichiSasaki{SASAKIKENICHI}|ToshihiroUemura{UEMURATOSHIHIRO}|GoNoguchi{NOGUCHIGO}|YuminaMuto{MUTOYUMINA}|TsukasaMasuda{MASUDATSUKASA}|TomoyukiKoguchi{KOGUCHITOMOYUKI}|ShunsukeGoto{GOTOSHUNSUKE}|TomoyaFukawa{FUKAWATOMOYA}____TakaoKamai{KAMAITAKAO}____TomonoriYaguchi{YAGUCHITOMONORI}|KenjiChamoto{CHAMOTOKENJI}|TomohiroFukui{FUKUITOMOHIRO}|ToshihiroMagaribuchi{MAGARIBUCHITOSHIHIRO}|TakayukiSumiyoshi{SUMIYOSHITAKAYUKI}|KitaYuki{YUKIKITA}|RyoichiSaito{SAITORYOICHI}|TakayukiGoto{GOTOTAKAYUKI}|SyusukeAkamatsu{AKAMATSUSYUSUKE}|TasukuHonjo{HONJOTASUKU}|TakashiKobayashi{KOBAYASHITAKASHI}|YutaTakeshima{TAKESHIMAYUTA}|MiwakoIwai{IWAIMIWAKO}|HiroshiFukuhara{FUKUHARAHIROSHI}|HarukiKume{KUMEHARUKI}|TomokiTodo{TODOTOMOKI}|AtsunariKawashima{KAWASHIMAATSUNARI}|KentaroJingushi{JINGUSHIKENTARO}|NesrineSassi{SASSINESRINE}|YukiHoribe{HORIBEYUKI}|AkinaruYamamoto{YAMAMOTOAKINARU}|LiuYutong{YUTONGLIU}|ToshikiOka{OKATOSHIKI}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|TaigoKato{KATOTAIGO}|KojiHatano{HATANOKOJI}|NorioNonomura{NONOMURANORIO}|RyosukeJikuya{JIKUYARYOSUKE}|ShinjiOhtake{OHTAKESHINJI}|MitsukoFuruya{FURUYAMITSUKO}|ShoheiKuraoka{KURAOKASHOHEI}|ToyonoriTsuzuki{TSUZUKITOYONORI}|FujiiSatoshi{SATOSHIFUJII}|HirojiUemura{UEMURAHIROJI}|TomomiKamba{KAMBATOMOMI}|RyuichiNishinakamura{NISHINAKAMURARYUICHI}|MasayaBaba{BABAMASAYA}|HisashiHasumi{HASUMIHISASHI}|KazuhideMakiyama{MAKIYAMAKAZUHIDE}|KazuyukiNumakura{NUMAKURAKAZUYUKI}|YuyaSekine{SEKINEYUYA}|MizukiKobayashi{KOBAYASHIMIZUKI}|SokiKashima{KASHIMASOKI}|RyoheiYamamoto{YAMAMOTORYOHEI}|NaraTaketoshi{TAKETOSHINARA}|MitsuruSaito{SAITOMITSURU}|ShintaroNarita{NARITASHINTARO}|YoheiYamamoto{YAMAMOTOYOHEI}|YasufumiOmori{OMORIYASUFUMI}|TomonoriHabuchi{HABUCHITOMONORI}|YutaKaneko{KANEKOYUTA}|NobuyukiTanaka{TANAKANOBUYUKI}|KimiharuTakamatsu{TAKAMATSUKIMIHARU}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|YotaYasumizu{YASUMIZUYOTA}|TakedaToshikazu{TOSHIKAZUTAKEDA}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|ShinyaMorita{MORITASHINYA}|TakeoKosaka{KOSAKATAKEO}|RyuichiMizuno{MIZUNORYUICHI}|HiroshiAsanuma{ASANUMAHIROSHI}|MototsuguOya{OYAMOTOTSUGU}|AkifumiOnagi{ONAGIAKIFUMI}|KeiYaginuma{YAGINUMAKEI}|ShunsukeYoshioka{YOSHIOKASHUNSUKE}|HirokiIwamatsu{IWAMATSUHIROKI}|TakahiroTsumori{TSUMORITAKAHIRO}|HiraguriAkari{AKARIHIRAGURI}|SyuntaMakabe{MAKABESYUNTA}|SeijiHoshi{HOSHISEIJI}|SoichiroOgawa{OGAWASOICHIRO}|MotohideUemura{UEMURAMOTOHIDE}|TakayukiHosoi{HOSOITAKAYUKI}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|KojiTamada{TAMADAKOJI}|MasatoshiEto{ETOMASATOSHI}|KeiDaizumoto{DAIZUMOTOKEI}|MitsukiNishiyama{NISHIYAMAMITSUKI}|SakiKobayashi{KOBAYASHISAKI}|YutaroSasaki{SASAKIYUTARO}|RyotaroTomida{TOMIDARYOTARO}|UenoYoshiteru{YOSHITERUUENO}|YoshitoKusuhara{KUSUHARAYOSHITO}|YasuyoYamamoto{YAMAMOTOYASUYO}|KunihisaYamaguchi{YAMAGUCHIKUNIHISA}|MasayukiTakahashi{TAKAHASHIMASAYUKI}|TakeshiNikawa{NIKAWATAKESHI}____総会賞ポスター 01腎腫瘍：基礎____Intratumoral and spatiotemporal heterogeneity of tumor microenvironment based on molecular subtypes in clear cell renal cell carcinoma淡明細胞型腎細胞癌における分子サブタイプの腫瘍間および腫瘍内多様性|Combination therapy for renal cell carcinoma using third-generation oncolytic herpes virus (G47Δ) and immune checkpoint inhibitors腎細胞癌に対する第三世代がん治療用HSV-1(G47Δ)と免疫チェックポイント阻害薬併用療法の開発|Bacterial DNA contained in serum extracellular vesicles reflects the status of perinephric adipose tissue in patients with clear cell renal cell carcinoma血清細胞外小胞に含まれる細菌DNAは脂肪組織の状態を反映する|Elucidation of tumorigenesis of ALK-rearranged renal cell carcinoma using kidney organoid model derived from human iPS cellsヒトiPS細胞由来腎癌オルガノイドモデル樹立によるALK融合遺伝子が引き起こす腎腫瘍化機構の解明|Activation of canonical pathway in mesenchymal stem cell induce tumor aggressiveness in renal cell carcinoma腎癌における脂肪由来間葉系幹細胞の働き|3D analysis of tumor microvasculature is prognostic and may serve as a biomarker for genomic alterations in patients with clear cell renal cell carcinoma腫瘍脈管の3次元解析による、淡明型腎細胞癌の予後予測因子および遺伝子変異バイオマーカーの検討|The association with invasive metastasis potential for renal cancer and myo-inositol metabolism腎癌の浸潤転移能に及ぼすミオイノシトール代謝の影響|Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells腫瘍浸潤リンパ球のimmunophenotypeに注目したIL-7/CCL19産生型ヒトCAR-T細胞の固形癌に対する抗腫瘍メカニズムの検討|Metabolic Alteration in Skeletal muscle cells and Mechanism of Muscle Atrophy Induced by Cancer-derived exosomesがん由来エクソソームによる筋細胞内代謝変化と筋萎縮発症機序の解明

AOP-01

総会賞ポスター 01
腎腫瘍：基礎

KenichiroIkeda{IKEDAKENICHIRO}|RyosukeJikuya{JIKUYARYOSUKE}|MasanoriHasegawa{HASEGAWAMASANORI}|TaigoKatou{KATOUTAIGO}|SatoshiKobayashi{KOBAYASHISATOSHI}|MasakiKobayashi{KOBAYASHIMASAKI}|MinoruInoue{INOUEMINORU}|ShigekiKoterazawa{KOTERAZAWASHIGEKI}|IchiroYonese{YONESEICHIRO}|HiroakiSato{SATOHIROAKI}____AkihiroIto{ITOAKIHIRO}____RikuNishioka{NISHIOKARIKU}|KenshiroTakemoto{TAKEMOTOKENSHIRO}|MikiNaito{NAITOMIKI}|ShunsukeMiyamoto{MIYAMOTOSHUNSUKE}|KoheiKobatake{KOBATAKEKOHEI}|SekinoYohei{YOHEISEKINO}|HiroyukiKitano{KITANOHIROYUKI}|KeisukeGoto{GOTOKEISUKE}|AkihiroGoriki{GORIKIAKIHIRO}|KeisukeHieda{HIEDAKEISUKE}|DaisukeKawahara{KAWAHARADAISUKE}|NobuyukiHinata{HINATANOBUYUKI}|GoNoguchi{NOGUCHIGO}|MitsukoFuruya{FURUYAMITSUKO}|ToyonoriTsuzuki{TSUZUKITOYONORI}|SatoshiFujii{FUJIISATOSHI}|HarukaHamanoue{HAMANOUEHARUKA}|BabaMasaya{MASAYABABA}|HirojiUemura{UEMURAHIROJI}|MasahiroYao{YAOMASAHIRO}|HidewakiNakagawa{NAKAGAWAHIDEWAKI}|HisashiHasumi{HASUMIHISASHI}|KazuhideMakiyama{MAKIYAMAKAZUHIDE}|MikioMikami{MIKAMIMIKIO}|KazuhiroTanabe{TANABEKAZUHIRO}|TomokoKatahira{KATAHIRATOMOKO}|TatsuyaUmemoto{UMEMOTOTATSUYA}|SoichiroYuzuriha{YUZURIHASOICHIRO}|OdaKazuya{KAZUYAODA}|NobuyukiNakajima{NAKAJIMANOBUYUKI}|MasahiroNitta{NITTAMASAHIRO}|YoshiakiKawamura{KAWAMURAYOSHIAKI}|SunaoShoji{SHOJISUNAO}|AkiraMiyajima{MIYAJIMAAKIRA}|AkihiroYoshimura{YOSHIMURAAKIHIRO}|KensakuNemoto{NEMOTOKENSAKU}|YoheiOkuda{OKUDAYOHEI}|AkinaruYamamoto{YAMAMOTOAKINARU}|ToshihiroUemura{UEMURATOSHIHIRO}|YamamichiGaku{GAKUYAMAMICHI}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|KojiHatano{HATANOKOJI}|AtsunariKawashima{KAWASHIMAATSUNARI}|KazumaKiyotani{KIYOTANIKAZUMA}|NorioNonomura{NONOMURANORIO}|KeijiTsukino{TSUKINOKEIJI}|JunMutaguchi{MUTAGUCHIJUN}|ShunsukeGoto{GOTOSHUNSUKE}|TakashiMatsumoto{MATSUMOTOTAKASHI}|MasakiShiota{SHIOTAMASAKI}|InokuchiJunichi{JUNICHIINOKUCHI}|MasatoshiEto{ETOMASATOSHI}|HajimeTanaka{TANAKAHAJIME}|ShoheiFukuda{FUKUDASHOHEI}|WeiChen{CHENWEI}|MotohiroFujiwara{FUJIWARAMOTOHIRO}|YukiNakamura{NAKAMURAYUKI}|IshikawaYudai{YUDAIISHIKAWA}|YumaWaseda{WASEDAYUMA}|SoichiroYoshida{YOSHIDASOICHIRO}|VirajAMaster{MASTERVIRAJA}|IthaarHDerweesh{DERWEESHITHAARH}|YasuhisaFujii{FUJIIYASUHISA}|KeitaIzumi{IZUMIKEITA}|AkinoriNakayama{NAKAYAMAAKINORI}|ChisatoOhe{OHECHISATO}|ShinichiBan{BANSHINICHI}|KazutakaSaito{SAITOKAZUTAKA}|TakayukiSumiyoshi{SUMIYOSHITAKAYUKI}|KatsuhiroIto{ITOKATSUHIRO}|KimihikoMasui{MASUIKIMIHIKO}|AtsushiIgarashi{IGARASHIATSUSHI}|KojiInoue{INOUEKOJI}|ItoNoriyuki{NORIYUKIITO}|JunWatanabe{WATANABEJUN}|KojiYoshimura{YOSHIMURAKOJI}|RyoichiSaito{SAITORYOICHI}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|ToshinariYamasaki{YAMASAKITOSHINARI}|TakashiKobayashi{KOBAYASHITAKASHI}|KosukeTakemura{TAKEMURAKOSUKE}|TakeshiYuasa{YUASATAKESHI}|KentaroInamura{INAMURAKENTARO}|GulanbarAmori{AMORIGULANBAR}|TatsuyaYamamoto{YAMAMOTOTATSUYA}|YoneokaYusuke{YUSUKEYONEOKA}|RyoFujiwara{FUJIWARARYO}|YosukeYasuda{YASUDAYOSUKE}|TomohikoOguchi{OGUCHITOMOHIKO}|NoboruNumao{NUMAONOBORU}|ShinyaYamamoto{YAMAMOTOSHINYA}|JunjiYonese{YONESEJUNJI}|RyoTsukamoto{TSUKAMOTORYO}|KeisukeAndo{ANDOKEISUKE}|ManatoKanesaka{KANESAKAMANATO}|YasutakaYamada{YAMADAYASUTAKA}|YusukeGoto{GOTOYUSUKE}|ImamuraYusuke{YUSUKEIMAMURA}|TomokazuSazuka{SAZUKATOMOKAZU}|ShinichiSakamoto{SAKAMOTOSHINICHI}|TomohikoIchikawa{ICHIKAWATOMOHIKO}____総会賞ポスター 02腎腫瘍：臨床____Radiomics-based survival risk prediction model for clear cell renal cell carcinoma and its possibility of clinical applicationRadiomicsを用いた淡明細胞型腎細胞癌の生存リスク予測モデル作成および臨床応用の可能性|Multi-omics analyses develop a foundation for precision medicine for chromophobe renal cell carcinoma and BHD-associated renal tumor散発性嫌色素性腎癌とBHD関連腎癌のマルチオミクス解析から明らかとなる腎癌の自然史に基づく精密医療の開発|Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Renal Cell Carcinoma腎細胞癌に対する新規バイオマーカー探索;包括的血清糖ペプチドスペクトル解析(CSGSA)|T-cell/ B-cell repertoire analysis predict immune-related adverse events following immune checkpoint inhibitors in advanced renal cell carcinomaTCR/BCRレパトア解析を用いた免疫チェックポイント阻害剤による免疫関連副作用発症予測|Development of an automatic segmentation system for 3D image generation in renal cancer treatment腎癌診療における3D画像生成に向けた自動セグメンテーションシステム開発|Racial disparities in clinical characteristics of metastatic recurrence after surgery in clear cell renal cell carcinoma淡明細胞型腎細胞癌根治術後の転移再発形式および再発後予後と人種の関係|Histologic-based tumor microenvironment characteristics of serum inflamed tumor in clear cell renal cell carcinoma淡明細胞型腎細胞癌における炎症反応亢進に伴う腫瘍微小環境特性|Risk stratification for postoperative recurrence in patients with pT3aN0M0 clear cell renal cell carcinomapT3aN0M0淡明細胞型腎細胞癌における術後再発のリスク層別化|Clinical presentation of fumarate hydratase-deficient renal carcinoma: A single-center case series当院における転移性FH欠損腎癌の臨床像|Clinical investigation of zinc replacement therapy in systemic treatment of renal cell carcinoma腎癌全身治療における亜鉛補充療法の臨床的検討

AOP-02

総会賞ポスター 02
腎腫瘍：臨床

RoderickVanDenBergh{BERGHRODERICKVANDEN}____YasutomoNasu{NASUYASUTOMO}________Invited Lecture 1【英語セッション】Prostate cancer screening; developments and opportunities____Prostate cancer screening; developments and opportunities

IL1

Invited Lecture 1【英語セッション】
Prostate cancer screening; developments and opportunities

IgorTsaur{TSAURIGOR}____OsamuUkimura{UKIMURAOSAMU}________Invited Lecture 2【英語セッション】Best practice in low volume mHSPC/oligometastatic disease: surgery or systemic therapy?____Best practice in low volume mHSPC/oligometastatic disease: surgery or systemic therapy?

IL2

Invited Lecture 2【英語セッション】
Best practice in low volume mHSPC/oligometastatic disease: surgery or systemic therapy?

JohnDenstedt{DENSTEDTJOHN}____KatsuhitoMiyazawa{MIYAZAWAKATSUHITO}________Invited Lecture 3【英語セッション】Management of Urolithiasis Update____Management of Urolithiasis Update

IL3

Invited Lecture 3【英語セッション】
Management of Urolithiasis Update

StevenCampbell{CAMPBELLSTEVEN}____YasuhisaFujii{FUJIIYASUHISA}________Invited Lecture 4【英語セッション】Surgical Management of Kidney Cancer Patients with Oligometastatic or Oligo-progressive Disease____Surgical Management of Kidney Cancer Patients with Oligometastatic or Oligo-progressive Disease

IL4

Invited Lecture 4【英語セッション】
Surgical Management of Kidney Cancer Patients with Oligometastatic or Oligo-progressive Disease

StephenA.boorjian{A.BOORJIANSTEPHEN}____NorihikoTsuchiya{TSUCHIYANORIHIKO}________Invited Lecture 5【英語セッション】Treatment of High Risk Non-muscle Invasive Bladder Cancer: What Happens When Guidelines Meet the Real World____Treatment of High Risk Non-muscle Invasive Bladder Cancer: What Happens When Guidelines Meet the Real World

IL5

Invited Lecture 5【英語セッション】
Treatment of High Risk Non-muscle Invasive Bladder Cancer: What Happens When Guidelines Meet the Real World

JaspreetSandhu{SANDHUJASPREET}____SigeoHorie{HORIESIGEO}________Invited Lecture 6【英語セッション】Current Strategies of BPH Management in USA____Current Strategies of BPH Management in USA

IL6

Invited Lecture 6【英語セッション】
Current Strategies of BPH Management in USA

AxelMerseburger{MERSEBURGERAXEL}____KazuhiroSuzuki{SUZUKIKAZUHIRO}________Invited Lecture 7【英語セッション】Metastatic Prostate Cancer: Navigating the Spectrum from mHSPC to mCRPC____Metastatic Prostate Cancer: Navigating the Spectrum from mHSPC to mCRPC

IL7

Invited Lecture 7【英語セッション】
Metastatic Prostate Cancer: Navigating the Spectrum from mHSPC to mCRPC

SeijiArai{ARAISEIJI}|RyouichiSaitou{SAITOURYOUICHI}|HiroshiFukushima{FUKUSHIMAHIROSHI}|NobuyukiTanaka{TANAKANOBUYUKI}|TakayukiOwaki{OWAKITAKAYUKI}|TomoyukiTatenuma{TATENUMATOMOYUKI}|YusukeSugino{SUGINOYUSUKE}|KenshiroTakemoto{TAKEMOTOKENSHIRO}|HideakiMiyoshi{MIYOSHIHIDEAKI}|SatoruMeguro{MEGUROSATORU}|ShunsukeTsuzuki{TSUZUKISHUNSUKE}____TeruoInamoto{INAMOTOTERUO}____TatsuhiroSawada{SAWADATATSUHIRO}|AkiraOhtsu{OHTSUAKIRA}|MaiKato{KATOMAI}|YutaMaeno{MAENOYUTA}|TakanoriShimizu{SHIMIZUTAKANORI}|SekineYoshitaka{YOSHITAKASEKINE}|KazuhiroSuzuki{SUZUKIKAZUHIRO}|KeiyuMatsumoto{MATSUMOTOKEIYU}|SoukiKashima{KASHIMASOUKI}|ToruSakatani{SAKATANITORU}|JunichiIkeda{IKEDAJUNICHI}|ChisatoOhe{OHECHISATO}|IkeuchiRyosuke{RYOSUKEIKEUCHI}|KenjiNakamura{NAKAMURAKENJI}|AkihiroHamada{HAMADAAKIHIRO}|KaoruMurakami{MURAKAMIKAORU}|YukiKita{KITAYUKI}|OsamuOgawa{OGAWAOSAMU}|TakashiKobayashi{KOBAYASHITAKASHI}|SeiichiroTakao{TAKAOSEIICHIRO}|AkiFurusawa{FURUSAWAAKI}|VladimirValeraRomero{ROMEROVLADIMIRVALERA}|SandeepGurram{GURRAMSANDEEP}|TakuyaKato{KATOTAKUYA}|OkuyamaShuhei{SHUHEIOKUYAMA}|MakotoKano{KANOMAKOTO}|PeterChoyke{CHOYKEPETER}|HisatakaKobayashi{KOBAYASHIHISATAKA}|KotaUmeda{UMEDAKOTA}|TomohiroIwasawa{IWASAWATOMOHIRO}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|YotaYasumizu{YASUMIZUYOTA}|ToshikazuTakeda{TAKEDATOSHIKAZU}|MoritaShinya{SHINYAMORITA}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|TakeoKosaka{KOSAKATAKEO}|RyuichiMizuno{MIZUNORYUICHI}|TakashiKamatani{KAMATANITAKASHI}|TatsuhikoTsunoda{TSUNODATATSUHIKO}|MototsuguOya{OYAMOTOTSUGU}|TadashiIida{IIDATADASHI}|YukiMiyai{MIYAIYUKI}|TomoyasuSano{SANOTOMOYASU}|YoshihisaMatsukawa{MATSUKAWAYOSHIHISA}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|EnomotoAtsushi{ATSUSHIENOMOTO}|TakuoMatsukawa{MATSUKAWATAKUO}|TakuroGoto{GOTOTAKURO}|RyosukeJikuya{JIKUYARYOSUKE}|HirokiIto{ITOHIROKI}|MitsuruKomeya{KOMEYAMITSURU}|ItoYusuke{YUSUKEITO}|KentaroMuraoka{MURAOKAKENTARO}|NarihikoHayashi{HAYASHINARIHIKO}|HisashiHasumi{HASUMIHISASHI}|KazuhideMakiyama{MAKIYAMAKAZUHIDE}|HiroshiMiyamoto{MIYAMOTOHIROSHI}|ShoSekito{SEKITOSHO}|TakumiKageyama{KAGEYAMATAKUMI}|TakeshiSasaki{SASAKITAKESHI}|SatoruMasui{MASUISATORU}|KouheiNishikawa{NISHIKAWAKOUHEI}|TanakaToshio{TOSHIOTANAKA}|YasuhitoShimada{SHIMADAYASUHITO}|LiqingZang{ZANGLIQING}|YasuhiroMurakawa{MURAKAWAYASUHIRO}|KenjiNakayama{NAKAYAMAKENJI}|KeishiTakano{TAKANOKEISHI}|TakahiroInoue{INOUETAKAHIRO}|KoheiKobatake{KOBATAKEKOHEI}|MikiNaito{NAITOMIKI}|ShunsukeMiyamoto{MIYAMOTOSHUNSUKE}|YoheiSekino{SEKINOYOHEI}|HiroyukiKitano{KITANOHIROYUKI}|GotoKeisuke{KEISUKEGOTO}|KenichiroIkeda{IKEDAKENICHIRO}|AkihiroGoriki{GORIKIAKIHIRO}|KeisukeHieda{HIEDAKEISUKE}|TetsutaroHayashi{HAYASHITETSUTARO}|OsamuKaminuma{KAMINUMAOSAMU}|NobuyukiHinata{HINATANOBUYUKI}|KosukeMiyai{MIYAIKOSUKE}|KoetsuHamamoto{HAMAMOTOKOETSU}|KazukiKawamura{KAWAMURAKAZUKI}|HiroakiKobayashi{KOBAYASHIHIROAKI}|MasayukiShinchi{SHINCHIMASAYUKI}|TsujitaYujiro{YUJIROTSUJITA}|KenjiKuroda{KURODAKENJI}|AkioHoriguchi{HORIGUCHIAKIO}|HitoshiTsuda{TSUDAHITOSHI}|KeiichiIto{ITOKEIICHI}|EminaKayama{KAYAMAEMINA}|KeiYaginuma{YAGINUMAKEI}|AkifumiOnagi{ONAGIAKIFUMI}|SeijiHoshi{HOSHISEIJI}|TomoyukiKoguchi{KOGUCHITOMOYUKI}|HataJunya{JUNYAHATA}|YuichiSato{SATOYUICHI}|HidenoriAkaihata{AKAIHATAHIDENORI}|MasaoKataoka{KATAOKAMASAO}|SoichiroOgawa{OGAWASOICHIRO}|MotohideUemura{UEMURAMOTOHIDE}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|MarikoHonda{HONDAMARIKO}|FumihikoUrabe{URABEFUMIHIKO}|YohtaShimada{SHIMADAYOHTA}|AyakoFujisaki{FUJISAKIAYAKO}|TakafumiKuroda{KURODATAKAFUMI}|OhnishiJunki{JUNKIOHNISHI}|ShunSato{SATOSHUN}|KazuakiTakahashi{TAKAHASHIKAZUAKI}|HiroyukiTakahashi{TAKAHASHIHIROYUKI}|HiroshiKobayashi{KOBAYASHIHIROSHI}|AikoOkamoto{OKAMOTOAIKO}|TakahiroKimura{KIMURATAKAHIRO}____総会賞ポスター 03尿路上皮腫瘍：基礎____PIK3CA mutation as a resistant mechanism of an FGFR inhibitor erdafitinib in urothelial cancer cellsPIK3CA変異は尿路上皮癌細胞においてFGFR阻害薬Erdafitinibの耐性メカニズムとなる|G-MDSC inhibition reactivated antitumor immunity in PD-1 blockade-resistant mouse urothelial tumors by remodeling tumor immune microenvironmentG-MDSCの抑制は腫瘍内免疫微小環境の改変によりPD1経路阻害抵抗性マウス膀胱癌に対する抗腫瘍免疫を再活性化する|Nectin-4-targeted near-infrared photoimmunotherapy in bladder cancer preclinical modelsNectin-4を標的とした近赤外光線免疫療法による膀胱癌新規治療法の開発|Whole-body analysis of clonal trajectories and spatial transcriptomics reveals inter- and intra-organ heterogeneity in urothelial carcinoma under immunotherapy転移性尿路上皮がんクローン進化と空間トランスクリプトミクスの統合理解による免疫療法下の臓器間・臓器内腫瘍不均一性の解明|Cancer-restraining cancer-associated fibroblasts regulate tumor immune microenvironment upstream towards immune checkpoint blockade therapy sensitivityがん抑制性がん関連線維芽細胞は腫瘍免疫微小環境を免疫チェックポイント阻害剤感受性へと上流調節する|The impact of GULP1 as a downstream effector of estrogen receptor-beta on modulating cisplatin sensitivity in bladder cancer膀胱癌におけるエストロゲン受容体βの下流因子としてのGULP1のシスプラチン感受性に対する影響について|Development of a zebrafish xenograft model to predict the efficacy of platinum-based neoadjuvant chemotherapy for muscle-invasive bladder cancer筋層浸潤性膀胱癌に対するプラチナベースの術前化学療法の効果を予測するためのゼブラフィッシュ異種移植モデルの開発|Clarification of the tumorigenic mechanisms associated with chronic kidney disease in bladder cancer膀胱癌における慢性腎臓病に関連した腫瘍活性メカニズムの解明|Impact of desmoplastic reaction (DR) at the invasion front on recurrence and prognosis in upper urinary tract urothelial carcinoma (UUTUC)上部尿路上皮癌における浸潤先進部のdesmoplastic reactionが再発と予後に与える影響|Senescent fibroblasts as aged microenvironment develop bladder cancer by CXCL12 secretion癌間質における老化した線維芽細胞はCXCL12の分泌により膀胱癌の成長を助長する|The role of Glutathione metabolism in proliferation of bladder cancer with ARID1A mutationグルタチオン代謝経路を介したARID1A遺伝子変異膀胱癌の増殖メカニズムの解明

AOP-03

総会賞ポスター 03
尿路上皮腫瘍：基礎

TakashiYoshida{YOSHIDATAKASHI}|ShinkuroYamamoto{YAMAMOTOSHINKURO}|DaichiTamura{TAMURADAICHI}|YukiKita{KITAYUKI}|ShoheiNagakawa{NAGAKAWASHOHEI}|KazumaYukihiro{YUKIHIROKAZUMA}|HajimeTanaka{TANAKAHAJIME}|YoshiyukiMatsui{MATSUIYOSHIYUKI}|TakahiroOsawa{OSAWATAKAHIRO}|ShogoAdomi{ADOMISHOGO}|NakanoriFujii{FUJIINAKANORI}____HiroyukiNishiyama{NISHIYAMAHIROYUKI}____TakahiroNakamoto{NAKAMOTOTAKAHIRO}|NahoAtsumi{ATSUMINAHO}|ChisatoOhe{OHECHISATO}|HidefumiKinoshita{KINOSHITAHIDEFUMI}|HirokazuNosato{NOSATOHIROKAZU}|AtsushiIkeda{IKEDAATSUSHI}|HideoFukuhara{FUKUHARAHIDEO}|KeijiInoue{INOUEKEIJI}|MasakazuAbe{ABEMASAKAZU}|DaikiIkarashi{IKARASHIDAIKI}|RenpeiKato{KATORENPEI}|YoichiroKato{KATOYOICHIRO}|ShigekatsuMaekawa{MAEKAWASHIGEKATSU}|KanehiraMitsugu{MITSUGUKANEHIRA}|RyoTakata{TAKATARYO}|YutakaSuzuki{SUZUKIYUTAKA}|HidewakiNakagawa{NAKAGAWAHIDEWAKI}|SatoshiNishizuka{NISHIZUKASATOSHI}|WataruObara{OBARAWATARU}|HikariOtsuka{OTSUKAHIKARI}|KatsuhiroIto{ITOKATSUHIRO}|TakutoHara{HARATAKUTO}|SoichiroShimura{SHIMURASOICHIRO}|SojunKanamaru{KANAMARUSOJUN}|KatoMinoru{MINORUKATO}|KojiInoue{INOUEKOJI}|HirokiIto{ITOHIROKI}|YoshiyukiMatsui{MATSUIYOSHIYUKI}|HiroyukiNishiyama{NISHIYAMAHIROYUKI}|HiroshiKitamura{KITAMURAHIROSHI}|TakashiKobayashi{KOBAYASHITAKASHI}|MasakiShiota{SHIOTAMASAKI}|ShigehiroTsukahara{TSUKAHARASHIGEHIRO}|TakashiMatsumoto{MATSUMOTOTAKASHI}|JunichiInokuchi{INOKUCHIJUNICHI}|MasatoshiEto{ETOMASATOSHI}|RyoTasaka{TASAKARYO}|KenshiroTakemoto{TAKEMOTOKENSHIRO}|TetsutaroHayashi{HAYASHITETSUTARO}|ShunsukeMiyamoto{MIYAMOTOSHUNSUKE}|KoheiKobatake{KOBATAKEKOHEI}|SekinoYohei{YOHEISEKINO}|HiroyukiKitano{KITANOHIROYUKI}|KeisukeGoto{GOTOKEISUKE}|KenichiroIkeda{IKEDAKENICHIRO}|AkihiroGoriki{GORIKIAKIHIRO}|KeisukeHieda{HIEDAKEISUKE}|NobuyukiHinata{HINATANOBUYUKI}|MotohiroFujiwara{FUJIWARAMOTOHIRO}|MasakiKobayashi{KOBAYASHIMASAKI}|YukiNakamura{NAKAMURAYUKI}|BoFan{FANBO}|YudaiIshikawa{ISHIKAWAYUDAI}|FukudaShohei{SHOHEIFUKUDA}|YumaWaseda{WASEDAYUMA}|SoichiroYoshida{YOSHIDASOICHIRO}|RyoichiYoshimura{YOSHIMURARYOICHI}|KazunoriKihara{KIHARAKAZUNORI}|YasuhisaFujii{FUJIIYASUHISA}|JunMiki{MIKIJUN}|WataruFukuokaya{FUKUOKAYAWATARU}|RikiyaTaoka{TAOKARIKIYA}|RyoichiSaito{SAITORYOICHI}|AyumuMatsuda{MATSUDAAYUMU}|OkunoTomoya{TOMOYAOKUNO}|TakahiroKirisawa{KIRISAWATAKAHIRO}|HajimeTakamori{TAKAMORIHAJIME}|NaotakaNishiyama{NISHIYAMANAOTAKA}|NobuakiMatsubara{MATSUBARANOBUAKI}|TaigoKato{KATOTAIGO}|TakashigeAbe{ABETAKASHIGE}|NobuoShinohara{SHINOHARANOBUO}|EtoMasatoshi{MASATOSHIETO}|KoshiroNishimoto{NISHIMOTOKOSHIRO}|MototsuguOya{OYAMOTOTSUGU}|TakaoFujisawa{FUJISAWATAKAO}|YoshiakiNakamura{NAKAMURAYOSHIAKI}|TakayukiYoshino{YOSHINOTAKAYUKI}|NorioNonomura{NONOMURANORIO}|KazutoshiFujita{FUJITAKAZUTOSHI}|KazukoSakai{SAKAIKAZUKO}|ShingoToyoda{TOYODASHINGO}|MitsuhisaNishimoto{NISHIMOTOMITSUHISA}|EriBanno{BANNOERI}|SaitoYoshitaka{YOSHITAKASAITO}|YujiroHayashi{HAYASHIYUJIRO}|TakafumiMinami{MINAMITAKAFUMI}|MasahiroNozawa{NOZAWAMASAHIRO}|KazuhiroYoshimura{YOSHIMURAKAZUHIRO}|KazutoNishio{NISHIOKAZUTO}|HirotsuguUemura{UEMURAHIROTSUGU}|HiroshiHirata{HIRATAHIROSHI}|YukihiroHitaka{HITAKAYUKIHIRO}|TakanoriTokunaga{TOKUNAGATAKANORI}|YuuichiMatsumoto{MATSUMOTOYUUICHI}|TomoyukiShimabukuro{SHIMABUKUROTOMOYUKI}|OkaShintaro{SHINTAROOKA}|KeitaKobayashi{KOBAYASHIKEITA}|KimihikoNakamura{NAKAMURAKIMIHIKO}|ToshiyaHiroyoshi{HIROYOSHITOSHIYA}|HideakiIto{ITOHIDEAKI}|NaohitoIsoyama{ISOYAMANAOHITO}|KojiShiraishi{SHIRAISHIKOJI}____総会賞ポスター 04尿路上皮腫瘍：臨床____Clinical implication of LAG-3/FGL1 pathway in advanced urothelial carcinoma treated with PD-(L)1 blockadePD-(L)1阻害薬で治療された進行性尿路上皮癌患者における、LAG-3/FGL1 pathwayの臨床的意義|Development of a deep learning-based false-positive detection method for photodynamic diagnosis光線力学診断における深層学習に基づいた偽陽性検出法の開発|Postoperative recurrence prediction using individualized circulating tumor DNA monitoring in upper tract urothelial carcinoma上部尿路上皮癌における個別化循環腫瘍DNAを用いた術後再発予測|Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan本邦での進行性尿路上皮癌患者の逐次治療パターンと臨床転帰の実態について|Independent validation of genetic risk model to progression after intravesical BCG therapy for NMIBC非筋層浸潤性膀胱癌におけるBCG療法後の進行に対する遺伝子リスクモデルの検証|A prospective study to observe the utility of photodynamic diagnosis in the diagnosis of renal pelvis and ureteral cancer腎盂尿管癌診断における光線力学診断の有用性を観察する前向き研究|Long-term oncologic outcomes of tetramodal bladder-preservation therapy for muscle-invasive bladder cancer筋層浸潤性膀胱癌に対する四者併用膀胱温存療法の腫瘍学的長期成績|The effect of histological variants on the outcomes of radical cystectomy for nonmetastatic bladder cancer非転移性膀胱がんにおける組織学的バリアントが根治的膀胱摘除術の予後に及ぼす影響|Genomic Alteration and Clinical Significance of Circulating Tumor DNA in Patients with Advanced Urothelial Cancer: SCRUM-Japan MONSTAR SCREEN Project進行尿路上皮がんに対する網羅的がんゲノム解析と臨床的有用性:SCRUM-Japan MONSTAR SCREEN Project|Gene mutation analysis of bladder cancer after radiotherapy for prostate cancer前立腺癌に対する放射線療法後の膀胱癌の遺伝子変異の解析|Exosome-lncRNA MAFG-AS1 predicts the clinical response to pembrolizumab in advanced urothelial carcinoma patients進行性尿路上皮癌におけるエクソソーム内lncRNA MAFG-AS1を用いたペムブロリズマブの治療効果予測マーカーの検討

AOP-04

総会賞ポスター 04
尿路上皮腫瘍：臨床

雑賀隆史{さいかたかしSAIKATAKASHI}____宮嶋哲{みやじまあきらMIYAJIMAAKIRA}________医療安全対策委員会報告医療安全対策委員会報告 -泌尿器科腹腔鏡手術およびロボット支援手術に関する術中・術後早期重大事故について-____医療安全対策委員会報告 -泌尿器科腹腔鏡手術およびロボット支援手術に関する術中・術後早期重大事故について-

IRYOANZEN

医療安全対策委員会報告
医療安全対策委員会報告 -泌尿器科腹腔鏡手術およびロボット支援手術に関する術中・術後早期重大事故について-

MotofumiSuzuki{SUZUKIMOTOFUMI}|DaisukeGotoh{GOTOHDAISUKE}|TsuyoshiYoshizawa{YOSHIZAWATSUYOSHI}|SatoruKira{KIRASATORU}____SatoruTakahashi{TAKAHASHISATORU}|YoshinoriNishino{NISHINOYOSHINORI}____KazumasaTorimoto{TORIMOTOKAZUMASA}|KiyohideFujimoto{FUJIMOTOKIYOHIDE}|SatoruTakahashi{TAKAHASHISATORU}|NorifumiSawada{SAWADANORIFUMI}|TakanoriMochizuki{MOCHIZUKITAKANORI}|HiroshiShimura{SHIMURAHIROSHI}|TakahikoMitsui{MITSUITAKAHIKO}____Panel Discussion 7Evidence and controversy in long-term medical therapies for benign prostatic hyperplasia.____Trends in drug treatment of benign prostatic hyperplasia in Japan based on the NDB Open DataNDBオープンデータからみる本邦における前立腺薬物治療のトレンド|Therapeutic effects of long-term drug therapy長期薬物療法の治療効果|Another stories of long-term pharmacotherapy: examining adverse effects長期薬物療法のアナザーストーリーズ:副次作用の検証|Long-term medical therapies in benign prostatic hyperplasia (BPH); pit fall and caution長期薬物療法; 思わぬ落とし穴とその留意点

PD7

Panel Discussion 7
Evidence and controversy in long-term medical therapies for benign prostatic hyperplasia.

HarukiKume{KUMEHARUKI}|ShingoHatakeyama{HATAKEYAMASHINGO}|ShintarouNarita{NARITASHINTAROU}|TakahiroOsawa{OSAWATAKAHIRO}____TohruNakagawa{NAKAGAWATOHRU}|IsaoHara{HARAISAO}____HarukaMiyata{MIYATAHARUKA}|RyujiMatsumoto{MATSUMOTORYUJI}|TakashigeAbe{ABETAKASHIGE}|NobuoShinohara{SHINOHARANOBUO}____Symposium 8Challenges in the treatment of urological cancer in the elderly____Challenges in the treatment of urological cancer in the elderly, overview|Challenges in assessing frailty in elderly patients with urological cancers高齢者泌尿器がん患者のフレイル評価の難しさ|Real-world clinical practice of systematic therapies for older patients with genitourinary malignancies高齢泌尿器がん患者における薬物療法の適応と実際|Indications and practice of urological cancer surgery in the elderly高齢者泌尿器がん手術の適応と実際

SY8

Symposium 8
Challenges in the treatment of urological cancer in the elderly

ToshikiOka{OKATOSHIKI}|NobuhitoMuramoto{MURAMOTONOBUHITO}|YotaYasumizu{YASUMIZUYOTA}|TaikiKamijima{KAMIJIMATAIKI}|TakuroSunada{SUNADATAKURO}|YasutakaYamada{YAMADAYASUTAKA}|TakumiKageyama{KAGEYAMATAKUMI}|KoNakamura{NAKAMURAKO}|YurieKura{KURAYURIE}|YoheiSekino{SEKINOYOHEI}____SeiichiSaito{SAITOSEIICHI}____KojiHatano{HATANOKOJI}|KeisukeNimura{NIMURAKEISUKE}|YuIshizuya{ISHIZUYAYU}|MasaruTani{TANIMASARU}|AkihiroYoshimura{YOSHIMURAAKIHIRO}|LiuYutong{YUTONGLIU}|EisukeTomiyama{TOMIYAMAEISUKE}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|TaigoKato{KATOTAIGO}|AtsunariKawashima{KAWASHIMAATSUNARI}|KazutoshiFujita{FUJITAKAZUTOSHI}|NorioNonomura{NONOMURANORIO}|MasayukiIwasaki{IWASAKIMASAYUKI}|YasuyukiSera{SERAYASUYUKI}|HisamitsuIde{IDEHISAMITSU}|ShoichiroMukai{MUKAISHOICHIRO}|TsuyoshiFukushima{FUKUSHIMATSUYOSHI}|KataokaHiroaki{HIROAKIKATAOKA}|SatoruMuto{MUTOSATORU}|ShigeoHorie{HORIESHIGEO}|HiroakiHonda{HONDAHIROAKI}|KoujiIzumi{IZUMIKOUJI}|RenToriumi{TORIUMIREN}|RyunosukeNakagawa{NAKAGAWARYUNOSUKE}|ShuheiAoyama{AOYAMASHUHEI}|RieFukuda{FUKUDARIE}|MakinoTomoyuki{TOMOYUKIMAKINO}|RenatoNaito{NAITORENATO}|HiroakiIwamoto{IWAMOTOHIROAKI}|HirokiNakata{NAKATAHIROKI}|HiroshiYaegashi{YAEGASHIHIROSHI}|TakahiroNohara{NOHARATAKAHIRO}|AtsushiMizokami{MIZOKAMIATSUSHI}|TakayukiGoto{GOTOTAKAYUKI}|MakiFujiwara{FUJIWARAMAKI}|KensukeHikami{HIKAMIKENSUKE}|ArinobuFukunaga{FUKUNAGAARINOBU}|TomohiroFukui{FUKUITOMOHIRO}|SumiyoshiTakayuki{TAKAYUKISUMIYOSHI}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|TakashiKobayashi{KOBAYASHITAKASHI}|ShinichiSakamoto{SAKAMOTOSHINICHI}|TomokazuSazuka{SAZUKATOMOKAZU}|YusukeImamura{IMAMURAYUSUKE}|TomohikoIchikawa{ICHIKAWATOMOHIKO}|ManabuKato{KATOMANABU}|ShoSekito{SEKITOSHO}|YusukeSugino{SUGINOYUSUKE}|TakeshiSasaki{SASAKITAKESHI}|SatoruMasui{MASUISATORU}|NishikawaKohei{KOHEINISHIKAWA}|YasuhiroMurakawa{MURAKAWAYASUHIRO}|TakahiroInoue{INOUETAKAHIRO}|TakeshiTsutsumi{TSUTSUMITAKESHI}|TakuyaTsujino{TSUJINOTAKUYA}|TomoakiTakai{TAKAITOMOAKI}|KazumasaKomura{KOMURAKAZUMASA}|HirofumiUehara{UEHARAHIROFUMI}|InamotoTeruo{TERUOINAMOTO}|HaruhitoAzuma{AZUMAHARUHITO}|MarcoA.DeVelasco{VELASCOMARCOA.DE}|KazukoSakai{SAKAIKAZUKO}|SyogoAdomi{ADOMISYOGO}|YasunoriMori{MORIYASUNORI}|TakafumiMinami{MINAMITAKAFUMI}|YoshimuraKazuhiro{KAZUHIROYOSHIMURA}|KazutoNishio{NISHIOKAZUTO}|HirotsuguUemura{UEMURAHIROTSUGU}|LiHongtao{HONGTAOLI}|MasatomoKaneko{KANEKOMASATOMO}|ZhouXinyi{XINYIZHOU}|LiangGangning{GANGNINGLIANG}|NobuyukiHinata{HINATANOBUYUKI}____総会賞ポスター 05前立腺癌：基礎____Genome-wide CRISPR screens identified DCLRE1C which regulates prostate cancer sensitivity to radiation therapyゲノムワイドCRISPRスクリーニングにより前立腺癌の放射線感受性を制御するDCLRE1Cを同定した|Loss of function of histone modifier UTX contributes to prostate cancer development through promoting inflammation and impairing DNA damage repairヒストン修飾因子UTXの機能欠失は、炎症の促進とDNA損傷修復機能低下によって前立腺癌の促進に寄与する|BRD4/Myc targeted therapy overcomes CDDP resistance in NEUROD1-positive NEPCBRD4/mycをターゲットとした治療は、NEUROD1陽性NEPCのCDDP耐性を克服する|FGF-KRAS signaling promotes the progression of double negative prostate cancerFGF-KRASシグナルはDNPCの進展を促進する。|Establishment and application of organoids derived from patient-derived xenografts(PDX) of castration resistant prostate cancer(CRPC)去勢抵抗性前立腺癌患者由来異種移植ゼノグラフトモデルを用いたオルガノイドの樹立と応用|Heterogeneity of PSMA expression and development of novel therapeutic approach for PSMA-targeted therapy unfit tumors in advanced prostate cancer進行前立腺癌におけるPSMA発現の多様性と標的治療不応病変に対する新規治療戦略の開発|Endothelial-mesenchymal transition in the tumor microenvironment promotes neuroendocrine differentiation of prostate cancer腫瘍微小環境における内皮間葉転換が前立腺癌の神経内分泌化を促進する|Expanding the Therapeutic Potential of PARP Inhibition: Insights from a Genome-Wide CRISPR/Cas9 Screen in Prostate Cancer Cells前立腺癌におけるCRISPR/Cas9スクリーニング～PARP阻害剤治療拡大への戦略～|Investigating the relationship between prostate cancer, colorectal cancer, and ulcerative colitis前立腺癌と大腸癌、そして潰瘍性大腸炎の関連性に関する研究|The possible role of gene body methylation of ONECUT2 in its transcriptional regulation and biomarker in prostate cancer前立腺癌においてgene bodyのメチル化がONECUT2の発現を制御し、有望なバイオマーカーとなりうる

AOP-05

総会賞ポスター 05
前立腺癌：基礎

KojiHatano{HATANOKOJI}|YutoBaba{BABAYUTO}|TakayukiSumiyoshi{SUMIYOSHITAKAYUKI}|HiromiUno{UNOHIROMI}|HiroakiKobayashi{KOBAYASHIHIROAKI}|HayatoYamamoto{YAMAMOTOHAYATO}|MitsuruKajiwara{KAJIWARAMITSURU}|SoichiroYoshida{YOSHIDASOICHIRO}|TakahikoSoma{SOMATAKAHIKO}|YoshitakaSekine{SEKINEYOSHITAKA}____AtsushiMizokami{MIZOKAMIATSUSHI}____YoshihikoTomofuji{TOMOFUJIYOSHIHIKO}|MakotoMatsushita{MATSUSHITAMAKOTO}|ToshikiOka{OKATOSHIKI}|SaizoFujimoto{FUJIMOTOSAIZO}|HataJunya{JUNYAHATA}|TsujimuraAkira{AKIRATSUJIMURA}|WataruObara{OBARAWATARU}|ShotaNakamura{NAKAMURASHOTA}|HirotsuguUemura{UEMURAHIROTSUGU}|YukinoriOkada{OKADAYUKINORI}|NorioNonomura{NONOMURANORIO}|KazutoshiFujita{FUJITAKAZUTOSHI}|TakeoKosaka{KOSAKATAKEO}|YotaYasumizu{YASUMIZUYOTA}|HiroshiHongo{HONGOHIROSHI}|NatsumiAoki{AOKINATSUMI}|ShigehisaKitano{KITANOSHIGEHISA}|UedaKouji{KOUJIUEDA}|ToshikazuTakeda{TAKEDATOSHIKAZU}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|HiroshiNishihara{NISHIHARAHIROSHI}|YutakaSuzuki{SUZUKIYUTAKA}|MototsuguOya{OYAMOTOTSUGU}|HiroshiFujiwara{FUJIWARAHIROSHI}|KaoruIto{ITOKAORU}|TakashiKawahara{KAWAHARATAKASHI}|RyomaKurahashi{KURAHASHIRYOMA}|YutoHattori{HATTORIYUTO}|ShiraishiYusuke{YUSUKESHIRAISHI}|YusukeHama{HAMAYUSUKE}|TakuroSunada{SUNADATAKURO}|TakayukiGoto{GOTOTAKAYUKI}|RyoichiSaito{SAITORYOICHI}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|TakashiKobayashi{KOBAYASHITAKASHI}|MasayukiTomioka{TOMIOKAMASAYUKI}|KensakuSeike{SEIKEKENSAKU}|KosukeMiyai{MIYAIKOSUKE}|TakakoAsano{ASANOTAKAKO}|KoheiNakamura{NAKAMURAKOHEI}|TokuhiroKimura{KIMURATOKUHIRO}|NishiharaHiroshi{HIROSHINISHIHARA}|HitoshiTsuda{TSUDAHITOSHI}|SusumuMatsukuma{MATSUKUMASUSUMU}|KeiichiIto{ITOKEIICHI}|TohruYoneyama{YONEYAMATOHRU}|NaokiFujita{FUJITANAOKI}|TeppeiOkamoto{OKAMOTOTEPPEI}|ShingoHatakeyama{HATAKEYAMASHINGO}|TakahiroYoneyama{YONEYAMATAKAHIRO}|HashimotoYasuhiro{YASUHIROHASHIMOTO}|ChikaraOhyama{OHYAMACHIKARA}|UkihideTateishi{TATEISHIUKIHIDE}|KoichiroKimura{KIMURAKOICHIRO}|JunichiTsuchiya{TSUCHIYAJUNICHI}|DaisukeKano{KANODAISUKE}|TadashiWatabe{WATABETADASHI}|NonomuraNorio{NORIONONOMURA}|KatsuhikoSaito{SAITOKATSUHIKO}|KotaYokoyama{YOKOYAMAKOTA}|KenYamagiwa{YAMAGIWAKEN}|TakuyaAdachi{ADACHITAKUYA}|MiraiKawano{KAWANOMIRAI}|YasuhisaFujii{FUJIIYASUHISA}|MasayaIto{ITOMASAYA}|IchiroYonese{YONESEICHIRO}|ShuzoIkuta{IKUTASHUZO}|MasahiroToide{TOIDEMASAHIRO}|FumitakaKoga{KOGAFUMITAKA}|YujiFujizuka{FUJIZUKAYUJI}|SyunNakazawa{NAKAZAWASYUN}|YusukeTsuji{TSUJIYUSUKE}|AkiraOhtsu{OHTSUAKIRA}|YoshiyukiMiyazawa{MIYAZAWAYOSHIYUKI}|AraiSeiji{SEIJIARAI}|MasashiNomura{NOMURAMASASHI}|HidekazuKoike{KOIKEHIDEKAZU}|HiroshiMatsui{MATSUIHIROSHI}|KeiShibuya{SHIBUYAKEI}|KazutoIto{ITOKAZUTO}|KazuhiroSuzuki{SUZUKIKAZUHIRO}____総会賞ポスター 06前立腺癌：疫学・診断____Polygenetic risk score for prostate cancer is associated with lipopolysaccharide pathway in gut microbiome前立腺癌のポリジェニックリスクスコアは腸内細菌叢のリポ多糖経路と関連する|Spatial transcriptomics reveal intra-tumor heterogeneity and niche factors in AR-indifferent prostate cancer空間トランスクリプトーム解析によりAR-indifferentな進行前立腺癌の腫瘍内不均一性とニッチ因子が明らかとなる|Clinical outcomes of de novo metastatic castration-sensitive prostate cancer patients with lung metastases診断時に肺転移を有する転移性去勢感受性前立腺癌患者の臨床成績|Margin assessment in focal therapy for prostate cancer: Analysis of distance between target outline and perilesional positive cores using MRI/US fusion biopsy前立腺癌に対する局所療法における治療マージンの治療前評価:MRI/US融合生検による標的と標的周囲陽性コア間距離の分析|Evaluation of the predictive ability of TP53 gene mutation by immunohistochemistry in Japanese patients with ductal adenocarcinoma of the prostate日本人の稀少前立腺導管癌におけるp53免疫染色による遺伝子変異予測能の評価|Characteristics of the alpha 2,3-sialyl N-glycosylated PSA as a biomarker for prostate cancer in men with grey zone levels of the PSAPSAグレイゾーンにおけるS23-PSAの診断精度|Phi could be a promising biomarker to reduce unnecessary biopsy for prostate cancer前立腺癌新規バイオマーカーphiはPSA gray zoneにおける不要な前立腺生検回避に有効である|Phase I/IIa Trial of 18F-Prostate Specific Membrane Antigen (PSMA) PET/CT in Healthy Volunteers and Prostate Cancer Patients健康成人および前立腺癌患者を対象とした，18F-PSMA-1007 PET/CTの安全性と有効性を検討する国内第I/IIa相治験|Deep learning model for predicting significant prostate cancer; can we bypass prostate biopsy prior to the curative treatment?前立腺癌を予測するDeep learningモデルの作成|Utility of combining prostate health index and MRI in diagnosing prostate cancer前立腺癌診断におけるprostate health indexとMRI併用の有用性

AOP-06

総会賞ポスター 06
前立腺癌：疫学・診断

冨士幸蔵{ふじこうぞうFUJIKOHZO}____髙橋悟{たかはしさとるTAKAHASHISATORU}________保険教育プログラム【指導医教育コース認定プログラム】保険診療への理解を深めよう　～2024年診療報酬改定のポイントを含めて～____保険診療への理解を深めよう　～2024年診療報酬改定のポイントを含めて～

HOKENKYOIKU

保険教育プログラム【指導医教育コース認定プログラム】
保険診療への理解を深めよう　～2024年診療報酬改定のポイントを含めて～

*指導医教育コース認定プログラム

TakuNaiki{NAIKITAKU}|ShigekatsuMaekawa{MAEKAWASHIGEKATSU}|TakumaKatou{KATOUTAKUMA}|KoujiIzumi{IZUMIKOUJI}|YusukeSato{SATOYUSUKE}|KouheiHashimoto{HASHIMOTOKOUHEI}|TakuyaTsujino{TSUJINOTAKUYA}|MasahiroOnishi{ONISHIMASAHIRO}|TakeshiSasaki{SASAKITAKESHI}|MakotoKawase{KAWASEMAKOTO}____ToshiyukiKamoto{KAMOTOTOSHIYUKI}____AyaNaiki-Ito{NAIKI-ITOAYA}|ToshikiEtani{ETANITOSHIKI}|TakashiNagai{NAGAITAKASHI}|MariaAoki{AOKIMARIA}|MasakazuGonda{GONDAMASAKAZU}|MorikawaToshiharu{TOSHIHARUMORIKAWA}|NoriyasuKawai{KAWAINORIYASU}|SatoruTakahashi{TAKAHASHISATORU}|TakahiroYasui{YASUITAKAHIRO}|KentaIshikawa{ISHIKAWAKENTA}|MasakazuAbe{ABEMASAKAZU}|EiShiomi{SHIOMIEI}|DaikiIkarashi{IKARASHIDAIKI}|TomohikoMatsuura{MATSUURATOMOHIKO}|KatoRenpei{RENPEIKATO}|MitsuguKanehira{KANEHIRAMITSUGU}|RyoTakata{TAKATARYO}|JunSugimura{SUGIMURAJUN}|WataruObara{OBARAWATARU}|RyujiMatsumoto{MATSUMOTORYUJI}|AkiraYokomizo{YOKOMIZOAKIRA}|YoichiroTohi{TOHIYOICHIRO}|KeiichiroMori{MORIKEIICHIRO}|YoichiFujii{FUJIIYOICHI}|FukuharaHiroshi{HIROSHIFUKUHARA}|TakumaSatou{SATOUTAKUMA}|JunichiInokuchi{INOKUCHIJUNICHI}|KatsuyoshiHashine{HASHINEKATSUYOSHI}|ShinichiSakamoto{SAKAMOTOSHINICHI}|MikioSugimoto{SUGIMOTOMIKIO}|YoshiyukiKakehi{KAKEHIYOSHIYUKI}|TomoyukiMakino{MAKINOTOMOYUKI}|RenatoNaito{NAITORENATO}|HiroakiIwamoto{IWAMOTOHIROAKI}|HiroshiYaegashi{YAEGASHIHIROSHI}|ShoheiKawaguchi{KAWAGUCHISHOHEI}|ShigeharaKazuyoshi{KAZUYOSHISHIGEHARA}|TakahiroNohara{NOHARATAKAHIRO}|ShizukoTakahara{TAKAHARASHIZUKO}|AtsushiMizokami{MIZOKAMIATSUSHI}|JunKamei{KAMEIJUN}|SatoruTaguchi{TAGUCHISATORU}|YoshiyukiAkiyama{AKIYAMAYOSHIYUKI}|YutaYamada{YAMADAYUTA}|YamadaDaisuke{DAISUKEYAMADA}|HarukiKume{KUMEHARUKI}|TetsuyaShindo{SHINDOTETSUYA}|TakutoOgasawara{OGASAWARATAKUTO}|KimitoTachikawa{TACHIKAWAKIMITO}|TakeshiMaehana{MAEHANATAKESHI}|YukiKyoda{KYODAYUKI}|KobayashiKo{KOKOBAYASHI}|ToshiakiTanaka{TANAKATOSHIAKI}|AtsushiTakahashi{TAKAHASHIATSUSHI}|TomokazuHasegawa{HASEGAWATOMOKAZU}|MasanoriSomeya{SOMEYAMASANORI}|Koh-IchiSakata{SAKATAKOH-ICHI}|NaoyaMasumori{MASUMORINAOYA}|KazumasaKomura{KOMURAKAZUMASA}|TakeshiHashimoto{HASHIMOTOTAKESHI}|KiyoshiTakahara{TAKAHARAKIYOSHI}|TeruoInamoto{INAMOTOTERUO}|TakahiroKimura{KIMURATAKAHIRO}|OhnoYoshio{YOSHIOOHNO}|RyoichiShiroki{SHIROKIRYOICHI}|HaruhitoAzuma{AZUMAHARUHITO}|HidemasaKawamura{KAWAMURAHIDEMASA}|YoshiyukiMiyazawa{MIYAZAWAYOSHIYUKI}|YoshitakaSekine{SEKINEYOSHITAKA}|HidekazuKoike{KOIKEHIDEKAZU}|HiroshiMatsui{MATSUIHIROSHI}|SuzukiKazuhiro{KAZUHIROSUZUKI}|TatsuyaOhno{OHNOTATSUYA}|IkuoKobayashi{KOBAYASHIIKUO}|KatsunoriUchida{UCHIDAKATSUNORI}|ShinichiroHigashi{HIGASHISHINICHIRO}|SatoruMasui{MASUISATORU}|KouheiNishikawa{NISHIKAWAKOUHEI}|TuzukiToyonori{TOYONORITUZUKI}|MasatoshiWatanabe{WATANABEMASATOSHI}|NaotoSassa{SASSANAOTO}|TakahiroInoue{INOUETAKAHIRO}|ShinEbara{EBARASHIN}|TomoyukiTatenuma{TATENUMATOMOYUKI}|TakeshiSasaki{SASAKITAKESHI}|YoshinoriIkehata{IKEHATAYOSHINORI}|AkinoriNakayama{NAKAYAMAAKINORI}|ToideMasahiro{MASAHIROTOIDE}|TatsuakiYoneda{YONEDATATSUAKI}|KazushigeSakaguchi{SAKAGUCHIKAZUSHIGE}|JunTeishima{TEISHIMAJUN}|TakuyaKoie{KOIETAKUYA}____総会賞ポスター 07前立腺癌：治療____Preliminary evidence for developing safety and clinical efficiency of luteolin treatment in prostate cancer前立腺発がん・進展予防を目的としたルテオリンを用いた臨床試験のための安全性の検証|Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide前立腺癌におけるCOMT発現のエンザルタミド奏功予測バイオマーカーとしての検討|Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage prostate cancer: the PRIAS-JAPAN study監視療法の多施設共同前向き観察研究の長期成績:PRIAS-JAPAN|Comparison of QOL between enzalutamide and abiraterone plus prednisolone for CRPC: ENABLE study for PCa sub-analysisCRPCにおけるエンザルタミドとアビラテロンのQOLの直接比較(多施設共同前向きランダム化比較試験ENABLE試験のサブ解析)|Results and trends of cancer genome profiling tests for prostate cancer in Japan本邦における前立腺癌に対するがん遺伝子パネル検査の実績と傾向|The impact of local radiotherapy on the prognosis of patients with locally advanced and metastatic castration-sensitive prostate cancer: the LORTIP trial転移を有する局所進行性去勢感受性前立腺癌に対する局所放射線治療の予後への影響:LORTIP研究|Real-World survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for non-metastatic castration-resistant prostate cancer非転移性去勢抵抗性前立腺癌におけるアビラテロンとエンザルタミドの比較～多施設共同リアルワールドデータ解析～|Comparative long-term outcomes of monotherapy vs. combined hormone therapy in favorable intermediate-risk prostate cancer treated with carbon Ion radiotherapy予後良好中リスク群に対する重粒子線治療における単独療法とホルモン療法併用の長期成績の比較|Impact of cribriform pattern 4 carcinoma/intraductal carcinoma of the prostate (CC/IDCP) on persistent PSA after robot-assisted radical prostatectomy (RARP)ロボット支援根治的前立腺全摘除術の手術日再発に対する篩状癌/前立腺管内癌(CC/IDCP)の影響に関する検討|Prognostic importance of lymphovascular invasion for specific subgroup of patients with prostate cancer after robot-assisted radical prostatectomy(MSUG94 group)脈管侵襲がロボット支援根治的前立腺摘除術後の予後に影響するサブグループの検討 (MSUG94グループ)

AOP-07

総会賞ポスター 07
前立腺癌：治療

MitsuruKomeya{KOMEYAMITSURU}|ShinichirouFukuhara{FUKUHARASHINICHIROU}|HideyukiKobayashi{KOBAYASHIHIDEYUKI}|AkiraKomiya{KOMIYAAKIRA}|TomokiTakeda{TAKEDATOMOKI}|HirokiNakata{NAKATAHIROKI}|SoichiroOgawa{OGAWASOICHIRO}|YoshinoriYanai{YANAIYOSHINORI}|MotohiroTaguchi{TAGUCHIMOTOHIRO}|TatsunoriOkada{OKADATATSUNORI}____KojiShiraishi{SHIRAISHIKOJI}____HisakazuOdaka{ODAKAHISAKAZU}|KiyoshiHashimoto{HASHIMOTOKIYOSHI}|ShinoNagata{NAGATASHINO}|YuIshikawa-Yamauchi{ISHIKAWA-YAMAUCHIYU}|TakuyaSato{SATOTAKUYA}|MakiyamaKazuhide{KAZUHIDEMAKIYAMA}|TakehikoOgawa{OGAWATAKEHIKO}|HiroakiKitakaze{KITAKAZEHIROAKI}|GoTsujimura{TSUJIMURAGO}|TakehiroImanaka{IMANAKATAKEHIRO}|SoheiKuribayashi{KURIBAYASHISOHEI}|YasushiMiyagawa{MIYAGAWAYASUSHI}|YamamotoHiroshi{HIROSHIYAMAMOTO}|ShigeyoshiSaito{SAITOSHIGEYOSHI}|NorioNonomura{NONOMURANORIO}|MasatoUetani{UETANIMASATO}|ShinjiroTakeuchi{TAKEUCHISHINJIRO}|FumitoYamabe{YAMABEFUMITO}|YozoMitsui{MITSUIYOZO}|KoichiNakajima{NAKAJIMAKOICHI}|NagaoKoichi{KOICHINAGAO}|KiyotakaKawai{KAWAIKIYOTAKA}|MakikoTajima{TAJIMAMAKIKO}|YukoTakayanagi{TAKAYANAGIYUKO}|YurieNako{NAKOYURIE}|KenichiroHiraoka{HIRAOKAKENICHIRO}|SujinoToshio{TOSHIOSUJINO}|HirokiShibata{SHIBATAHIROKI}|TomohikoIchikawa{ICHIKAWATOMOHIKO}|ShoichiroIwatsuki{IWATSUKISHOICHIRO}|HirokiKubota{KUBOTAHIROKI}|HiroyukiKamiya{KAMIYAHIROYUKI}|ShoichiSasaki{SASAKISHOICHI}|YukihiroUmemoto{UMEMOTOYUKIHIRO}|YasuiTakahiro{TAKAHIROYASUI}|ShoichiIseki{ISEKISHOICHI}|AtsushiMizokami{MIZOKAMIATSUSHI}|TomoyukiKumekawa{KUMEKAWATOMOYUKI}|SyuntaMakabe{MAKABESYUNTA}|YukiHarigane{HARIGANEYUKI}|KeiYaginuma{YAGINUMAKEI}|HitomiImai{IMAIHITOMI}|TanjiRyo{RYOTANJI}|SeijiHoshi{HOSHISEIJI}|JunyaHata{HATAJUNYA}|YuichiSato{SATOYUICHI}|HidenoriAkaihata{AKAIHATAHIDENORI}|MotohideUemura{UEMURAMOTOHIDE}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|TakeoKosaka{KOSAKATAKEO}|ShujiMikami{MIKAMISHUJI}|MasashiArai{ARAIMASASHI}|YutoBaba{BABAYUTO}|KeitaroWatanabe{WATANABEKEITARO}|YoshimineShunsuke{SHUNSUKEYOSHIMINE}|ToshikazuTakeda{TAKEDATOSHIKAZU}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|ShinyaMorita{MORITASHINYA}|MakikoYamashita{YAMASHITAMAKIKO}|ShigehisaKitano{KITANOSHIGEHISA}|MototsuguOya{OYAMOTOTSUGU}|AkihiroKanematsu{KANEMATSUAKIHIRO}|HiroyukiIio{IIOHIROYUKI}|ToekiYanagi{YANAGITOEKI}|ShingoYamamoto{YAMAMOTOSHINGO}|SeijiNagasawa{NAGASAWASEIJI}|KondohNobuyuki{NOBUYUKIKONDOH}|AyamiOkabe{OKABEAYAMI}|RetsuMitsui{MITSUIRETSU}|HikaruHashitani{HASHITANIHIKARU}|ShunichiKajioka{KAJIOKASHUNICHI}|MasatoshiEto{ETOMASATOSHI}____総会賞ポスター 08アンドロロジー・不妊・性機能____In vitro spermatogenesis through the meiotic stage based on the two-dimensional cell culture systemin vitro精子形成を実現するための細胞培養法の開発|Development of a novel non-invasive method for evaluation of spermatogenesis function in the testes with Cr-CEST-MRICr-CEST-MRIを用いた新規非侵襲的精巣内造精機能評価法の開発|AI model for predicting risk of male infertility from serum hormone levels without semen analysis血液検査から男性不妊症のリスク判定を行うAIモデルの構築|Conventional semen analysis, sperm motility parameters and sperm DNA fragmentation index to identify infertile men男性不妊症診断のための精液検査のパラメータ、精子DNA断片化率の閾値の同定|The relationship between serum anti-Müllerian hormone levels and the number of Sertoli cells血清抗ミュラー管ホルモン値とSertoli細胞数の関連|Three-dimensional structures of efferent and caput epididymal ducts in humansヒト精巣輸出管・上体管の三次元構造|Possibility of testicular MRI as a predictive tool for spermatogenesis in patients with male infertility男性不妊症患者における精子形成能予測ツールとしての精巣MRIの可能性|Effects of androgen regulation on the immune microenvironment of the prostateアンドロゲン制御による前立腺微小免疫環境への影響|Involvement of nutcracker syndrome in adolescent varicocele testis精索静脈瘤とナットクラッカー症候群の関連についての検討|Elucidation of physiological function of human seminal vesicle smooth muscleヒト精嚢平滑筋の生理学的機能の解明

AOP-08

総会賞ポスター 08
アンドロロジー・不妊・性機能

TakashiYoshioka{YOSHIOKATAKASHI}|TaroIguchi{IGUCHITARO}|ShimpeiYamashita{YAMASHITASHIMPEI}|KazumiTaguchi{TAGUCHIKAZUMI}____ShinichiSakamoto{SAKAMOTOSHINICHI}|RyosukeAndo{ANDORYOSUKE}____AtsushiOkada{OKADAATSUSHI}|ShinichiSakamoto{SAKAMOTOSHINICHI}|KatsuhitoMiyazawa{MIYAZAWAKATSUHITO}|ZenkokuekigakucyosaiinJus-8CommitteeMember{JUS-8COMMITTEEMEMBERZENKOKUEKIGAKUCYOSAIIN}|YasuoKohjimoto{KOHJIMOTOYASUO}|IsaoHara{HARAISAO}|TakahiroYanase{YANASETAKAHIRO}|YuyaSasaki{SASAKIYUYA}|RyosukeAndo{ANDORYOSUKE}|MihokoMaruyama{MARUYAMAMIHOKO}|TakahiroYasui{YASUITAKAHIRO}____Symposium 9Urolithiasis revealed by national epidemiological surveys____The present and future of urolithiasis through the lens of society: perspectives from epidemiology, public health, and health economics社会のレンズを通して見る尿路結石症の現在と未来: 疫学・公衆衛生・医療経済の立場から|Recent trends of urolithiasis in Japan according to epidemiological study. ~ Road to Japan Urolithiasis Survey, 8th Edition (JUS-8) ~疫学調査からわかる尿路結石 ～第8回尿路結石症全国疫学調査にむけて|The association of metabolic syndrome and urolithiasisメタボリックシンドロームと尿路結石|AI-Enhanced Prediction of Urolithiasis in the General Population: A Step Forward in establishing a new survey method人工知能を用いた尿路結石発症予測の確立に向けて:検診データからの研究例

SY9

Symposium 9
Urolithiasis revealed by national epidemiological surveys

ChiharukoUshimoto{USHIMOTOCHIHARUKO}|NaohikoAnzai{ANZAINAOHIKO}|GoAnan{ANANGO}|YutaroTanaka{TANAKAYUTARO}____YasuoKohjimoto{KOHJIMOTOYASUO}|AtsushiOkada{OKADAATSUSHI}____KenshiroKunii{KUNIIKENSHIRO}|RyokoAkai{AKAIRYOKO}|TakaoIwawaki{IWAWAKITAKAO}|KatsuhitoMiyazawa{MIYAZAWAKATSUHITO}|ShinichiSakamoto{SAKAMOTOSHINICHI}|TomohikoIchikawa{ICHIKAWATOMOHIKO}|TakuoHirose{HIROSETAKUO}|DaisukeKikuchi{KIKUCHIDAISUKE}|TakefumiMori{MORITAKEFUMI}|YoshihiroFurukawa{FURUKAWAYOSHIHIRO}|KoichiMomma{MOMMAKOICHI}|RieTajiri{TAJIRIRIE}|KazufumiTakano{TAKANOKAZUFUMI}|KazumiTaguchi{TAGUCHIKAZUMI}|HamamotoShuzo{SHUZOHAMAMOTO}|AtsushiOkada{OKADAATSUSHI}|KenjiroKohri{KOHRIKENJIRO}|TakahiroYasui{YASUITAKAHIRO}|MasashiYoshimura{YOSHIMURAMASASHI}|YusukeMori{MORIYUSUKE}|MihokoMaruyama{MARUYAMAMIHOKO}____Symposium 10【他診療科・多職種連携セッション】Beyond BoudaryーMastering treatment options based on the mechanism of formation of urinary tract stones____Oxidative stress and calcium oxalate crystal formation酸化ストレスとシュウ酸カルシウム結晶形成|Renal tubular organic anion transporters and urinary stone formation腎尿細管有機酸トランスポーターと尿路結石形成|Relationship between SGLT2 inhibition and renal stone formation from a collaborative study with NephrologySGLT2阻害と尿路結石の関係-腎臓内科との共同研究より|New insights into urinary stone treatment developed through crystal engineering結晶工学から拓く尿路結石治療の新たな展望

SY10

Symposium 10【他診療科・多職種連携セッション】
Beyond BoudaryーMastering treatment options based on the mechanism of formation of urinary tract stones

JunKamei{KAMEIJUN}|TakuyaSadahira{SADAHIRATAKUYA}|YoshikiHiyama{HIYAMAYOSHIKI}|MasahiroMatsumoto{MATSUMOTOMASAHIRO}____ShingoYamamoto{YAMAMOTOSHINGO}|KazushiTanaka{TANAKAKAZUSHI}____NaotakaNishiyama{NISHIYAMANAOTAKA}|HiroshiKitamura{KITAMURAHIROSHI}____Panel Discussion 8Now's the chance to change your regimen to prevent the infection following transrectal prostate biopsy？____Risk factors for infectious complication following prostate biopsy and recommended regimens of antimicrobial prophylaxis生検後感染症のリスクファクターと推奨される予防抗菌薬レジメン|A significance of post-prostate biopsy acute bacterial prostatitis and screening cultures using selective media生検前直腸スワブ培養の意義|Efficacy of multi-antimicrobial agent prophylaxis for transrectal prostate biopsy多剤併用療法の必要性・有用性|Treatment of infection after prostate biopsy前立生検後感染症の治療

PD8

Panel Discussion 8
Now's the chance to change your regimen to prevent the infection following transrectal prostate biopsy？

YoshikazuTogo{TOGOYOSHIKAZU}|MasaakiAkahane{AKAHANEMASAAKI}|KeiNishiyama{NISHIYAMAKEI}____KeiNishiyama{NISHIYAMAKEI}|KoichiroWada{WADAKOICHIRO}________Symposium 11【他診療科・多職種連携セッション】What is required in emergency treatment for severe infectious diseases____Antibiotic administration, urinary stent, nephrostomy抗菌薬投与、尿路ステント、腎瘻|Interventional radiology in urological infectious diseases泌尿器領域感染症におけるIVR|Three key points in the treatment of severe sepsis: evaluation, treatment, and regional systematization.重症敗血症診療における3つのポイント:評価・治療・地域システム化

SY11

Symposium 11【他診療科・多職種連携セッション】
What is required in emergency treatment for severe infectious diseases

TakahiroImanaka{IMANAKATAKAHIRO}|ReiUnno{UNNOREI}|KotaKawase{KAWASEKOTA}|MamoruHashimoto{HASHIMOTOMAMORU}|YukiHarigane{HARIGANEYUKI}|YuichiIshizuka{ISHIZUKAYUICHI}____HitomiSasaki{SASAKIHITOMI}____KentaroTakezawa{TAKEZAWAKENTARO}|HiroakiKitakaze{KITAKAZEHIROAKI}|GoTsujimura{TSUJIMURAGO}|SoheiKuribayashi{KURIBAYASHISOHEI}|NorichikaUeda{UEDANORICHIKA}|FukuharaShinichiro{SHINICHIROFUKUHARA}|NorioNonomura{NONOMURANORIO}|JonAkutagawa{AKUTAGAWAJON}|HanbingSong{SONGHANBING}|KelianaHui{HUIKELIANA}|RebeccaChen{CHENREBECCA}|JuliaPham{PHAMJULIA}|YangHeiko{HEIKOYANG}|ThomasChi{CHITHOMAS}|FranklinHuang{HUANGFRANKLIN}|TakahiroYasui{YASUITAKAHIRO}|KanakoMatsuoka{MATSUOKAKANAKO}|NobutakaShimizu{SHIMIZUNOBUTAKA}|KazutoshiFujita{FUJITAKAZUTOSHI}|AkihideHirayama{HIRAYAMAAKIHIDE}|HirotsuguUemura{UEMURAHIROTSUGU}|YoshimuraNaoki{NAOKIYOSHIMURA}|HidenoriAkaihata{AKAIHATAHIDENORI}|HirokiIwamatsu{IWAMATSUHIROKI}|TakahiroTsumori{TSUMORITAKAHIRO}|AkariHiraguri{HIRAGURIAKARI}|ImaiHitomi{HITOMIIMAI}|RyoTanji{TANJIRYO}|JunyaHata{HATAJUNYA}|YuichiSato{SATOYUICHI}|SoichiroOgawa{OGAWASOICHIRO}|MotohideUemura{UEMURAMOTOHIDE}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|YoheiSatake{SATAKEYOHEI}|ShingoKimura{KIMURASHINGO}|NaokiKawamorita{KAWAMORITANAOKI}|AkihiroIto{ITOAKIHIRO}____総会賞ポスター 09排尿障害：基礎____Effects of exercise on salt-induced nocturnal polyuria and elucidation of its mechanisms食塩誘発性夜間多尿に対する運動の効果とその機序解明|Single cell transcriptional profiles of BPH reveals a progenitor-like luminal epithelial cell state within an inflammatory microenvironmentBPH の単一細胞転写プロファイルは、炎症性微小環境内の前駆細胞様管腔上皮細胞のサブタイプを明らかにする|Development of dopamine receptor-mediated urinary continence mechanisms using a sneeze-induced rat modelくしゃみ誘発ラットモデルを用いたドパミン受容体を介した尿禁制反射の解明|Imidazoline 2 receptor activation improves lower urinary tract dysfunction induced by spinal cord injury in miceイミダゾリン2型受容体を介する薬理作用は脊髄損傷マウスの下部尿路機能障害を改善する|Brain regulatory mechanism of overactive bladder associated with vesical adaptation response to diuresis利尿適応性障害に伴う過活動膀胱の中枢神経制御機構の解明|Statin improves ischemia-induced overactive bladder in ratsラット慢性骨盤虚血モデルにおけるスタチンによる過活動膀胱改善効果

AOP-09

総会賞ポスター 09
排尿障害：基礎

－|YujiOkuno{OKUNOYUJI}|SeisukeNofuji{NOFUJISEISUKE}|TakeshiOkinami{OKINAMITAKESHI}|JunyaHata{HATAJUNYA}|AsatoOhtsubo{OHTSUBOASATO}|MasayukiShinchi{SHINCHIMASAYUKI}|NarihitoSeki{SEKINARIHITO}|MasaoKataoka{KATAOKAMASAO}|AkihisaHasegawa{HASEGAWAAKIHISA}____TakahikoMitsui{MITSUITAKAHIKO}____MasahikoShibuya{SHIBUYAMASAHIKO}|KoichiMiyazaki{MIYAZAKIKOICHI}|MasayaNakata{NAKATAMASAYA}|AtsuhikoKawabe{KAWABEATSUHIKO}|TakuNakasone{NAKASONETAKU}|SakaiNobuaki{NOBUAKISAKAI}|YusukeTsuji{TSUJIYUSUKE}|YukiKyohda{KYOHDAYUKI}|FumimasaFukuta{FUKUTAFUMIMASA}|ManabuOkada{OKADAMANABU}|RyuichiKato{KATORYUICHI}|AtsushiTakahashi{TAKAHASHIATSUSHI}|TachikiHitoshi{HITOSHITACHIKI}|NoriomiMiyao{MIYAONORIOMI}|KoheiHashimoto{HASHIMOTOKOHEI}|KoKobayashi{KOBAYASHIKO}|ToshiakiTanaka{TANAKATOSHIAKI}|NaoyaMasumori{MASUMORINAOYA}|TsubasaOhno{OHNOTSUBASA}|NobuyukiNisihikawa{NISIHIKAWANOBUYUKI}|TomoyukiKumekawa{KUMEKAWATOMOYUKI}|YukiHariigane{HARIIGANEYUKI}|KeiYaginuma{YAGINUMAKEI}|SyuntaMakabe{MAKABESYUNTA}|HitomiImai{IMAIHITOMI}|OnagiAkifumi{AKIFUMIONAGI}|RyoTanji{TANJIRYO}|SeijiHoshi{HOSHISEIJI}|YuichiSato{SATOYUICHI}|HidenoriAkaihata{AKAIHATAHIDENORI}|SoichiroOgawa{OGAWASOICHIRO}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|RyoSagawa{SAGAWARYO}|KouichiShimazaki{SHIMAZAKIKOUICHI}|KenichiSakota{SAKOTAKENICHI}|TomohiroMatsuo{MATSUOTOMOHIRO}|RyoichiImamura{IMAMURARYOICHI}|SakaiHideki{HIDEKISAKAI}|AkioHoriguchi{HORIGUCHIAKIO}|KenichiroOjima{OJIMAKENICHIRO}|YusukeHirano{HIRANOYUSUKE}|KazukiTakekawa{TAKEKAWAKAZUKI}|YoshiyukiFurukawa{FURUKAWAYOSHIYUKI}|TakahashiEiji{EIJITAKAHASHI}|JunichiAsakuma{ASAKUMAJUNICHI}|FumihiroKimura{KIMURAFUMIHIRO}|KeiichiIto{ITOKEIICHI}|YooHyonSong{SONGYOOHYON}|TakashiDejima{DEJIMATAKASHI}|HiroyukiMasaoka{MASAOKAHIROYUKI}|YoshiakiSato{SATOYOSHIAKI}|ShoutaroMaeda{MAEDASHOUTARO}|RurikoTakinami{TAKINAMIRURIKO}|JunyaHata{HATAJUNYA}|YuichiSatoh{SATOHYUICHI}|AkaihataHidenori{HIDENORIAKAIHATA}|SouichiroOgawa{OGAWASOUICHIRO}|EminaKayama{KAYAMAEMINA}|TomohikoYanagida{YANAGIDATOMOHIKO}|FusaoMurakami{MURAKAMIFUSAO}|HisashiUchida{UCHIDAHISASHI}____総会賞ポスター 10排尿障害：臨床____Withdrawn|Transcatheter arterial embolization of abnormal neovessels for refractory chronic prostatitis: a retrospective study of 57 patients慢性前立腺炎に対して経動脈的塞栓術を行なった57例の後方視的解析|Efficacy of dutasteride for patients with prostate volume of less than 30 mL- a prospective multicenter study30mL以下の前立腺に対するデュタステリドの効果 - 多施設共同前向き試験|Underweight, dementia and not being fully independent for upper body dressing are risk factors for urinary incontinence in older people低体重、認知症、上半身更衣動作の非自立は高齢者の尿失禁のリスク因子である|Usefulness of urinary complement C4 concentration as a predictive marker for treatment of benign prostatic hyperplasia前立腺肥大症治療予測マーカーとしての尿中補体C4濃度の有用性|Voiding dysfunction that developed during hospitalization improve with rehabilitation入院中に出現した排尿障害はリハビリテーションで改善する|Efficacy and safety of non-transecting excision and primary anastomosis for short bulbar urethral stricture短い球部尿道狭窄症に対するnon-transecting excision and primary anastomosis (ntEPA)の有効性と安全性|Evaluation of the effectiveness of vibegron for remaining overactive bladder symptoms after laser prostate vaporization (VAPOR trial)レーザー前立腺蒸散術後に残存する過活動膀胱症状に対するビベグロンの有用性に関する検討(VAPOR trial)|Elucidation of mechanism of the postoperative urinary incontinence induced by high-frequency current during robot-assisted total prostatectomyロボット支援前立腺全摘除術時の高周波電流による術後尿失禁発症メカニズムの解明|Cross sectional area of psoas major muscle predicts de novo OAB after robot-assisted radical prostatectomy腸腰筋の断面積はロボット支援前立腺全摘除術後のde novo OABを予測できる

AOP-10

総会賞ポスター 10
排尿障害：臨床

TomoakiYamanoi{YAMANOITOMOAKI}|TomoakiIwai{IWAITOMOAKI}|YouichiKakuta{KAKUTAYOUICHI}|KouheiNishikawa{NISHIKAWAKOUHEI}____HitomiSasaki{SASAKIHITOMI}|MotooAraki{ARAKIMOTOO}____MotooAraki{ARAKIMOTOO}|ShingoNishimura{NISHIMURASHINGO}|TakanoriSekito{SEKITOTAKANORI}|KasumiYoshinaga{YOSHINAGAKASUMI}|YusukeTominaga{TOMINAGAYUSUKE}|SadahiraTakuya{TAKUYASADAHIRA}|SatoshiKatayama{KATAYAMASATOSHI}|TakehiroIwata{IWATATAKEHIRO}|KensukeBekku{BEKKUKENSUKE}|KoheiEdamura{EDAMURAKOHEI}|TomokoKobayashi{KOBAYASHITOMOKO}|YasuyukiKobayashi{KOBAYASHIYASUYUKI}|KazuyaKabei{KABEIKAZUYA}|YuichiMachida{MACHIDAYUICHI}|JunjiUchida{UCHIDAJUNJI}|SoichiMatsumura{MATSUMURASOICHI}|ShotaFukae{FUKAESHOTA}|RyoTanaka{TANAKARYO}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KazuakiYamanaka{YAMANAKAKAZUAKI}|NonomuraNorio{NORIONONOMURA}|RyotaIkadai{IKADAIRYOTA}|YushiroTakeuchi{TAKEUCHIYUSHIRO}|SyunsukeOwa{OWASYUNSUKE}|TaketomoNishikawa{NISHIKAWATAKETOMO}|MomokoKato{KATOMOMOKO}|HigashiShinichiro{SHINICHIROHIGASHI}|TakeshiSasaki{SASAKITAKESHI}|SatoruMasui{MASUISATORU}|TakahiroInoue{INOUETAKAHIRO}____Symposium 12【日本臨床腎移植学会教育セミナー】New Therapeutic Developments for Donor-Specific Antibodies and Antibody-Associated Rejection____Current status of antibody-mediated rejection in kidney transplantation抗体関連型拒絶反応に対する現状|Efforts toward living donor kidney transplantation with pre-formed anti-donor specific antibodies at Osaka Metropolitan University大阪公立大学におけるドナー特異的抗体陽性症例に対する生体腎移植の取り組み|Management of Antibody-Mediated Rejection in kidney transplantation at Osaka University: Current Status and Novel Approaches大阪大学での腎移植における抗体関連型拒絶反応に対する取り組み:現状と新たな試み|Current Status of Chronic Antibody-associated Rejection after Kidney Transplantation in Our Institution当科における慢性抗体関連型拒絶反応の現状

SY12

Symposium 12【日本臨床腎移植学会教育セミナー】
New Therapeutic Developments for Donor-Specific Antibodies and Antibody-Associated Rejection

*日本臨床腎移植学会腎移植専門医更新単位

矢西正明{やにしまさあきYANISHIMASAAKI}|磯貝和也{いそがいかずやISOGAIKAZUYA}|松沢良太{まつざわりょうたMATSUZAWARYOTA}|古谷順也{ふるたにじゅんやFURUTANIJUNYA}|村上穣{むらかみみのるMURAKAMIMINORU}____齋藤和英{さいとうかずひでSAITOKAZUHIDE}|今村亮一{いまむらりょういちIMAMURARYOICHI}____松下純{まつしたじゅんMATSUSHITAJYUN}|小糸悠也{こいとゆうやKOITOYUYA}|木下秀文{きのしたひでふみKINOSHITAHIDEFUMI}|青木愛{あおきあいAOKIAI}|蘆田彩{あしだあやASHIDAAYA}|外山聡{とやまあきらTOYAMAAKIRA}|齋藤和英{さいとうかずひでSAITOKAZUHIDE}|浦添由麻{うらぞえゆまURAZOEYUMA}|高島美和{たかしまみわTAKASHIMAMIWA}|倉田博基{くらたひろきKURATAHIROKI}|望月保志{もちづきやすしMOCHIZUKIYASUSHI}|今村亮一{いまむらりょういちIMAMURARYOICHI}|石田英樹{いしだひできISHIDAHIDEKI}____Workshop 1【日本語セッション】【他診療科・多職種セッション】多職種連携による腎移植後マネージメント____多職種連携による腎移植マネージメント～泌尿器科医の立場から～Kidney transplant management through multidisciplinary collaboration ~ from the perspective of a urologist ~|臨床薬剤師の立場からPharmaceutical care for renal transplantation patients by clinical pharmacists|腎臓リハビリテーションの展開:理学療法士の立場からAdvancing Renal Rehabilitation: Perspectives from a Physiotherapist|管理栄養士の立場から～移植腎を長持ちさせる食生活を継続するには～From a Registered Dietitian's Perspective - How to maintain a diet that prolongs the life of a transplanted kidney.|腎臓内科医および腎移植レシピエントの立場からFrom the perspective of both a nephrologist and a kidney transplant recipient

WS1

Workshop 1【日本語セッション】【他診療科・多職種セッション】
多職種連携による腎移植後マネージメント

NaotoTanaka{TANAKANAOTO}|KazuyoshiNakao{NAKAOKAZUYOSHI}|TomokiOkada{OKADATOMOKI}|MasahikoIsogai{ISOGAIMASAHIKO}|ShinsakuTasaka{TASAKASHINSAKU}|NaokiFujita{FUJITANAOKI}|RyosukeChaya{CHAYARYOSUKE}|TatsuyaHattori{HATTORITATSUYA}|YumaWaseda{WASEDAYUMA}|DaiKoguchi{KOGUCHIDAI}____KoichiroWada{WADAKOICHIRO}____CarloJose{JOSECARLO}|DaikiKatsura{KATSURADAIKI}|MasaichiroFujita{FUJITAMASAICHIRO}|FukashiYamamichi{YAMAMICHIFUKASHI}|TakaakiInoue{INOUETAKAAKI}|TakashiYoshida{YOSHIDATAKASHI}|TakahiroNakamoto{NAKAMOTOTAKAHIRO}|KentaTakayasu{TAKAYASUKENTA}|TakaoMishima{MISHIMATAKAO}|HidefumiKinoshita{KINOSHITAHIDEFUMI}|AtsushiOkada{OKADAATSUSHI}|TatsuyaHattori{HATTORITATSUYA}|RyosukeChaya{CHAYARYOSUKE}|KengoKawase{KAWASEKENGO}|ReiUnno{UNNOREI}|FujiiYasuhiro{YASUHIROFUJII}|KazumiTaguchi{TAGUCHIKAZUMI}|ShuzoHamamoto{HAMAMOTOSHUZO}|RyosukeAndo{ANDORYOSUKE}|IsseiShimada{SHIMADAISSEI}|TamihideMatsunaga{MATSUNAGATAMIHIDE}|TakahiroYasui{YASUITAKAHIRO}|KoeiTorii{TORIIKOEI}|YasuhitoSue{SUEYASUHITO}|TomokiOkada{OKADATOMOKI}|ChayaRyosuke{RYOSUKECHAYA}|YasuhikoIto{ITOYASUHIKO}|MikioIkeda{IKEDAMIKIO}|RyuheiKanaoka{KANAOKARYUHEI}|MutsuoHayashi{HAYASHIMUTSUO}|YukiKohada{KOHADAYUKI}|TohruYoneyama{YONEYAMATOHRU}|YukiTobisawa{TOBISAWAYUKI}|MasakiMomota{MOMOTAMASAKI}|OsamuSoma{SOMAOSAMU}|DaisukeNoro{NORODAISUKE}|YoneyamaTakahiro{TAKAHIROYONEYAMA}|YasuhiroHashimoto{HASHIMOTOYASUHIRO}|ChikaraOhyama{OHYAMACHIKARA}|ShingoHatakeyama{HATAKEYAMASHINGO}|TakahiroYanase{YANASETAKAHIRO}|KawaseKengo{KENGOKAWASE}|YukinoriOkada{OKADAYUKINORI}|UnnoRei{REIUNNO}|RyosukueAndo{ANDORYOSUKUE}|RikoIkeda{IKEDARIKO}|ShunyaMatsumoto{MATSUMOTOSHUNYA}|KasumiYoshitomi{YOSHITOMIKASUMI}|BoFan{FANBO}|MasakiKobayashi{KOBAYASHIMASAKI}|FujiwaraMotohiro{MOTOHIROFUJIWARA}|YukiNakamura{NAKAMURAYUKI}|YudaiIshikawa{ISHIKAWAYUDAI}|ShoheiFukuda{FUKUDASHOHEI}|HajimeTanaka{TANAKAHAJIME}|SoichiroYoshida{YOSHIDASOICHIRO}|YasuhisaFujii{FUJIIYASUHISA}|HideyasuTsumura{TSUMURAHIDEYASU}|Ken-IchiTabata{TABATAKEN-ICHI}|TakehumiSatoh{SATOHTAKEHUMI}|MasaomiIkeda{IKEDAMASAOMI}|SoichiroShimura{SHIMURASOICHIRO}|MoriKohei{KOHEIMORI}|KazumasaMatsumoto{MATSUMOTOKAZUMASA}|MasatsuguIwamura{IWAMURAMASATSUGU}____総会賞ポスター 11感染症・尿路結石症____Intrarenal pressure assessment using LithoVue Elite®; in porcine kidney modelsLithoVue Elite®を用いた豚モデルでの腎盂内圧に関する検討|Comparison of efficacy of pulsed thulium YAG laser versus holmium YAG laser on dusting lithotripsy, analysis using an optical motion capture systemダスティング結石破砕におけるパルス・ツリウム・ヤグレーザーとホルミウム・ヤグレーザーの有効性の比較、光モーションキャプチャーシステムを用いた解析|Establishment of phagocytosis model of calcium oxalate monohydrate crystals using human induced pluripotent stem cell-derived macrophagesヒトiPS細胞由来マクロファージを用いたCOM結晶貪食モデルの確立|Development of a new kidney stone treatment mediated by gut microbiota腸内細菌を利用した新たな腎結石治療の開発|Usefulness of the Modified 5-Items Frailty Index as a Predictor of Treatment Outcomes and Perioperative Complications of Transurethral LithotripsyTULにおける治療結果と周術期合併症の予測因子としてのModified 5-Items Frailty Indexの有用性|Protective role of serum immunoglobulin N-glycans in endothelial glycocalyx injury in urological sepsis敗血症性尿路感染症患者における血清免疫グロブリンN型糖鎖の血管内皮グリコカリックス保護効果|Cross-species multi-omics analysis between human GWAS and a mouse model for urolithiasis reveals novel clinically relevant renal molecules尿路結石症ヒトGWASと結石マウスモデルの種横断的統合オミクス解析は新規尿路結石関連遺伝子を同定する|Osteopontin inhibits macrophage crystal adhesion and activates inflammatory pathways: an in vitro functional analysisオステオポンチンはマクロファージの結晶接着を抑制し、炎症経路を活性化させる: in vitroでの機能解析。|Optimal timing of surgical intervention after diagnosis of upper urinary tract stone in terms of renal function protection腎機能保護の観点からみた上部尿路結石症診断後の外科的治療介入の最適なタイミング|Impact of combination strategy of rectal swab culture with amikacin for levofloxacin-resistant Escherichia coli in transrectal ultrasound-guided prostate biopsy経直腸的前立腺生検における直腸スワブ培養に基づいたレボフロキサシン耐性大腸菌に対するアミカシン予防投与の有用性

AOP-11

総会賞ポスター 11
感染症・尿路結石症

RyoTanaka{TANAKARYO}|JunTakahashi{TAKAHASHIJUN}|SotaroKitaoka{KITAOKASOTARO}|RyuichiroSagehashi{SAGEHASHIRYUICHIRO}|MizukiHisano{HISANOMIZUKI}|SatoshiAshimine{ASHIMINESATOSHI}|TakehiroOhyama{OHYAMATAKEHIRO}____RyoichiImamura{IMAMURARYOICHI}____SoichiMatsumura{MATSUMURASOICHI}|ShotaFukae{FUKAESHOTA}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KazuakiYamanaka{YAMANAKAKAZUAKI}|YoichiKakuta{KAKUTAYOICHI}|ImamuraRyoichi{RYOICHIIMAMURA}|NorioNonomura{NONOMURANORIO}|YosukeTanaka{TANAKAYOSUKE}|YusukeSato{SATOYUSUKE}|TetsuoUshiku{USHIKUTETSUO}|HarukiKume{KUMEHARUKI}|HiroyoshiNishikawa{NISHIKAWAHIROYOSHI}|ManoHiroyuki{HIROYUKIMANO}|TadashiYoshida{YOSHIDATADASHI}|ShinyaMorita{MORITASHINYA}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|YotaYasumizu{YASUMIZUYOTA}|NobuyukiTanaka{TANAKANOBUYUKI}|TakedaToshikazu{TOSHIKAZUTAKEDA}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|TakeoKosaka{KOSAKATAKEO}|RyuichiMizuno{MIZUNORYUICHI}|HiroshiAsanuma{ASANUMAHIROSHI}|MototsuguOya{OYAMOTOTSUGU}|MitsuruSaito{SAITOMITSURU}|TakeruUrayama{URAYAMATAKERU}|MasayoshiMiura{MIURAMASAYOSHI}|ShingoHatakeyama{HATAKEYAMASHINGO}|KiyohikoHotta{HOTTAKIYOHIKO}|YamamotoRyohei{RYOHEIYAMAMOTO}|NobuhiroFujiyama{FUJIYAMANOBUHIRO}|MizukiKobayashi{KOBAYASHIMIZUKI}|TaketoshiNara{NARATAKETOSHI}|KazuyukiNumakura{NUMAKURAKAZUYUKI}|ShintaroNarita{NARITASHINTARO}|TomonoriHabuchi{HABUCHITOMONORI}|TakayaAbe{ABETAKAYA}|TomohikoMatsuura{MATSUURATOMOHIKO}|RenpeiKato{KATORENPEI}|ShigekatsuMaekawa{MAEKAWASHIGEKATSU}|MitsuguKanehira{KANEHIRAMITSUGU}|SugimuraJun{JUNSUGIMURA}|ToshikazuAbe{ABETOSHIKAZU}|WataruObara{OBARAWATARU}|MehdiTavacol{TAVACOLMEHDI}|SeanWoolen{WOOLENSEAN}|RuthGoldstein{GOLDSTEINRUTH}|Sang-MoKang{KANGSANG-MO}|AyatoItoh{ITOHAYATO}|KyokoMinamisono{MINAMISONOKYOKO}|ShouNishida{NISHIDASHOU}|DaikiIwami{IWAMIDAIKI}____総会賞ポスター 12腎不全・腎移植____Silicon-based agents ameliorate renal fibrosis induced by urinary tract obstruction via suppressing oxidative stress and complement activityシリコンは酸化ストレスと補体活性を抑制し、腎後性腎不全による線維化を改善する|Spatial immunogenomic analysis of oncogenic process in acquired cystic disease of the kidney in long-term dialysis patients空間的免疫ゲノム解析による長期透析患者における後天性嚢胞腎の発がん機構の解明|Inhalation of hydrogen gas ameliorates short and long-term renal ischemia-reperfusion injury in a rat model水素ガス吸入はラット腎虚血再灌流障害モデルにおいて短期および長期的に改善させる|Association between BK polyomavirus nephropathy and preoperative antibody titer against BK polyomavirus生体腎移植における移植前抗体価によるBKポリオーマウィルス関連腎症のリスク評価の検討|The utility of Indoxyl sulfate as a biomarker for early detection of CKD健常人におけるインドキシル硫酸濃度に関する検討|Ultrasound usage for detection of early surgical complications requiring reoperation after kidney transplantation腎移植後の再手術を要する術後早期合併症診断における超音波検査の意義|A study of clinical outcomes in kidney transplant patients under preoperative antithrombotic medication術前抗血栓薬内服下の腎移植症例の検討

AOP-12

総会賞ポスター 12
腎不全・腎移植

KojiShiraishi{SHIRAISHIKOJI}|ReikoHorikawa{HORIKAWAREIKO}|NorikoMakita{MAKITANORIKO}|YasushiYumura{YUMURAYASUSHI}____KoichiNagao{NAGAOKOICHI}|KojiShiraishi{SHIRAISHIKOJI}________Symposium 13【他診療科・多職種連携セッション】Male hypogonadism as a transition medicine：revisited____Male hypogonadism as a transition medicine: Overview移行期医療としての男性性腺機能低下症:Overview|Division of Endocrinology and Metabolism, National Center for Child Health and Development|Male Hypogonadism from the Perspective of an Endocrinologist内分泌内科における男性性腺機能低下症|Examination of cases of decreased serum testosterone after completion of Micro-TESEMicro-TESE終了後の血清テストステロン低下症例の検討

SY13

Symposium 13【他診療科・多職種連携セッション】
Male hypogonadism as a transition medicine：revisited

YukoAkehi{AKEHIYUKO}|KoKobayashi{KOBAYASHIKO}|HisamitsuIde{IDEHISAMITSU}|HisanoriTaniguchi{TANIGUCHIHISANORI}____AkiraTsujimura{TSUJIMURAAKIRA}|ShinichiroFukuhara{FUKUHARASHINICHIRO}____ShigeoHorie{HORIESHIGEO}____Symposium 14【他診療科・多職種連携セッション】How are the levels of testosterone interpreted in the management of LOH syndrome?____Fractionation of testosterone and its physiological effectsテストステロンの分画とそれぞれの生理作用|Relationship between the levels of testosterone and clinical symptomsテストステロン値と症状の関連について|Significance of testosterone levels for LOH treatmentLOH治療に対するテストステロン値の意義|A study of testosterone levels and the efficacy of testosterone replacement therapy in patients who visited specialized hypogonadism outpatient clinic.男性更年期外来を受診した患者のテストステロン値とテストステロン補充療法の効果に関する検討

SY14

Symposium 14【他診療科・多職種連携セッション】
How are the levels of testosterone interpreted in the management of LOH syndrome?

SayaIto{ITOSAYA}|NobuhikoShimizu{SHIMIZUNOBUHIKO}|KyoheiHakozaki{HAKOZAKIKYOHEI}|HajimeFukushima{FUKUSHIMAHAJIME}|MikiNaito{NAITOMIKI}|ToruSugihara{SUGIHARATORU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|HiroshiYaegashi{YAEGASHIHIROSHI}____TsukasaIgawa{IGAWATSUKASA}____TakuNaiki{NAIKITAKU}|MariaAoki{AOKIMARIA}|ToshiharuMorikawa{MORIKAWATOSHIHARU}|MasakazuGonda{GONDAMASAKAZU}|TakashiNagai{NAGAITAKASHI}|EtaniToshiki{TOSHIKIETANI}|NoriyasuKawai{KAWAINORIYASU}|TakahiroYasui{YASUITAKAHIRO}|ToshikazuTakeda{TAKEDATOSHIKAZU}|YoshitakeYamada{YAMADAYOSHITAKE}|KeisirouFukumoto{FUKUMOTOKEISIROU}|YotaYasumizu{YASUMIZUYOTA}|NobuyukiTanaka{TANAKANOBUYUKI}|MatsumotoKazuhiro{KAZUHIROMATSUMOTO}|ShinyaMorita{MORITASHINYA}|TakeoKosaka{KOSAKATAKEO}|RyuichiMizuno{MIZUNORYUICHI}|MasahiroJinzaki{JINZAKIMASAHIRO}|MototsuguOya{OYAMOTOTSUGU}|ToshikiMatsushima{MATSUSHIMATOSHIKI}|JunkiHarada{HARADAJUNKI}|YuichiroNakamura{NAKAMURAYUICHIRO}|KensukeMitsunari{MITSUNARIKENSUKE}|TomohiroMatsuo{MATSUOTOMOHIRO}|OhbaKojiro{KOJIROOHBA}|YasushiMochizuki{MOCHIZUKIYASUSHI}|RyoichiImamura{IMAMURARYOICHI}|KenshiroTakemoto{TAKEMOTOKENSHIRO}|ShunsukeMiyamoto{MIYAMOTOSHUNSUKE}|KoheiKobatake{KOBATAKEKOHEI}|YoheiSekino{SEKINOYOHEI}|HiroyukiKitano{KITANOHIROYUKI}|GotoKeisuke{KEISUKEGOTO}|KenichiroIkeda{IKEDAKENICHIRO}|AkihiroGoriki{GORIKIAKIHIRO}|KeisukeHieda{HIEDAKEISUKE}|TetsutaroHayashi{HAYASHITETSUTARO}|NobuyukiHinata{HINATANOBUYUKI}|HayatoYamana{YAMANAHAYATO}|HideoYasunaga{YASUNAGAHIDEO}|TetsuyaFujimura{FUJIMURATETSUYA}|AtsunariKawashima{KAWASHIMAATSUNARI}|YuIshizuya{ISHIZUYAYU}|NorichikaUeda{UEDANORICHIKA}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KentaroTakezawa{TAKEZAWAKENTARO}|YamanakaKazuaki{KAZUAKIYAMANAKA}|TaigoKato{KATOTAIGO}|KojiHatano{HATANOKOJI}|YoichiKakuta{KAKUTAYOICHI}|ShinichiroFukuhara{FUKUHARASHINICHIRO}|NorioNonomura{NONOMURANORIO}|HiroshiKanou{KANOUHIROSHI}|TomoyukiMakino{MAKINOTOMOYUKI}|RenatoNaito{NAITORENATO}|HiroakiIwamoto{IWAMOTOHIROAKI}|ShoheiKawaguchi{KAWAGUCHISHOHEI}|ShigeharaKazuyoshi{KAZUYOSHISHIGEHARA}|TakahiroNohara{NOHARATAKAHIRO}|KoujiIzumi{IZUMIKOUJI}|AtsushiMizokami{MIZOKAMIATSUSHI}____総会賞ポスター 13副腎腫瘍・後腹膜腫瘍・精巣腫瘍____A testis-specific lncRNA promotes apoptosis of testicular germ cell tumor cells via regulation of MDM2 pathway精巣特異的lncRNAによる精巣腫瘍細胞のアポトーシス制御メカニズムの解明|The clarification of the mechanism of anticancer effect in testicular tumors with lysine-specific demethylase 1 inhibitors, NCL1 and NCD38ヒストン脱メチル化酵素(LSD1)阻害剤であるNCL1とNCD38を用いた精巣腫瘍における増殖抑制メカニズムの解明|Predictors of the duration of prolonged postoperative steroid replacement for Cushing's syndromeクッシング症候群における術後ステロイド補充療法長期化の予測因子に関する検討|Prognostic predictors of hypertension outcomes after adrenalectomy in primary aldosteronism原発性アルドステロン症に対する副腎摘除術後の高血圧転帰に対する予後予測因子の検討|Treatment outcomes of robotic adrenalectomy compared to laparoscopic adrenalectomy: a propensity score-matching studyロボット支援下副腎摘出術の治療成績と傾向スコアマッチングを用いたロボット支援下手術と腹腔鏡手術の比較検討|Relationship between timing of high orchiectomy and postoperative recurrence rates among testicular tumor patients. Administrative Claims database診断から高位精巣摘除術までの期間の遅延は精巣腫瘍の術後の90日超再発率に影響を与えるか?診療報酬ビッグデータ分析|Robotic adrenalectomy contributes to shorter operation time compared with conventional laparoscopic surgeryロボット支援副腎摘除術は腹腔鏡下副腎摘除術と比較して手術時間短縮に寄与する|Clinical outcomes of patients with metastatic germ cell tumors: A single-institutional verification of treatment trends転移性胚細胞腫瘍患者の治療成績: 単一施設による治療傾向の検証

AOP-13

総会賞ポスター 13
副腎腫瘍・後腹膜腫瘍・精巣腫瘍

AtsushiIkeda{IKEDAATSUSHI}|ChikaoAoyagi{AOYAGICHIKAO}|DaisukeMatsumoto{MATSUMOTODAISUKE}|KyoTogashi{TOGASHIKYO}|ToekiYanagi{YANAGITOEKI}|YusukeKimura{KIMURAYUSUKE}|YoshiyukiFurukawa{FURUKAWAYOSHIYUKI}|NatsukiUemura{UEMURANATSUKI}|MakiKawasaki{KAWASAKIMAKI}|ShugoYajima{YAJIMASHUGO}____HiroshiAsanuma{ASANUMAHIROSHI}____RyuunosukeKounosu{KOUNOSURYUUNOSUKE}|WonjikKim{KIMWONJIK}|HirokazuNosato{NOSATOHIROKAZU}|YuuNakajima{NAKAJIMAYUU}|HiroyukiNishiyama{NISHIYAMAHIROYUKI}|TomokoTanaka{TANAKATOMOKO}|ToshihikoYanase{YANASETOSHIHIKO}|NobuhiroHaga{HAGANOBUHIRO}|ShohtaKodama{KODAMASHOHTA}|KentaroMizuno{MIZUNOKENTARO}|TakuyaSakata{SAKATATAKUYA}|HidenoriNishio{NISHIOHIDENORI}|TakahiroYasui{YASUITAKAHIRO}|YutaroHayashi{HAYASHIYUTARO}|ShingoHatakeyama{HATAKEYAMASHINGO}|NaokiFujita{FUJITANAOKI}|ToshikazuTanaka{TANAKATOSHIKAZU}|DaisukeNoro{NORODAISUKE}|OsamuSoma{SOMAOSAMU}|UemuraNozomi{NOZOMIUEMURA}|TakuroIwane{IWANETAKURO}|TeppeiOkamoto{OKAMOTOTEPPEI}|HayatoYamamoto{YAMAMOTOHAYATO}|TakahiroYoneyama{YONEYAMATAKAHIRO}|YasuhiroHashimoto{HASHIMOTOYASUHIRO}|ChikaraOyama{OYAMACHIKARA}|AkihiroKanematsu{KANEMATSUAKIHIRO}|ShinpeiYoshioka{YOSHIOKASHINPEI}|YurinaFujimori{FUJIMORIYURINA}|WataruTanaka{TANAKAWATARU}|MotohiroTaguchi{TAGUCHIMOTOHIRO}|ShinkaiYasuhiro{YASUHIROSHINKAI}|KimihiroShimatani{SHIMATANIKIMIHIRO}|YukakoShinkai{SHINKAIYUKAKO}|YusukeYamada{YAMADAYUSUKE}|ShukenGo{GOSHUKEN}|ShingoYamamoto{YAMAMOTOSHINGO}|YuriKoyama{KOYAMAYURI}|AtsushiYamanoto{YAMANOTOATSUSHI}|HiroshiYamane{YAMANEHIROSHI}|RyutaroShimizu{SHIMIZURYUTARO}|RyomaNishikawa{NISHIKAWARYOMA}|YamaguchiNoriya{NORIYAYAMAGUCHI}|ShuichiMorizane{MORIZANESHUICHI}|KatsuyaHikita{HIKITAKATSUYA}|MasashiHonda{HONDAMASASHI}|AtsushiTakenaka{TAKENAKAATSUSHI}|KentaFujiyama{FUJIYAMAKENTA}|MasayukiMuto{MUTOMASAYUKI}|TakashiBabasaki{BABASAKITAKASHI}|KojiMita{MITAKOJI}|MinikaYukimoto{YUKIMOTOMINIKA}|AkihiroMaeda{MAEDAAKIHIRO}|KeiNagase{NAGASEKEI}|SyuheiKusano{KUSANOSYUHEI}|YukaKakinoki{KAKINOKIYUKA}|KakinokiHiroaki{HIROAKIKAKINOKI}|KazumaUdo{UDOKAZUMA}|SyoheiTobu{TOBUSYOHEI}|MitsuruNoguchi{NOGUCHIMITSURU}|RyoOgasawara{OGASAWARARYO}|NaokiImasato{IMASATONAOKI}|KoheiHirose{HIROSEKOHEI}|SaoKatsumura{KATSUMURASAO}|MadokaKataoka{KATAOKAMADOKA}|NakanishiYasukazu{YASUKAZUNAKANISHI}|HitoshiMasuda{MASUDAHITOSHI}____総会賞ポスター 14小児泌尿器科・その他____Cystoscopy AI using Pre-training with Automatically Generated Images膀胱内視鏡AIへの自動生成画像を用いた事前学習の適応|Effect of implantation of NR5A1-induced steroidogenic cells derived from human adipose tissue-derived MSCs into adrenal-insufficiency model miceヒト脂肪組織由来間葉系幹細胞由来ステロイド産生細胞の副腎不全モデルマウスへの移植効果の検討|Histological examination of testes in juvenile hypothyroid rats induced by propylthiouracil幼若期甲状腺機能低下モデルラットの精巣の組織学的検討|Utility of the age discrepancy between frailty-based biological age and expected life age in patients with urological cancers泌尿器癌患者におけるフレイルに基づく生物学的年齢と期待余命との不一致についての検討|Adult-Onset neourethral stricture after childhood hypospadias repair: myth or fact尿道下裂に対する二期的下裂形成術後の成人期形成尿道狭窄発生について|Long-Term Outcomes of Health-Related Quality of Life after Robotic-Assisted Radical Prostatectomyロボット支援前立腺全摘除術後における健康関連QOLの長期成績|Urethral reconstructive surgery for synchronous urethral stricture in male男性における複数個所の狭窄に対する尿道形成術|Characteristics of biopsy guns and comparison between males and females in their selection前立腺生検針の特徴と選択時における男女別の比較|Analysis of biomarkers related to the mechanisms of pelvic organ prolapse骨盤臓器脱発症メカニズム関するバイオマ-カ-解析|Heterogeneity of postoperative delirium: patients with hallucinatory delirium have a higher preoperative cognitive function than those without hallucinations術後せん妄の異質性:幻覚性せん妄患者は幻覚を伴わないせん妄患者より術前の認知機能が高い

AOP-14

総会賞ポスター 14
小児泌尿器科・その他

TokikoNiimura{NIIMURATOKIKO}|KeitaNakane{NAKANEKEITA}|ManabuIchino{ICHINOMANABU}|YasukuniYoshimura{YOSHIMURAYASUKUNI}____TetsuyaFujimura{FUJIMURATETSUYA}|TokikoNiimura{NIIMURATOKIKO}____KouseiMiwa{MIWAKOUSEI}|ShinjiNiimura{NIIMURASHINJI}|AkashiIkehara{IKEHARAAKASHI}|KeiIha{IHAKEI}|MitsugiMatsumoto{MATSUMOTOMITSUGI}|HiroyukiIto{ITOHIROYUKI}|KazumasaMurase{MURASEKAZUMASA}|FumiyaSugino{SUGINOFUMIYA}|SanaeNamiki{NAMIKISANAE}|NaotakaKumada{KUMADANAOTAKA}|KatoDaiki{DAIKIKATO}|ManabuTakai{TAKAIMANABU}|KojiIinuma{IINUMAKOJI}|YukiTobisawa{TOBISAWAYUKI}|TakuyaKoie{KOIETAKUYA}|KenjiZennami{ZENNAMIKENJI}|HitomiSasaki{SASAKIHITOMI}|MasashiTakenaka{TAKENAKAMASASHI}|KiyoshiTakahara{TAKAHARAKIYOSHI}|RyoichiShiroki{SHIROKIRYOICHI}____Symposium 15Considering Anterior Entercele after female total cystectomy____How to avoid Anterior Enterocele after female RARC女性RARC後の前方小腸瘤をどう防ぐか|Female Pelvic Organ Prolapse after Robotic Assisted Radical Cystectomy and Urinary DiversionRARCおよび尿路変向術後の女性骨盤内臓器脱|Prevention and Treatment of Pelvic Organ Prolapse Following Robot-Assisted Radical Cystectomy at Our Institution.当施設におけるロボット支援根治的膀胱全摘術後の骨盤臓器脱の予防と治療|Transvaginal Management of Anterior Enterocele (AE) Following Robot-Assisted Radical Cystectomy (RARC) for Bladder Cancer in FemalesRARC後の骨盤臓器脱の治療

SY15

Symposium 15
Considering Anterior Entercele after female total cystectomy

ManamiKinjo{KINJOMANAMI}|YoshiyukiOkada{OKADAYOSHIYUKI}|TomokoKuwata{KUWATATOMOKO}|ShinoTokiwa{TOKIWASHINO}____MomokazuGotoh{GOTOHMOMOKAZU}|ManamiKinjo{KINJOMANAMI}____TakuyaYashima{YASHIMATAKUYA}|ChieNakagawa{NAKAGAWACHIE}|YukikoNomura{NOMURAYUKIKO}|YasukuniYoshimura{YOSHIMURAYASUKUNI}|HiromiKashihara{KASHIHARAHIROMI}|ChikakoKato{KATOCHIKAKO}|MasamiTakeyama{TAKEYAMAMASAMI}____Panel Discussion 9【他診療科・多職種連携セッション】Let's reconsider the TVM surgery !____Prolapse repair surgery for the elderly patients ~ our style in TVM surgery~高齢者に対する臓器脱修復術～私が行うTVM～|The Clinical Positioning of TVM (transvaginal mesh) during treatment in JapanTVMが可能な日本における、TVMの位置付けと工夫|TVM that I perform私が行うTVM|Our TVM Surgery私が行うTVM

PD9

Panel Discussion 9【他診療科・多職種連携セッション】
Let's reconsider the TVM surgery !

田畑健一{たばたけんいちTABATAKEN-ICHI}____－________Robotic & Laparoscopic Block (I)Hugo RASシステムの導入と機能温存RARPの実際____Hugo RASシステムの導入と機能温存RARPの実際

TH1

Robotic & Laparoscopic Block (I)
Hugo RASシステムの導入と機能温存RARPの実際

高橋正幸{たかはしまさゆきTAKAHASHIMASAYUKI}____－________Robotic & Laparoscopic Block (I)進化するロボット支援手術システム：hinotori____進化するロボット支援手術システム：hinotori

TH2

Robotic & Laparoscopic Block (I)
進化するロボット支援手術システム：hinotori

雑賀隆史{さいかたかしSAIKATAKASHI}____－________Robotic & Laparoscopic Block (I)RARP拡大摘除、拡大郭清のTips and tricks____RARP拡大摘除、拡大郭清のTips and tricks

TH3

Robotic & Laparoscopic Block (I)
RARP拡大摘除、拡大郭清のTips and tricks

槙山和秀{まきやまかずひでMAKIYAMAKAZUHIDE}____－________Robotic & Laparoscopic Block (I)RAPN切除中における解剖構造の見極め____RAPN切除中における解剖構造の見極め

TH4

Robotic & Laparoscopic Block (I)
RAPN切除中における解剖構造の見極め

坂田純{さかたじゅんSAKATAJUN}____－________Basic Block泌尿器科医に必要な消化器手術手技____泌尿器科医に必要な消化器手術手技

TH5

Basic Block
泌尿器科医に必要な消化器手術手技

三島健人{みしまたけひとMISHIMATAKEHITO}____－________Basic Block血管縫合の基本____血管縫合の基本

TH6

Basic Block
血管縫合の基本

曽束洋平{そつかようへいSOTSUKAYOHEI}____－________Basic Block深さや間隔を意識した運針の皮膚縫合____深さや間隔を意識した運針の皮膚縫合

TH7

Basic Block
深さや間隔を意識した運針の皮膚縫合

藤本清秀{ふじもときよひでFUJIMOTOKIYOHIDE}____－________Basic BlockここがポイントTUR-BT-根治性と安全性のために-____ここがポイントTUR-BT-根治性と安全性のために-

TH8

Basic Block
ここがポイントTUR-BT-根治性と安全性のために-

堀口明男{ほりぐちあきおHORIGUCHIAKIO}____－________ミートザエキスパート 1尿道外傷・尿道狭窄症・尿道形成術____尿道外傷・尿道狭窄症・尿道形成術

MTE1

ミートザエキスパート 1
尿道外傷・尿道狭窄症・尿道形成術

斎藤忠則{さいとうただのりSAITOHTADANORI}____－________ミートザエキスパート 2泌尿器科保険診療の勘所____泌尿器科保険診療の勘所

MTE2

ミートザエキスパート 2
泌尿器科保険診療の勘所

関口由紀{せきぐちゆきSEKIGUCHIYUKI}____－________ミートザエキスパート 3女性泌尿器科____女性泌尿器科

MTE3

ミートザエキスパート 3
女性泌尿器科

松田公志{まつだただしMATSUDATADASHI}____－________ミートザエキスパート 4副腎腫瘍の外科治療____副腎腫瘍の外科治療

MTE4

ミートザエキスパート 4
副腎腫瘍の外科治療

小林恭{こばやしたかしKOBAYASHITAKASHI}____－________ミートザエキスパート 5論文査読の現状と問題点____論文査読の現状と問題点

MTE5

ミートザエキスパート 5
論文査読の現状と問題点

坂井清英{さかいきよひでSAKAIKIYOHIDE}____－________ミートザエキスパート 6VUR/逆流性腎症の長期予後____VUR/逆流性腎症の長期予後

MTE6

ミートザエキスパート 6
VUR/逆流性腎症の長期予後

HayatoNishida{NISHIDAHAYATO}|SoichiMatsumura{MATSUMURASOICHI}|YukiTashiro{TASHIROYUKI}|MasatakaKawamura{KAWAMURAMASATAKA}|JunMatsushita{MATSUSHITAJUN}|ShotaFukae{FUKAESHOTA}|YoheiAbe{ABEYOHEI}|ToshihitoHirai{HIRAITOSHIHITO}|MitsuruTomizawa{TOMIZAWAMITSURU}|YuKijima{KIJIMAYU}____KojiMita{MITAKOJI}|MinekatsuTaga{TAGAMINEKATSU}____HirokiFukuhara{FUKUHARAHIROKI}|SatoshiTakai{TAKAISATOSHI}|TakaakiNawano{NAWANOTAKAAKI}|TomohiroTakehara{TAKEHARATOMOHIRO}|TakafumiNarisawa{NARISAWATAKAFUMI}|KannnoHidenori{HIDENORIKANNNO}|MayuYagi{YAGIMAYU}|AtsushiYamagishi{YAMAGISHIATSUSHI}|SeiNaito{NAITOSEI}|NorihikoTsuchiya{TSUCHIYANORIHIKO}|AkiraMaeda{MAEDAAKIRA}|ShotaFukae{FUKAESHOTA}|RyoTanaka{TANAKARYO}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KazuakiYamanaka{YAMANAKAKAZUAKI}|KakutaYoichi{YOICHIKAKUTA}|ChiyoshiToyama{TOYAMACHIYOSHI}|ShujiMiyagawa{MIYAGAWASHUJI}|NorioNonomura{NONOMURANORIO}|YojiHyodo{HYODOYOJI}|TakuyaFujimoto{FUJIMOTOTAKUYA}|TakahitoEndo{ENDOTAKAHITO}|ShunNishioka{NISHIOKASHUN}|NaokiYokoyama{YOKOYAMANAOKI}|NakanoYuzo{YUZONAKANO}|MasatoFujisawa{FUJISAWAMASATO}|AtsushiHesaka{HESAKAATSUSHI}|AyumuTaniguchi{TANIGUCHIAYUMU}|ToyofumiAbe{ABETOYOFUMI}|MakotoHirata{HIRATAMAKOTO}|SakateRyuichi{RYUICHISAKATE}|MasaruHorio{HORIOMASARU}|ShiroTakahara{TAKAHARASHIRO}|YoshitakaIsaka{ISAKAYOSHITAKA}|RyoichiImamura{IMAMURARYOICHI}|TomonoriKimura{KIMURATOMONORI}|ToshihitoHirai{HIRAITOSHIHITO}|MasaakiYanishi{YANISHIMASAAKI}|TomokazuShimizu{SHIMIZUTOMOKAZU}|HidefumiKinoshita{KINOSHITAHIDEFUMI}|ToshioTakagi{TAKAGITOSHIO}|IshidaHideki{HIDEKIISHIDA}|SoichiMatsumura{MATSUMURASOICHI}|TaigoKato{KATOTAIGO}|KiyotaniKazuma{KAZUMAKIYOTANI}|YoichiKakuta{KAKUTAYOICHI}|TomokoHonda{HONDATOMOKO}|YuOsaki{OSAKIYU}|HirohitoNaito{NAITOHIROHITO}|YoichiroTohi{TOHIYOICHIRO}|YukiMatsuoka{MATSUOKAYUKI}|KatoTakuma{TAKUMAKATO}|HomareOkazoe{OKAZOEHOMARE}|RikiyaTaoka{TAOKARIKIYA}|NobufumiUeda{UEDANOBUFUMI}|MikioSugimoto{SUGIMOTOMIKIO}|TaroBanno{BANNOTARO}|KotaIshii{ISHIIKOTA}|RikakoOoki{OOKIRIKAKO}|KoheiUnagami{UNAGAMIKOHEI}|KazuyaOmoto{OMOTOKAZUYA}|ShimizuTomokazu{TOMOKAZUSHIMIZU}|HidekiIshida{ISHIDAHIDEKI}|ShuntaHori{HORISHUNTA}|FumisatoMaesaka{MAESAKAFUMISATO}|TakutoShimizu{SHIMIZUTAKUTO}|KentaOnishi{ONISHIKENTA}|YosukeMorizawa{MORIZAWAYOSUKE}|GotohDaisuke{DAISUKEGOTOH}|YasushiNakai{NAKAIYASUSHI}|MakitoMiyake{MIYAKEMAKITO}|KazumasaTorimoto{TORIMOTOKAZUMASA}|TatsuoYoneda{YONEDATATSUO}|NobumichiTanaka{TANAKANOBUMICHI}|KiyohideFujimoto{FUJIMOTOKIYOHIDE}|KazuhiroIwadoh{IWADOHKAZUHIRO}|KenichiroMiura{MIURAKENICHIRO}|MotoshiHattori{HATTORIMOTOSHI}____ポスターディスカッション 01腎移植/基礎・臨床①____Evaluation of the preventive effect of pre-transplant live attenuated herpes zoster vaccine administration on herpes zoster after kidney transplantation移植前弱毒生水痘ワクチン接種による腎移植後帯状疱疹予防効果の検討|Suppression of innate immune-induced rejection by a membrane-type human surfactant protein-A in xenotransplantation異種移植におけるヒトサーファクタントタンパク質Aによる自然免疫拒絶反応抑制効果の検討|Association between the FCGR3A polymorphisms and clinical outcome in kidney transplant recipients after preoperative Rituximab therapy脱感作Rituximab療法後の腎移植患者におけるFCGR3A 158遺伝子多型と臨床経過|Measurement of glomerular filtration rate using endogenous d-serine clearance in living kidney transplant donors and recipients生体腎移植ドナーおよびレシピエントにおける内因性d-セリンクリアランスを用いた糸球体濾過量の測定|Validity of automatic diagnosis system for transplant kidney pathology : Comparison with diagnosis by pathologist移植腎病理AI自動診断システムの妥当性:病理医による診断との比較検討|T cell receptor repertoire in kidney transplant recipients with BK polyomavirus nephropathy腎移植後BKウイルス腎症におけるTCRレパトア解析|Evaluation of pharmacokinetic interactions of tacrolimus and fentanyl in patients receiving kidney transplantation生体腎移植術の周術期におけるタクロリムスとフェンタニルの薬物動態学的相互作用に関する検討|The potential of donor-derived-cell-free DNA for rejection diagnosis in Japanese cohort日本人コホートにおけるドナー由来セルフリーDNAの拒絶反応診断能力|Association between immunosuppressant-induced muscle loss and rectal mucus production in miceマウスにおける免疫抑制剤による筋量低下と直腸粘液産の関連|Prediction of 10-yr renal graft survival of deceased donors based on preoperative data using machine learning術前データの機械学習から算出された献腎移植の10年生着率予測式

PDA-01

ポスターディスカッション 01
腎移植/基礎・臨床①

YouichiKakuta{KAKUTAYOUICHI}|TakashiSakaguchi{SAKAGUCHITAKASHI}|RyoheiYamamoto{YAMAMOTORYOHEI}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KeitaKawashiro{KAWASHIROKEITA}|YojiHyodo{HYODOYOJI}|KiyoshiSetoguchi{SETOGUCHIKIYOSHI}|KeiichiroIzumi{IZUMIKEIICHIRO}|NaokiYokoyama{YOKOYAMANAOKI}|MasakiMuramatsu{MURAMATSUMASAKI}____TatsuoYoneda{YONEDATATSUO}|RisaKubota{KUBOTARISA}____SoichiMatsumura{MATSUMURASOICHI}|ShotaFukae{FUKAESHOTA}|RyoTanaka{TANAKARYO}|ShigeakiNakazawa{NAKAZAWASHIGEAKI}|KazuakiYamanaka{YAMANAKAKAZUAKI}|NonomuraNorio{NORIONONOMURA}|RisakoOgawa{OGAWARISAKO}|HimawariTakeyama{TAKEYAMAHIMAWARI}|WataruFukumoto{FUKUMOTOWATARU}|AkihikoMitsuke{MITSUKEAKIHIKO}|YoichiOsako{OSAKOYOICHI}|SugitaSatoshi{SATOSHISUGITA}|SatoruInoguchi{INOGUCHISATORU}|RyosukeMatsushita{MATSUSHITARYOSUKE}|HirofumiYoshino{YOSHINOHIROFUMI}|ShuichiTatarano{TATARANOSHUICHI}|YasutoshiYamada{YAMADAYASUTOSHI}|HidekiEnokida{ENOKIDAHIDEKI}|MitsuruSaito{SAITOMITSURU}|TomohikoMatsuura{MATSUURATOMOHIKO}|ShingoHatakeyama{HATAKEYAMASHINGO}|HayatoNishida{NISHIDAHAYATO}|ShinyaMaita{MAITASHINYA}|MurakamiReiichi{REIICHIMURAKAMI}|YasushiTomita{TOMITAYASUSHI}|HisaoSaito{SAITOHISAO}|NorihikoTuchiya{TUCHIYANORIHIKO}|ChikaraOyama{OYAMACHIKARA}|KouObara{OBARAKOU}|TomonoriHabuchi{HABUCHITOMONORI}|YoichiKakuta{KAKUTAYOICHI}|KiyohikoHotta{HOTTAKIYOHIKO}|TakayukiHirose{HIROSETAKAYUKI}|NaoyaIwahara{IWAHARANAOYA}|RigelSuzuki{SUZUKIRIGEL}|TakasukeFukuhara{FUKUHARATAKASUKE}|ShinoharaNobuo{NOBUOSHINOHARA}|YukiTashiro{TASHIROYUKI}|ShunNishioka{NISHIOKASHUN}|TakahitoEndo{ENDOTAKAHITO}|NaokiYokoyama{YOKOYAMANAOKI}|TakeshiIshimura{ISHIMURATAKESHI}|FujisawaMasato{MASATOFUJISAWA}|TadahikoTokumoto{TOKUMOTOTADAHIKO}|KazutakaSaito{SAITOKAZUTAKA}|MasakiMuramatsu{MURAMATSUMASAKI}|TakashiYonekura{YONEKURATAKASHI}|KentaNishikawa{NISHIKAWAKENTA}|KeiSakurabayashi{SAKURABAYASHIKEI}|MahoMaeda{MAEDAMAHO}|AokiYujiro{YUJIROAOKI}|YoshihiroItabashi{ITABASHIYOSHIHIRO}|SeiichiroShishido{SHISHIDOSEIICHIRO}|TakeshiKawamura{KAWAMURATAKESHI}|KenSakai{SAKAIKEN}|YojiHyodo{HYODOYOJI}|KojiChiba{CHIBAKOJI}|FurukawaJunya{JUNYAFURUKAWA}|JunTeishima{TEISHIMAJUN}|KatsumiShigemura{SHIGEMURAKATSUMI}|YuzoNakano{NAKANOYUZO}|MasatoFujisawa{FUJISAWAMASATO}|JunyaHashimoto{HASHIMOTOJUNYA}|HideyoOguchi{OGUCHIHIDEYO}|YonekuraTakashi{TAKASHIYONEKURA}|YujiroAoki{AOKIYUJIRO}|YukoHamasaki{HAMASAKIYUKO}____ポスターディスカッション 02腎移植/基礎・臨床②____Outcome of early steroid withdrawal therapy in living kidney transplantation生体腎移植における早期ステロイド離脱療法の成績|Evaluation of antiviral treatment and risk factors for disease severity in kidney transplant recipients with COVID-19 during omicron subvariants dominant eraオミクロン変異株流行期における腎移植後COVID-19に対する抗ウイルス療法と重症化リスク因子の評価|The Impact of Pre-operative Obesity in Kidney Transplant Recipients on Transplant Outcomes: A Study from the Michinoku Renal Transplant Network腎移植レシピエントとドナーの術前肥満が移植腎予後に与える影響―みちのく腎移植ネットワーク研究―|MAG scintigraphy accurately depicts renal function in the early postoperative periodMAG3腎シンチグラフィは移植後早期の腎機能を予測する|Clinical effect of SARS-CoV-2 vaccination in kidney transplant recipients upon SARS-CoV-2 infectionSARS-CoV-2既感染の腎移植レシピエントにおけるSARS-CoV-2ワクチンの臨床的有効性。|Incidence of chronic active antibody-mediated rejection in ABO-incompatible and HLA-incompatible kidney transplantation with protocol biopsiesプロトコール生検におけるABO不適合、HLA不適合生体腎移植の慢性活動性抗体関連型拒絶反応の発症率について|Desensitization in anti-donor specific antibody positive kidney transplant recipients抗ドナー抗体陽性患者に対する脱感作療法後の生体腎移植の短期成績|Risk factors for lymphocele after living renal transplants: a single-center experience生体腎移植における術後リンパ嚢腫の検討|Incidence of malignancy after kidney transplantation: a single-center experience当院における腎移植後発症の悪性腫瘍について|Comparisons of pathological changes in renal graft between pediatric and adult transplants小児と成人の生体腎移植における経時的組織変化の比較検討

PDA-02

ポスターディスカッション 02
腎移植/基礎・臨床②

KotaIida{IIDAKOTA}|RyutaroShimizu{SHIMIZURYUTARO}|TomohiroMatsuo{MATSUOTOMOHIRO}|MamoruHashimoto{HASHIMOTOMAMORU}|KazunoriShojo{SHOJOKAZUNORI}|MinoruKato{KATOMINORU}|YusukeYamagata{YAMAGATAYUSUKE}|TomokoHamaya{HAMAYATOMOKO}|KazuhiroTakahashi{TAKAHASHIKAZUHIRO}|AsumiNirazuka{NIRAZUKAASUMI}____NozomiHayakawa{HAYAKAWANOZOMI}|TomoyasuSano{SANOTOMOYASU}____MakitoMiyake{MIYAKEMAKITO}|NobutakaNishimura{NISHIMURANOBUTAKA}|HideyasuMatsuyama{MATSUYAMAHIDEYASU}|KazumasaKomura{KOMURAKAZUMASA}|TeruoInamoto{INAMOTOTERUO}|AzumaHaruhito{HARUHITOAZUMA}|HidekiEnokida{ENOKIDAHIDEKI}|HideoFukuhara{FUKUHARAHIDEO}|KeijiInoue{INOUEKEIJI}|TakashiYoshida{YOSHIDATAKASHI}|HidefumiKinoshita{KINOSHITAHIDEFUMI}|KiyohideFujimoto{FUJIMOTOKIYOHIDE}|ShuichiMorizane{MORIZANESHUICHI}|AtsushiYamamoto{YAMAMOTOATSUSHI}|HiroshiYamane{YAMANEHIROSHI}|RyomaNishikawa{NISHIKAWARYOMA}|YusukeKimura{KIMURAYUSUKE}|YamaguchiNoriya{NORIYAYAMAGUCHI}|KatsuyaHikita{HIKITAKATSUYA}|MasashiHonda{HONDAMASASHI}|AtsushiTakenaka{TAKENAKAATSUSHI}|ShotaKakita{KAKITASHOTA}|HiroyukiHonda{HONDAHIROYUKI}|ShintaroMori{MORISHINTARO}|KyoheiAraki{ARAKIKYOHEI}|KensukeMitsunari{MITSUNARIKENSUKE}|OhbaKojiro{KOJIROOHBA}|YasushiMochizuki{MOCHIZUKIYASUSHI}|RyoichiImamura{IMAMURARYOICHI}|DaisukeMaenosono{MAENOSONODAISUKE}|TsuyoshiMorita{MORITATSUYOSHI}|KenFukiage{FUKIAGEKEN}|HiroyukiKita{KITAHIROYUKI}|ShingoToyoda{TOYODASHINGO}|TomiyamaEisuke{EISUKETOMIYAMA}|TakashiKikuchi{KIKUCHITAKASHI}|TakafumiMinami{MINAMITAKAFUMI}|MasahiroNozawa{NOZAWAMASAHIRO}|KazuhiroYoshimura{YOSHIMURAKAZUHIRO}|KazutoshiFujita{FUJITAKAZUTOSHI}|HirotsuguUemura{UEMURAHIROTSUGU}|ToshikazuTakeda{TAKEDATOSHIKAZU}|HirotakaAkita{AKITAHIROTAKA}|TatsuyaSuzuki{SUZUKITATSUYA}|ShujiMikami{MIKAMISHUJI}|KeisukeShigeta{SHIGETAKEISUKE}|YasumizuYota{YOTAYASUMIZU}|NobuyukiTanaka{TANAKANOBUYUKI}|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|TakeoKosaka{KOSAKATAKEO}|RyuichiMizuno{MIZUNORYUICHI}|MasahiroJinzaki{JINZAKIMASAHIRO}|MototsuguOya{OYAMOTOTSUGU}|TaisukeMatsue{MATSUETAISUKE}|ShomaYamamoto{YAMAMOTOSHOMA}|NaoYukimatsu{YUKIMATSUNAO}|TaiyoOtoshi{OTOSHITAIYO}|TakeshiYamasaki{YAMASAKITAKESHI}|KuratsukuriKatsuyuki{KATSUYUKIKURATSUKURI}|JunjiUchida{UCHIDAJUNJI}|ToruHarabayashi{HARABAYASHITORU}|NorikataTakada{TAKADANORIKATA}|SatoruMaruyama{MARUYAMASATORU}|ShingoHatakeyama{HATAKEYAMASHINGO}|ToshikazuTanaka{TANAKATOSHIKAZU}|YukaKubota{KUBOTAYUKA}|NaokiFujita{FUJITANAOKI}|ShogoHosogoe{HOSOGOESHOGO}|TokuiNoriko{NORIKOTOKUI}|RyujiTabata{TABATARYUJI}|YoheiKawashima{KAWASHIMAYOHEI}|TakahiroYoneyama{YONEYAMATAKAHIRO}|YasuhiroHashimoto{HASHIMOTOYASUHIRO}|SatoshiSato{SATOSATOSHI}|ChikaraOhyama{OHYAMACHIKARA}|FumihikoUrabe{URABEFUMIHIKO}|TakafumiYanagisawa{YANAGISAWATAKAFUMI}|HirokazuAbe{ABEHIROKAZU}|TakahiroKimura{KIMURATAKAHIRO}|KeitaIzumi{IZUMIKEITA}|ErikaIkezoe{IKEZOEERIKA}|MinoruInoue{INOUEMINORU}|HirokiTsujioka{TSUJIOKAHIROKI}|KintaroHasegawa{HASEGAWAKINTARO}|OsakaAkiyoshi{AKIYOSHIOSAKA}|YukaYasuda{YASUDAYUKA}|AkinoriNakayama{NAKAYAMAAKINORI}|KiyoshiSetoguchi{SETOGUCHIKIYOSHI}|KazutakaSaito{SAITOKAZUTAKA}____ポスターディスカッション 03上部尿路癌/臨床（リスク、AC）____Site-specific risk stratification models for prognosis in UTUC patients undergoing radical nephroureterectomy: Better stratification for adjuvant therapy上部尿路上皮癌の腎尿管全摘術後部位別リスク分類について|Investigation of preoperative factors predicting pT stage in upper urinary tract urothelial carcinoma腎盂尿管癌のpTstageを予測する因子の検討|Evaluation of gamma-glutamyl transpeptidase-to-lymphocyte ratio as prognostic factors in patients with metastatic upper urinary tract cancer転移性上部尿路癌患者における予後予測因子としてのγ-GTP/リンパ球比(GLR)の検討|The impact of immunohistochemical expression of HER2, EGFR, and Nectin-4 on survival in upper urinary tract urothelial carcinoma腎盂尿管癌患者におけるHER2、EGFR、Nectin-4の予後予測因子としての役割|Predictors of clinical T2 or lower to pathological T3 tumor up-staging after radical nephroureterectomy上部尿路上皮癌の術前ステージングにおけるCTの精度評価とupstageに関わる因子の検討|Investigation of eligibility for adjuvant therapy from real-world data of patients undergoing radical cystectomy and radical nephroureterectomy根治的膀胱全摘除術および腎尿管全摘除術を受けた尿路上皮がん患者の実臨床データから術後補助療法の適格性を検討する|Treatment results of chemotherapy for upper urinary tract cancer by radiological and ureteroscopic risk criteria画像検査/尿管鏡によるリスク分類に基づいた上部尿路上皮癌に対するネオアジュバント化学療法の治療成績|The update of the neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicenter retrospective study当科における高リスク上部尿路上皮癌における術前化学療法と腫瘍学的転帰の傾向に関するアップデート|Comparative effectiveness of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma上部尿路上皮癌における術前化学療法と術後補助化学療法の有効性の比較|Algorithm for neoadjuvant chemotherapy in non-metastatic upper tract urothelial carcinoma非転移性尿路上皮癌における術前化学療法のアルゴリズム

PDA-03

ポスターディスカッション 03
上部尿路癌/臨床（リスク、AC）

KotaroSuzuki{SUZUKIKOTARO}|MinekatsuTaga{TAGAMINEKATSU}|－|KentoMorozumi{MOROZUMIKENTO}|HikariMiura{MIURAHIKARI}|TakashiUeda{UEDATAKASHI}|YutongLiu{LIUYUTONG}|ToshikiMugita{MUGITATOSHIKI}|TomoakiTerakawa{TERAKAWATOMOAKI}____KojiYoshimura{YOSHIMURAKOJI}|KaoriOzawa{OZAWAKAORI}____YusukeShiraishi{SHIRAISHIYUSUKE}|YasuyoshiOkamura{OKAMURAYASUYOSHI}|YukariBando{BANDOYUKARI}|TakutoHara{HARATAKUTO}|TomoakiTerakawa{TERAKAWATOMOAKI}|FurukawaJunya{JUNYAFURUKAWA}|JunTeishima{TEISHIMAJUN}|YuzoNakano{NAKANOYUZO}|MasatoFujisawa{FUJISAWAMASATO}|TadashiKakitsuba{KAKITSUBATADASHI}|WonseokSeo{SEOWONSEOK}|TakafumiKabuto{KABUTOTAKAFUMI}|TomochikaShinagawa{SHINAGAWATOMOCHIKA}|TadahiroKobayashi{KOBAYASHITADAHIRO}|KadonoYoshifumi{YOSHIFUMIKADONO}|NaokiTerada{TERADANAOKI}|AtsushiMiyagi{MIYAGIATSUSHI}|TomohikoIshii{ISHIITOMOHIKO}|ShingoHatakeyama{HATAKEYAMASHINGO}|TeppeiOkamoto{OKAMOTOTEPPEI}|HayatoYamamoto{YAMAMOTOHAYATO}|TakahiroYoneyama{YONEYAMATAKAHIRO}|YasuhiroHashimoto{HASHIMOTOYASUHIRO}|OhyamaChikara{CHIKARAOHYAMA}|TakumiShiraishi{SHIRAISHITAKUMI}|MasatsuguMiyashita{MIYASHITAMASATSUGU}|NaruhiroKayukawa{KAYUKAWANARUHIRO}|YusukeGabata{GABATAYUSUKE}|SatoshiSako{SAKOSATOSHI}|OguraRyota{RYOTAOGURA}|AtsukoFujihara{FUJIHARAATSUKO}|MasayosiOkumi{OKUMIMASAYOSI}|FumiyaHongo{HONGOFUMIYA}|KojiOkihara{OKIHARAKOJI}|OsamuUkimura{UKIMURAOSAMU}|KojiHatano{HATANOKOJI}|ToshikiOka{OKATOSHIKI}|MasaruTani{TANIMASARU}|YukiHoribe{HORIBEYUKI}|AkihiroYoshimura{YOSHIMURAAKIHIRO}|SassiNesrine{NESRINESASSI}|YoheiOkuda{OKUDAYOHEI}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|TaigoKato{KATOTAIGO}|AtsunaniKawashima{KAWASHIMAATSUNANI}|NorioNonomura{NONOMURANORIO}|ShojiMori{MORISHOJI}|TakeruTsunoda{TSUNODATAKERU}|ShoOkada{OKADASHO}|YoshikiTsunokawa{TSUNOKAWAYOSHIKI}|YukiIchimura{ICHIMURAYUKI}|InoueTatsuki{TATSUKIINOUE}|MadokaOmizu{OMIZUMADOKA}|MotokiYamagishi{YAMAGISHIMOTOKI}|YoshihiroNakagami{NAKAGAMIYOSHIHIRO}|YoshikoMaeda{MAEDAYOSHIKO}|KazuhikoOshinomi{OSHINOMIKAZUHIKO}|TakashiFukagai{FUKAGAITAKASHI}|YasumasaTobe{TOBEYASUMASA}|JunnichiHirata{HIRATAJUNNICHI}|HidetoUeki{UEKIHIDETO}|YusukeShiraisi{SHIRAISIYUSUKE}|NaotoWakita{WAKITANAOTO}|SuzukiKotaro{KOTAROSUZUKI}____ポスターディスカッション 04前立腺腫瘍/薬物療法①____Clinical outcomes of second-Line therapy after androgen receptor-axis-targeted treatment for metastatic hormone-sensitive prostate cancer転移性ホルモン感受性前立腺癌に対するupfront ARAT療法後の2次治療における臨床的検討|The outcome of upfront ARAT for metastatic hormone-sensitive prostate cancer in Fukui転移性去勢感受性前立腺癌に対するARAT治療成績の検討|演題取り下げ|Reducing Early Side Effects through Introduction of a Treatment Algorithm for Metastatic Hormone-Sensitive Prostate Cancer転移性ホルモン感受性前立腺癌の治療アルゴリズムの導入による早期副作用の低減|Upfront treatment of metastatic hormone-sensitive prostate cancer real world date転移性去勢感受性前立腺がんに対するUpfront治療のreal-world date|Withdrawn|Comparison of efficacy of apalutamide with that of bicalutamide for patients with metastatic hormone-sensitive prostate cancer転移性去勢感受性前立腺癌に対するアンドロゲン除去療法併用下におけるアパルタミドとビカルタミドの後ろ向き比較試験|Early PSA reduction after the initiation of Enzalutamide treatment predicts overall survival in castration resistant prostate cancer patientsエンザルタミド治療開始後早期のPSA低下は去勢抵抗性前立腺癌患者における全生存期間を予測する|Current status of sequential treatment for castration-resistant prostate cancer at Showa University hospital昭和大学病院における去勢抵抗性前立腺癌に対する逐次治療の実態に関する検討|Clinical outcome of chemotherapy in 22 prostate cancer patients with neuroendocrine differentiation治療経過中に神経内分泌転化をきたした前立腺癌22症例に対する化学療法の成績

PDA-04

ポスターディスカッション 04
前立腺腫瘍/薬物療法①

HisaeNishii{NISHIIHISAE}|MariYamasaki{YAMASAKIMARI}|TomoyukiShimabukuro{SHIMABUKUROTOMOYUKI}|MayuYagi{YAGIMAYU}|HirofumiKurose{KUROSEHIROFUMI}|ShinjiKageyama{KAGEYAMASHINJI}|YoshinagaOkumura{OKUMURAYOSHINAGA}|AsukaAshikari{ASHIKARIASUKA}|YasunoriAkashi{AKASHIYASUNORI}|YoshikoMaeda{MAEDAYOSHIKO}____KatsuyukiKuratsukuri{KURATSUKURIKATSUYUKI}|NaokoTakazawa{TAKAZAWANAOKO}____MasakiKamiya{KAMIYAMASAKI}|ShigenoriNishizaki{NISHIZAKISHIGENORI}|YasukoHirama{HIRAMAYASUKO}|TakaeYasue{YASUETAKAE}|NaokiItoh{ITOHNAOKI}|KagayaHitoshi{HITOSHIKAGAYA}|MasanoriNomiya{NOMIYAMASANORI}|EriKawada{KAWADAERI}|FumikoMiyamoto{MIYAMOTOFUMIKO}|ChinamiKamada{KAMADACHINAMI}|TomokoHashimoto{HASHIMOTOTOMOKO}|KanaFujii{FUJIIKANA}|MiyamaChiyo{CHIYOMIYAMA}|RieYamauchi{YAMAUCHIRIE}|TakakoYamashita{YAMASHITATAKAKO}|NaomiKitayama{KITAYAMANAOMI}|NaoyaKameyama{KAMEYAMANAOYA}|TakehiroSuenaga{SUENAGATAKEHIRO}|HiromiHirama{HIRAMAHIROMI}|KenichiSawamura{SAWAMURAKENICHI}|EmikoMatsumoto{MATSUMOTOEMIKO}|YuriMiyatake{MIYATAKEYURI}|KaoriTsubone{TSUBONEKAORI}|AyakoYamada{YAMADAAYAKO}|KuritaChikako{CHIKAKOKURITA}|YasuhiroKunimoto{KUNIMOTOYASUHIRO}|NorihikoTsuchiya{TSUCHIYANORIHIKO}|SeiNaito{NAITOSEI}|HayatoNishida{NISHIDAHAYATO}|HidenoriKanno{KANNOHIDENORI}|AtsushiYamagishi{YAMAGISHIATSUSHI}|NarisawaTakahumi{TAKAHUMINARISAWA}|HirokiFukuhara{FUKUHARAHIROKI}|SatoshiTakai{TAKAISATOSHI}|YukiTakai{TAKAIYUKI}|UedaKosuke{KOSUKEUEDA}|KiyoakiNishihara{NISHIHARAKIYOAKI}|MakotoNakiri{NAKIRIMAKOTO}|ShigetakaSuekane{SUEKANESHIGETAKA}|TsukasaIgawa{IGAWATSUKASA}|SouNobukawa{NOBUKAWASOU}|TomoakiIshibashi{ISHIBASHITOMOAKI}|TetsuyaTakahashi{TAKAHASHITETSUYA}|HisatoKobayashi{KOBAYASHIHISATO}|ManamiTsutsumiuchi{TSUTSUMIUCHIMANAMI}|SekiMasaya{MASAYASEKI}|SouInamura{INAMURASOU}|MinekatsuTaga{TAGAMINEKATSU}|MasatoFukushima{FUKUSHIMAMASATO}|HirotakaKosaka{KOSAKAHIROTAKA}|OsamuYokoyama{YOKOYAMAOSAMU}|NaokiTerada{TERADANAOKI}|MinoruMiyazato{MIYAZATOMINORU}|ShinKoike{KOIKESHIN}|KeiichiroIzumi{IZUMIKEIICHIRO}|RyuKimura{KIMURARYU}|ShotaroNakanishi{NAKANISHISHOTARO}|SaitoSeiichi{SEIICHISAITO}|KoujiMiki{MIKIKOUJI}|KeisukeKiba{KIBAKEISUKE}|YutakaYamamoto{YAMAMOTOYUTAKA}|AkihideHirayama{HIRAYAMAAKIHIDE}|YoshihiroNakagami{NAKAGAMIYOSHIHIRO}|KazuhikoOshinomi{OSHINOMIKAZUHIKO}|TakashiFukagai{FUKAGAITAKASHI}____ポスターディスカッション 05排尿機能・神経泌尿器科/臨床____Evaluation of the effects of intervention on lower urinary tract function and toilet-related activities by multidisciplinary urinary care team多職種チームによる下部尿路機能および排尿関連動作への介入の効果の検討|The status and issues of calculation of Comprehensive Continence Care Fee in KKR Takamatsu HospitalKKR高松病院の排尿自立支援加算・外来排尿自立指導料算定の現状と課題|The Impact of Everyday Attire on Functional Independence in Convalescent Rehabilitation Ward Persons回復期リハビリテーション病棟入棟者における日々の装いが機能的自立度に及ぼす影響|Association between overactive bladder and sarcopenia in elderly in Yamagata Cohort Study山形コホート研究における高齢者の過活動膀胱とサルコペニアとの関連|Investigating the effects of one year administration of desmopressin on sleep, patients' QOL and frailty to patients with nocturnal polyuria夜間多尿患者に対するデスモプレシン1年間の長期投与が睡眠、患者QOL、フレイルに与える影響～単一施設129例の検討～|Less than 150 minutes for HUS in male patients with nocturia, vasopressin preparations may be recommended before OAB treatment drugs男性夜間頻尿患者のHUSが150分以内ならOAB治療薬より、バゾプレッシン製剤を先行すべきかもしれない|Appropriate bedtime and regular sleep habits extends hours to the first urination after sleep onset and enhanced sleep quality就寝後夜間第一尿までの時間と睡眠の質は適正な就寝時刻と規則的な睡眠により改善する|Study of the effect of wearing elastic stockings during the day on nocturia夜間頻尿に対する日中弾性ストッキング着用による効果の検証|Evaluation of nocturnal diuresis in elderly men高齢男性における夜間利尿状態に関する検討|Outcome of treatment of interstitial cystitis with DMSO.DMSOによる間質性膀胱炎の治療成績

PDA-05

ポスターディスカッション 05
排尿機能・神経泌尿器科/臨床

KentaTakahashi{TAKAHASHIKENTA}|JunyaArima{ARIMAJUNYA}|YujiroNagata{NAGATAYUJIRO}|NaokiUchida{UCHIDANAOKI}|KeiDaizumoto{DAIZUMOTOKEI}|AkinaruYamamoto{YAMAMOTOAKINARU}|SeijiHoshi{HOSHISEIJI}|IchiroKawahara{KAWAHARAICHIRO}|MasakazuGonda{GONDAMASAKAZU}|DaichiSasaki{SASAKIDAICHI}____YasushiMiyagawa{MIYAGAWAYASUSHI}|RyutaWatanabe{WATANABERYUTA}____DaikiIkarashi{IKARASHIDAIKI}|EiShiomi{SHIOMIEI}|TomohikoMatsuura{MATSUURATOMOHIKO}|ShigekatsuMaekawa{MAEKAWASHIGEKATSU}|RenpeiKato{KATORENPEI}|KanehiraMitsugu{MITSUGUKANEHIRA}|JunSugimura{SUGIMURAJUN}|TakayaAbe{ABETAKAYA}|NaokiYanagawa{YANAGAWANAOKI}|WataruObara{OBARAWATARU}|TakuoMatsukawa{MATSUKAWATAKUO}|TakuroGoto{GOTOTAKURO}|NaohiroFujimoto{FUJIMOTONAOHIRO}|HiroshiMiyamoto{MIYAMOTOHIROSHI}|TatsuyaTakemoto{TAKEMOTOTATSUYA}|ToyomasaKatagiri{KATAGIRITOYOMASA}|MitsukiNishiyama{NISHIYAMAMITSUKI}|SakiKobayashi{KOBAYASHISAKI}|RyotaroTomida{TOMIDARYOTARO}|KusuharaYoshito{YOSHITOKUSUHARA}|TomoyaFukawa{FUKAWATOMOYA}|MasayukiTakahashi{TAKAHASHIMASAYUKI}|AtsunariKawashima{KAWASHIMAATSUNARI}|TomonoriKimura{KIMURATOMONORI}|MasashiMita{MITAMASASHI}|SassiNesrine{NESRINESASSI}|YukiHoribe{HORIBEYUKI}|TaniMasaru{MASARUTANI}|ToshihiroUemura{UEMURATOSHIHIRO}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|TaigoKato{KATOTAIGO}|KojiHatano{HATANOKOJI}|NorioNonomura{NONOMURANORIO}|TakahiroTsumori{TSUMORITAKAHIRO}|TomoyukiKumekawa{KUMEKAWATOMOYUKI}|SyuntaMakabe{MAKABESYUNTA}|KeiYaginuma{YAGINUMAKEI}|AkifumiOnagi{ONAGIAKIFUMI}|TanjiRyo{RYOTANJI}|JunyaHata{HATAJUNYA}|YuichiSato{SATOYUICHI}|HidenoriAkaihata{AKAIHATAHIDENORI}|SoichiroOgawa{OGAWASOICHIRO}|MotohideUemura{UEMURAMOTOHIDE}|YoshiyukiKojima{KOJIMAYOSHIYUKI}|NoriyasuKawai{KAWAINORIYASU}|MasahiroKaneko{KANEKOMASAHIRO}|ToshikiEtani{ETANITOSHIKI}|TakuNaiki{NAIKITAKU}|AkiraIto{ITOAKIRA}|YasuiTakahiro{TAKAHIROYASUI}|ShingoHatakeyama{HATAKEYAMASHINGO}|YukiMiura{MIURAYUKI}|KaiOzaki{OZAKIKAI}|YusukeOzaki{OZAKIYUSUKE}|TakahiroYoneyama{YONEYAMATAKAHIRO}|HashimotoYasuhiro{YASUHIROHASHIMOTO}|ChikaraOyama{OYAMACHIKARA}____ポスターディスカッション 06尿路上皮腫瘍/基礎____The Tumor Microenvironment of Upper Tract Urothelial Carcinoma Using Multiplex Fluorescence Immunohistochemistry上部尿路上皮癌における蛍光多重免疫染色を用いた腫瘍微小環境の検討|A Potential Diagnostic and Therapeutic Target: Serum Exosomal BCYRN1 in Bladder Cancer膀胱癌における血清エクソソーム中BCYRN1の診断治療的可能性|Mineralocorticoid receptor signaling prevents the development of urothelial cancer鉱質コルチコイド受容体シグナルは尿路上皮発癌を予防する|Effect of variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinoma after radical nephroureterectomy上部尿路上皮癌の日本人患者における根治的腎尿管切除術後の腫瘍学的転帰に及ぼす変異組織像の影響|Significance of DDX31 in the mechanism of invasive bladder cancer and multi-step progression筋層浸潤性膀胱癌・多段階進展機構におけるDDX31の重要性|D-alanine, a bacterial-specific metabolite, is elevated in urothelial carcinoma patients and enhances malignant potential of urothelial carcinoma cell細菌特異的代謝産物であるD-アラニンは尿路上皮癌患者で高値を示し尿路上皮癌細胞の悪性ポテンシャルを亢進する|Adhesion factor integrin beta 8 induces recurrence in non-muscle invasive bladder cancer by suppressing immune response after BCG therapy接着因子インテグリンβ8のBCG療法後免疫応答抑制による非筋肉浸潤性膀胱癌の再発機序解明|Strategies for Overcoming Drug Resistance in Advanced Bladder Cancer through Metabolic Reprogramming代謝再プログラムによる高度な膀胱がんにおける薬剤耐性克服の戦略|Basic research on magnetic hyperthermia using magnetite for bladder cancer膀胱癌に対するマグネタイトを用いた癌温熱療法の基礎研究|Is PDL1 expression induced by preoperative chemotherapy for muscle layer invasive bladder cancer?筋層浸潤性膀胱癌に対する術前化学療法によりPDL1発現は誘導されるか?

PDA-06

ポスターディスカッション 06
尿路上皮腫瘍/基礎

YukiTanaka{TANAKAYUKI}|NaotoWakita{WAKITANAOTO}|YoshiharuOkuyama{OKUYAMAYOSHIHARU}|MamoruKusaka{KUSAKAMAMORU}|SachikoHongou{HONGOUSACHIKO}|JunNagayama{NAGAYAMAJUN}|ShinsukeMizoguchi{MIZOGUCHISHINSUKE}|IsaoTaguchi{TAGUCHIISAO}|KeitaTamura{TAMURAKEITA}|EiichiroTakaoka{TAKAOKAEIICHIRO}____YasuhideMiyoshi{MIYOSHIYASUHIDE}|HayatoHoshina{HOSHINAHAYATO}____MasanaoShinohara{SHINOHARAMASANAO}|ShingoMoriyama{MORIYAMASHINGO}|RisaFukuda{FUKUDARISA}|DaisukeIgarashi{IGARASHIDAISUKE}|ReikaTanaka{TANAKAREIKA}|InuiKouhei{KOUHEIINUI}|KazueOgawa{OGAWAKAZUE}|DaijiFujimori{FUJIMORIDAIJI}|YouheiKawashima{KAWASHIMAYOUHEI}|KiichirouFujita{FUJITAKIICHIROU}|YujiKato{KATOYUJI}|SatoshiSato{SATOSATOSHI}|YasuyoshiOkamura{OKAMURAYASUYOSHI}|YukariBando{BANDOYUKARI}|KotaroSuzuki{SUZUKIKOTARO}|TakutoHara{HARATAKUTO}|TomoakiTerakawa{TERAKAWATOMOAKI}|FurukawaJyunya{JYUNYAFURUKAWA}|YuzoNakano{NAKANOYUZO}|MasatoFujisawa{FUJISAWAMASATO}|ShingoHatakeyama{HATAKEYAMASHINGO}|OsamuSoma{SOMAOSAMU}|NaokiFujita{FUJITANAOKI}|TeppeiOkamoto{OKAMOTOTEPPEI}|HayatoYamamoto{YAMAMOTOHAYATO}|YoneyamaTakahiro{TAKAHIROYONEYAMA}|YasuhiroHashimoto{HASHIMOTOYASUHIRO}|ChikaraOhyama{OHYAMACHIKARA}|AkihiroKawai{KAWAIAKIHIRO}|TakumaruIshikawa{ISHIKAWATAKUMARU}|MasakiIkeda{IKEDAMASAKI}|KenjiZennami{ZENNAMIKENJI}|KiyoshiTakahara{TAKAHARAKIYOSHI}|ShirokiRyoichi{RYOICHISHIROKI}|AiriMiki{MIKIAIRI}|AtsukiMatsukawa{MATSUKAWAATSUKI}|ShunsukeInokuchi{INOKUCHISHUNSUKE}|YousukeSekii{SEKIIYOUSUKE}|YusukeInagaki{INAGAKIYUSUKE}|YazawaKouji{KOUJIYAZAWA}|ShingoTakada{TAKADASHINGO}|KosukeTochigi{TOCHIGIKOSUKE}|YoshieKanada{KANADAYOSHIE}|KouyaMorishita{MORISHITAKOUYA}|HirotakaMatsui{MATSUIHIROTAKA}|YuriYuguchi{YUGUCHIYURI}|KondoYohei{YOHEIKONDO}|YukiSai{SAIYUKI}|ShoheiIshida{ISHIDASHOHEI}|YoshihisaMatsukawa{MATSUKAWAYOSHIHISA}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|KazuhikoYoshida{YOSHIDAKAZUHIKO}|RyoMinoda{MINODARYO}|YukiKobari{KOBARIYUKI}|HironoriFukuda{FUKUDAHIRONORI}|JunpeiIizuka{IIZUKAJUNPEI}|KondoTsunenori{TSUNENORIKONDO}|ToshioTakagi{TAKAGITOSHIO}|SyoheiMorita{MORITASYOHEI}|HiroakiSakamoto{SAKAMOTOHIROAKI}|YutaTakase{TAKASEYUTA}|HiroyukiDen{DENHIROYUKI}|MasatoOkuno{OKUNOMASATO}|KawabataGaku{GAKUKAWABATA}|KyoheiWatanabe{WATANABEKYOHEI}|YutoMatsushita{MATSUSHITAYUTO}|HiromitsuWatanabe{WATANABEHIROMITSU}|DaisukeMotoyama{MOTOYAMADAISUKE}|AtsushiOtsuka{OTSUKAATSUSHI}|MiyakeHideaki{HIDEAKIMIYAKE}|JunKamei{KAMEIJUN}|HirotoKishino{KISHINOHIROTO}|AtsushiYanase{YANASEATSUSHI}|RisakoWatanabe{WATANABERISAKO}|YutoHoshina{HOSHINAYUTO}|EndoKaori{KAORIENDO}|ToruSugihara{SUGIHARATORU}|SatoshiAndo{ANDOSATOSHI}|TetsuyaFujimura{FUJIMURATETSUYA}____ポスターディスカッション 07ロボット支援手術/膀胱腫瘍、その他____Perioperative outcomes of robot-assisted radical cystectomy (RARC) and urinary diversion (ICUD or ECUD) at our hospital当院におけるロボット支援根治的膀胱全摘術(RARC)及び尿路変向術(ECUDまたはICUD)の周術期治療成績|Treatment outcomes of robotic-assisted radical cystectomy. A multicenter retrospective studyロボット支援根治的膀胱全摘除術における治療効果と安全性についての多施設での後方視的検討|Is robot assisted radical cystectomy minimally invasive? A comparison of perioperative mortality within 90 daysロボット膀胱全摘除術は低侵襲か?周術期死亡率の検討|Perioperative outcomes of robot-assisted radical cystectomy and initiatives for early postoperative recovery当院におけるロボット支援膀胱全摘除術の周術期成績と術後早期回復を目指した取り組み|Pelvic floor disorders and measures after robot-assisted laparoscopic total cystectomy for women女性に対するロボット支援腹腔鏡下膀胱全摘除術後の骨盤底の問題と対策|The comparison of laparotomy with minimally invasive surgery in prognostic analysis of advanced muscle-invasive bladder cancer after neoadjuvant chemotherapy化学療法不応筋層浸潤性膀胱癌における開腹手術と低侵襲手術の予後比較|Comparison of Perioperative Outcomes between Robot-Assisted Laparoscopic Radical Nephroureterectomy and Laparoscopic Radical Nephroureterectomy当院におけるロボット支援腹腔鏡下腎尿管全摘術と鏡視下腎尿管全摘術の周術期成績の比較検討|Robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction: experience in our department当科におけるロボット支援腎盂形成術の検討|Comparative assessments of robot-assisted pyeloplasty in patients with ureteropelvic junctional obstruction: da Vinci versus hinotori腎盂尿管移行部狭窄症に対するロボット支援下腎盂形成術の評価:da Vinci versus hinotori|Identification of factors that influence the time required for anterior vesicovaginal wall dissection in robot-assisted sacral colpopexy (RSC)ロボット支援仙骨膣固定術における膀胱膣前壁剥離所要時間に影響する因子の同定

PDA-07

ポスターディスカッション 07
ロボット支援手術/膀胱腫瘍、その他

YuichiroOiwa{OIWAYUICHIRO}|RyoheiAzuma{AZUMARYOHEI}|TakahiroMatsumoto{MATSUMOTOTAKAHIRO}|KengoKawase{KAWASEKENGO}|KatsuhitoHori{HORIKATSUHITO}|RyoseiOkawa{OKAWARYOSEI}|MasatoYanagi{YANAGIMASATO}____YuzoNakano{NAKANOYUZO}|ShinyaInoue{INOUESHINYA}____KikuoNutahara{NUTAHARAKIKUO}|AkihiroOdagane{ODAGANEAKIHIRO}|NaoshiItaya{ITAYANAOSHI}|ShujiYoshino{YOSHINOSHUJI}|TakatsuguOkegawa{OKEGAWATAKATSUGU}|MasayukiUsami{USAMIMASAYUKI}|EmiNazato{NAZATOEMI}|NaokoOkuda{OKUDANAOKO}|DaichiKobayashi{KOBAYASHIDAICHI}|YoshihiroHashimoto{HASHIMOTOYOSHIHIRO}|IwaseYutaka{YUTAKAIWASE}|TakahiroYasui{YASUITAKAHIRO}|RyoKasahara{KASAHARARYO}|AtsushiNonaka{NONAKAATSUSHI}|MasanobuYamazaki{YAMAZAKIMASANOBU}|AkihitoHashizume{HASHIZUMEAKIHITO}|TeiichiroUeki{UEKITEIICHIRO}|ShuzoHamamoto{HAMAMOTOSHUZO}|KoeiTorii{TORIIKOEI}|MasahikoIsogai{ISOGAIMASAHIKO}|TomokiOkada{OKADATOMOKI}|RyosukeChaya{CHAYARYOSUKE}|SuginoTeruaki{TERUAKISUGINO}|ReiUnno{UNNOREI}|KazumiTaguchi{TAGUCHIKAZUMI}|TakahiroKobayashi{KOBAYASHITAKAHIRO}|AtsushiOkada{OKADAATSUSHI}|TakuyaTsuzioka{TSUZIOKATAKUYA}|ShujiKita{KITASHUJI}|TaikiHayashi{HAYASHITAIKI}|TakeshiMiyake{MIYAKETAKESHI}|KazuyosiIzumi{IZUMIKAZUYOSI}|FujiwaraAtsuko{ATSUKOFUJIWARA}|YasuoKawanishi{KAWANISHIYASUO}|MasahitoYamanaka{YAMANAKAMASAHITO}|GensukeOkazaki{OKAZAKIGENSUKE}|SousukeNiwa{NIWASOUSUKE}|TakahideTorii{TORIITAKAHIDE}|MasatakaAzemoto{AZEMOTOMASATAKA}|TaguchiKazumi{KAZUMITAGUCHI}|SyuzoHamamoto{HAMAMOTOSYUZO}|KeiichiTozawa{TOZAWAKEIICHI}|HiroyoshiKono{KONOHIROYOSHI}|AkifumiKatsu{KATSUAKIFUMI}|RyojiKimata{KIMATARYOJI}|KentaSuzumura{SUZUMURAKENTA}|TsutomuHamasaki{HAMASAKITSUTOMU}|NishimuraTaiji{TAIJINISHIMURA}|YukihiroKondo{KONDOYUKIHIRO}____ポスターディスカッション 08結石/外科的治療（内視鏡を含む）____ECIRS , one-year experience in Musashino Tokusyukai Hospital武蔵野徳洲会病院におけるECIRSの開始後1年の治療成績|Outcomes of ECIRS at our hospital当院におけるECIRSの治療成績|A study on the practicality and safety of absorbable local hemostatic agents for surgical treatment in endoscopic combined intrarenal surgeryEndoscopic combined intrarenal surgery (ECIRS)における外科治療用吸収性局所止血剤の実用性と安全性の検討|Pathological examination of ureteral strictures caused by endoscopic treatment for urinary stones結石内視鏡治療による尿管狭窄症の病理学的検討|Can ultrasound guided TUL be safely and effectively performed in obese patients?エコーガイド下TULは肥満患者においても安全に、効果的に施行できるか?|Efficacy and safety of endoscopic combined intrarenal surgery in children's large kidney stones小児上部尿路結石における内視鏡併用腎内手術の有効性と適切なデバイス選択について|Is history of obstructive pyelonephritis treated without drainage a risk factor for post-ureteroscopic lithotripsy febrile urinary tract infection?ドレナージ無く治癒した結石性腎盂腎炎の既往は経尿道的尿管結石砕石術の術後の発熱性尿路感染症のリスク因子になりうるか?

PDA-08

ポスターディスカッション 08
結石/外科的治療（内視鏡を含む）

SaoriNishijima{NISHIJIMASAORI}|TakamitsuInoue{INOUETAKAMITSU}|YuyaIwahashi{IWAHASHIYUYA}|YukimasaIde{IDEYUKIMASA}|NorichikaUeda{UEDANORICHIKA}|KentaroTakezawa{TAKEZAWAKENTARO}|KazumasaTorimoto{TORIMOTOKAZUMASA}|HiroshiNagae{NAGAEHIROSHI}|ManamiKinjo{KINJOMANAMI}____YasuhiroKaiho{KAIHOYASUHIRO}|YukiKyoda{KYODAYUKI}____KimioSugaya{SUGAYAKIMIO}|KatsumiKadekawa{KADEKAWAKATSUMI}|KatsuhiroAshitomi{ASHITOMIKATSUHIRO}|SeijiMatsumoto{MATSUMOTOSEIJI}|IchiroChihara{CHIHARAICHIRO}|HiromitsuNegoro{NEGOROHIROMITSU}|HiroyukiNishiyama{NISHIYAMAHIROYUKI}|JunMiyazaki{MIYAZAKIJUN}|YukoIshida{ISHIDAYUKO}|ShimpeiYamashita{YAMASHITASHIMPEI}|AkikoIshigami{ISHIGAMIAKIKO}|MizuhoNosaka{NOSAKAMIZUHO}|AkihikoKimura{KIMURAAKIHIKO}|KohjimotoYasuo{YASUOKOHJIMOTO}|NaohumiMukaida{MUKAIDANAOHUMI}|ToshikazuKondo{KONDOTOSHIKAZU}|IsaoHara{HARAISAO}|RioNinomiya{NINOMIYARIO}|TomokoOgawa{OGAWATOMOKO}|HajimeTakeda{TAKEDAHAJIME}|HiroakiKitakaze{KITAKAZEHIROAKI}|GoTsujimura{TSUJIMURAGO}|TakahiroImanaka{IMANAKATAKAHIRO}|SoheiKuribayashi{KURIBAYASHISOHEI}|KentaroTakezawa{TAKEZAWAKENTARO}|FukuharaShinichiro{SHINICHIROFUKUHARA}|HiroshiKiuchi{KIUCHIHIROSHI}|NorioNonomura{NONOMURANORIO}|NorichikaUeda{UEDANORICHIKA}|DaisukeGotoh{GOTOHDAISUKE}|YosukeMorizawa{MORIZAWAYOSUKE}|ShuntaHori{HORISHUNTA}|KentaOnishi{ONISHIKENTA}|MakitoMiyake{MIYAKEMAKITO}|NakaiYasushi{YASUSHINAKAI}|TakutoShimizu{SHIMIZUTAKUTO}|MitsuruTomizawa{TOMIZAWAMITSURU}|DaikiIchii{ICHIIDAIKI}|RyotaroKawashima{KAWASHIMARYOTARO}|KiyohideFujimoto{FUJIMOTOKIYOHIDE}|NaomiMaehori{MAEHORINAOMI}|RyoutaUmeda{UMEDARYOUTA}|MisakiSeki{SEKIMISAKI}|IkunoNishijima{NISHIJIMAIKUNO}|YoshinobuTomita{TOMITAYOSHINOBU}|MioSamejima{SAMEJIMAMIO}|KitamuraJyunnji{JYUNNJIKITAMURA}|KazukiMasuda{MASUDAKAZUKI}|JinpeiMiyakawa{MIYAKAWAJINPEI}|YuNakamura{NAKAMURAYU}|MitsuhiroTambo{TAMBOMITSUHIRO}|HiroshiFukuhara{FUKUHARAHIROSHI}____ポスターディスカッション 09排尿機能・神経泌尿器科/基礎、尿失禁____Characteristics of experimental autoimmune cystitis rat model and similarities with interstitial cystitis/bladder pain syndrome (IC/BPS)実験的自己免疫性膀胱炎ラットモデルの特徴と間質性膀胱炎/膀胱痛症候群(IC/BPS)との類似点|The creation of a defunctionalized atrophic bladder model in female rats using bilateral ureterovaginal anastomosis両側尿管膣吻合を用いたメスラット尿路変更による廃用性萎縮膀胱モデルの作成|Fractalkine/CX3CR1 axis contribute to renal fibrosis induced by unilateral ureteral obstruction尿管結紮モデルマウスにおけるFractalkine/CX3CR1の分子病理学的役割の解明|Verification of the results of preoperative pelvic floor muscle training instruction and preoperative instruction time for radical prostatectomy前立腺全摘除術に対する術前の骨盤底筋訓練指導の成果と術前指導時間の検証|Post-RARP urethrocystography can be useful for early detection of patients with refractory urinary incontinenceRARP術後の膀胱尿道造影は難治性尿失禁患者の早期発見に役立つ可能性がある|Outcomes of artificial urinary sphincter implantation: a single-center, retrospective study人工尿道括約筋植込み術の治療成績|The progress of patients who underwent sacral neuromodulation for overactive bladder at Nara Medical University Hospital奈良県立医科大学附属病院において過活動膀胱に対して仙骨神経刺激療法を受けた患者の経過|Comparison of vibegron and mirabegron in patients with benign prostatic hyperplasia and overactive bladder: A randomized controlled trial過活動膀胱を伴う前立腺肥大症患者に対するビベグロンとミラベグロンの無作為化群間比較試験|Comparison of mirabegron and vibegron in patients with female treatment nadir overactive bladder. randomized control study.未治療女性過活動膀胱患者に対するミラベグロンとビべグロンのランダム化比較研究

PDA-09

ポスターディスカッション 09
排尿機能・神経泌尿器科/基礎、尿失禁

ShinichiSakamoto{SAKAMOTOSHINICHI}|NamiTomiyama{TOMIYAMANAMI}|HiroakiIwamoto{IWAMOTOHIROAKI}|ShokoIshikawa{ISHIKAWASHOKO}|MichioNoda{NODAMICHIO}|－|KazuhiroMatsumoto{MATSUMOTOKAZUHIRO}|TakahiroYamaguchi{YAMAGUCHITAKAHIRO}|KatsuakiChikui{CHIKUIKATSUAKI}|WataruNakamura{NAKAMURAWATARU}|TakahiroKimura{KIMURATAKAHIRO}____AkinobuGotoh{GOTOHAKINOBU}|HiroakiIwamoto{IWAMOTOHIROAKI}____KodaiSato{SATOKODAI}|TakahiroKimura{KIMURATAKAHIRO}|NaokiTerada{TERADANAOKI}|MasaakiShiota{SHIOTAMASAAKI}|ToshihiroSaito{SAITOTOSHIHIRO}|YokomizoAkira{AKIRAYOKOMIZO}|NaokiKohei{KOHEINAOKI}|NaotakaNishiyama{NISHIYAMANAOTAKA}|TomohikoIchikawa{ICHIKAWATOMOHIKO}|HiroshiKitamura{KITAMURAHIROSHI}|KeitarouIida{IIDAKEITAROU}|TakashiNagai{NAGAITAKASHI}|ToshikiEtani{ETANITOSHIKI}|TakuNaiki{NAIKITAKU}|AkihiroNakane{NAKANEAKIHIRO}|KawaiNoriyasu{NORIYASUKAWAI}|TakahiroYasui{YASUITAKAHIRO}|TomoyukiMakino{MAKINOTOMOYUKI}|RenatoNaito{NAITORENATO}|HiroshiYaegashi{YAEGASHIHIROSHI}|ShoheiKawaguchi{KAWAGUCHISHOHEI}|KazuyoshiShigehara{SHIGEHARAKAZUYOSHI}|NoharaTakahiro{TAKAHIRONOHARA}|KoujiIzumi{IZUMIKOUJI}|AtsushiMizokami{MIZOKAMIATSUSHI}|HiroyukiYamazaki{YAMAZAKIHIROYUKI}|KazuhiroKobayashi{KOBAYASHIKAZUHIRO}|ToshikiTanikawa{TANIKAWATOSHIKI}|TakashiKawasaki{KAWASAKITAKASHI}|TaketoKawai{KAWAITAKETO}|TeneiOno{ONOTENEI}|MasahiroGoto{GOTOMASAHIRO}|HazukiInoue{INOUEHAZUKI}|TakashiUjiie{UJIIETAKASHI}|YamamineNaoki{NAOKIYAMAMINE}|ToyoshiSeito{SEITOTOYOSHI}|KazukiYanagida{YANAGIDAKAZUKI}|YuumiTokura{TOKURAYUUMI}|ItsukiYoshimura{YOSHIMURAITSUKI}|TomoyukiKaneko{KANEKOTOMOYUKI}|TohruNakagawa{NAKAGAWATOHRU}|TakeoKosaka{KOSAKATAKEO}|ToshikazuTakeda{TAKEDATOSHIKAZU}|KeishiroFukumoto{FUKUMOTOKEISHIRO}|YotaYasumizu{YASUMIZUYOTA}|NobuyukiTanaka{TANAKANOBUYUKI}|MoritaShinya{SHINYAMORITA}|RyuichiMizuno{MIZUNORYUICHI}|HiroshiAsanuma{ASANUMAHIROSHI}|MototsuguOya{OYAMOTOTSUGU}|TakayukiSumiyoshi{SUMIYOSHITAKAYUKI}|HajimeTakamori{TAKAMORIHAJIME}|TakuroSunada{SUNADATAKURO}|KaoruMurakami{MURAKAMIKAORU}|JinKono{KONOJIN}|KitaYuki{YUKIKITA}|KimihikoMasui{MASUIKIMIHIKO}|TakayukiGoto{GOTOTAKAYUKI}|RyoichiSaito{SAITORYOICHI}|TakashiKobayashi{KOBAYASHITAKASHI}|HirokiSuekane{SUEKANEHIROKI}|TasukuHiroshige{HIROSHIGETASUKU}|HirofumiKurose{KUROSEHIROFUMI}|KoutaWatanabe{WATANABEKOUTA}|HisajiKumagae{KUMAGAEHISAJI}|UedaKousuke{KOUSUKEUEDA}|KeiichiroUemura{UEMURAKEIICHIRO}|KiyoakiNishihara{NISHIHARAKIYOAKI}|MakotoNakiri{NAKIRIMAKOTO}|MitsunoriMatsuo{MATSUOMITSUNORI}|ShigetakaSuekane{SUEKANESHIGETAKA}|TsukasaIgawa{IGAWATSUKASA}|TakuhisaNukaya{NUKAYATAKUHISA}|MasashiTakenaka{TAKENAKAMASASHI}|KenjiZennami{ZENNAMIKENJI}|KiyoshiTakahara{TAKAHARAKIYOSHI}|ManabuIchino{ICHINOMANABU}|SumitomoMakoto{MAKOTOSUMITOMO}|RyoichiShiroki{SHIROKIRYOICHI}|TakumaIto{ITOTAKUMA}|ToshifumiSugitani{SUGITANITOSHIFUMI}|ArmelNgami{NGAMIARMEL}____ポスターディスカッション 10前立腺腫瘍/薬物療法②____Prognostic and predictive factor analysis using machine learning analysis in metastatic prostate cancer: the JUOG multicentre study転移性前立腺癌における機械学習解析を用いた予後予測因子解析:JUOG多施設研究|Do androgen receptor axis-targeted agents improve metastatic hormone-sensitive prostate cancer outcomes than combined androgen blockade therapy in elderly?高齢者の転移性前立腺癌に対する新規ホルモン剤はCABと比較し予後を改善するのか|Examination of treatment strategies for patients with low risk metastatic castration-sensitive prostate cancerLow risk mCSPC患者に対する治療戦略の検討|Retrospective analysis of upfront therapy for metastatic hormone sensitive prostate cancer転移性ホルモン感受性前立腺癌に対するupfront治療の検討|Comparison of upfront ARAT and CAB outcomes for metastatic castration-sensitive prostate cancer at our institution当院における転移性去勢感受性前立腺癌に対するupfront ARATとCABの成績の比較|演題取り下げ|Optimal PSA threshold for the non-metastatic castration resistant prostate cancer (nmCRPC) definition非転移性去勢抵抗性前立腺癌と診断するための適切なPSA閾値|Treatment efficacy of docetaxel in metastatic castration-resistant prostate cancer since the introduction of androgen receptor axis-targeted therapy agents転移性去勢抵抗性前立腺癌における新規アンドロゲン受容体阻害剤登場以降のドセタキセルの有効性の検討|Re-evaluating the current efficacy and optimal therapeutic positioning of docetaxel for castration-resistant prostate cancer去勢抵抗性前立腺癌に対するドセタキセルの現在の有効性と最適な治療法の検討|Initial Experience with Carboplatin-Paclitaxel Therapy for Metastatic Castration-resistant Prostate Cancer Refractory to Standard Chemotherapy標準化学療法抵抗性の転移性去勢抵抗性前立腺癌に対するカルボプラチン・パクリタキセル療法の初期治療経験|Real world treatment patterns and resource utilization among patients with metastatic hormone-sensitive prostate cancer (mHSPC): a retrospective study in Japan転移性ホルモン感受性前立腺がん患者におけるリアルワールドの治療パターンと資源利用:日本におけるレトロスペクティブスタディ

PDA-10

ポスターディスカッション 10
前立腺腫瘍/薬物療法②

TakatsuguOkegawa{OKEGAWATAKATSUGU}|YukiNakamura{NAKAMURAYUKI}|ShuheiSuzuki{SUZUKISHUHEI}|HiroyukiHonda{HONDAHIROYUKI}|TakashiNagai{NAGAITAKASHI}|ShuichiroKobayashi{KOBAYASHISHUICHIRO}|RyoFujiwara{FUJIWARARYO}|KeiichiroMori{MORIKEIICHIRO}|TakuSasaki{SASAKITAKU}____KenMorita{MORITAKEN}|AkiraOhtsu{OHTSUAKIRA}____YuNakamura{NAKAMURAYU}|MitsuhiroTambo{TAMBOMITSUHIRO}|HiroshiFukuhara{FUKUHARAHIROSHI}|TomokoYoshino{YOSHINOTOMOKO}|YudaiIshikawa{ISHIKAWAYUDAI}|MasakiKobayashi{KOBAYASHIMASAKI}|MotohiroFujiwara{FUJIWARAMOTOHIRO}|BoFan{FANBO}|ShoheiFukuda{FUKUDASHOHEI}|WasedaYuma{YUMAWASEDA}|HajimeTanaka{TANAKAHAJIME}|SoichiroYoshida{YOSHIDASOICHIRO}|YasuhisaFujii{FUJIIYASUHISA}|AtsushiIkeda{IKEDAATSUSHI}|YoshiyukiNagumo{NAGUMOYOSHIYUKI}|KousukeKojo{KOJOKOUSUKE}|TakashiKawahara{KAWAHARATAKASHI}|SatoshiNitta{NITTASATOSHI}|ChiharaIchiro{ICHIROCHIHARA}|MasanobuShiga{SHIGAMASANOBU}|ShuyaKandori{KANDORISHUYA}|AkioHoshi{HOSHIAKIO}|HiromitsuNegoro{NEGOROHIROMITSU}|HiroyukiNishiyama{NISHIYAMAHIROYUKI}|ShotaKakita{KAKITASHOTA}|ShintaroMori{MORISHINTARO}|KyoheiAraki{ARAKIKYOHEI}|KensukeMitsunari{MITSUNARIKENSUKE}|TomohiroMatsuo{MATSUOTOMOHIRO}|OhbaKojiro{KOJIROOHBA}|YasushiMochizuki{MOCHIZUKIYASUSHI}|RyoichiImamura{IMAMURARYOICHI}|TakuNaiki{NAIKITAKU}|ToshikiEtani{ETANITOSHIKI}|NobuhikoShimizu{SHIMIZUNOBUHIKO}|SosukeNiwa{NIWASOSUKE}|TomokiTakeda{TAKEDATOMOKI}|BannoRika{RIKABANNO}|HirokiKubota{KUBOTAHIROKI}|ShuzoHamamoto{HAMAMOTOSHUZO}|TakahiroYasui{YASUITAKAHIRO}|KenjiTanabe{TANABEKENJI}|TakashiTamiya{TAMIYATAKASHI}|TsuzumiKonishi{KONISHITSUZUMI}|AkiraNoro{NOROAKIRA}|NoboruNumao{NUMAONOBORU}|KosukeTakemura{TAKEMURAKOSUKE}|TomohikoOguchi{OGUCHITOMOHIKO}|ShinyaYamamoto{YAMAMOTOSHINYA}|YosukeYasuda{YASUDAYOSUKE}|YoneokaYusuke{YUSUKEYONEOKA}|TakeshiYuasa{YUASATAKESHI}|JunjiYonese{YONESEJUNJI}|TakafumiYanagisawa{YANAGISAWATAKAFUMI}|ShahrokhShariat{SHARIATSHAHROKH}|TakahiroKimura{KIMURATAKAHIRO}|HirokiIto{ITOHIROKI}|TetsuyaAoki{AOKITETSUYA}|YosukeShibata{SHIBATAYOSUKE}|TakahikoWatanabe{WATANABETAKAHIKO}|MasashiImano{IMANOMASASHI}|InoueMasahiro{MASAHIROINOUE}|DaikiUeno{UENODAIKI}|KazukiKobayashi{KOBAYASHIKAZUKI}____ポスターディスカッション 11尿路上皮腫瘍/診断・バイオマーカー____Clinical Utility of Circulating Tumor Cell and Circulating Tumor DNA Assays in Patients with Metastatic Urothelial Carcinoma, 2nd Report転移性尿路上皮がん患者に対する循環腫瘍細胞および循環腫瘍DNAアッセイによる臨床的有用性(第2報)|Can photodynamic diagnosis-guided biopsy replace bladder mapping biopsy?光力学診断(PDD)補助下生検は膀胱マッピング生検を代替可能か|Transition in diagnostic performance of PDD-assisted TURBT according to surgical experiencePDD-assisted TURBTにおける手術経験に伴う診断成績の推移|Evaluation of the systemic immunoinflammatory index as a prognostic factor in patients with metastatic bladder cancer転移性膀胱癌における予後予測因子としてのsystemic immunoinflammatory indexの検討|The Utility of the Modified Glasgow Prognostic Score as a Prognostic Predictor in Patients with Metastatic Urothelial Carcinoma転移性尿路上皮癌患者におけるModified Glasgow Prognostic Scoreの予後予測マーカーとしての有用性|Gustave Roussy Immune score after failure of first-line platinum-based chemotherapy as a prognostic indicator in patients with metastatic urothelial carcinoma転移性尿路上皮癌患者におけるプラチナ製剤での一次化学療法治療後のGRImスコアの予後予測能|Frequency and risk factor for venous thromboembolism in patients treated with neoadjuvant chemotherapy for bladder cancer膀胱癌の術前抗がん剤治療に対する静脈血栓塞栓症の発症頻度とリスク因子に関する研究|Panel of preoperative blood-based biomarkers in patients with urothelial carcinoma of the bladder treated with radical cystectomy根治的膀胱全摘術を受けた膀胱癌患者における術前バイオマーカーパネルの検討|Predictive factors for the multiple recurrence of the bladder cancer in 113 patients with intermediate-risk of bladder cancer当院における膀胱癌中リスク群113例に対する複数回再発予測因子の検討

PDA-11

ポスターディスカッション 11
尿路上皮腫瘍/診断・バイオマーカー

NoboruSakamoto{SAKAMOTONOBORU}|MasatomoKaneko{KANEKOMASATOMO}|TakashiUjiie{UJIIETAKASHI}|KeinaNozaki{NOZAKIKEINA}|MasahiroToide{TOIDEMASAHIRO}|AtsukoFujihara{FUJIHARAATSUKO}|HirokiOshiro{OSHIROHIROKI}|TaisukeMatsue{MATSUETAISUKE}|KojiroTashiro{TASHIROKOJIRO}|ShoYamagiwa{YAMAGIWASHO}|GakuYamamichi{YAMAMICHIGAKU}____MitsuhiroNarita{NARITAMITSUHIRO}|TasukuHiroshige{HIROSHIGETASUKU}____SyuuNakasuga{NAKASUGASYUU}|SyuuichirouNarita{NARITASYUUICHIROU}|KiichiHagiwara{HAGIWARAKIICHI}|ToshihiroShimizu{SHIMIZUTOSHIHIRO}|YoshiyukiKawano{KAWANOYOSHIYUKI}|TukudaFumio{FUMIOTUKUDA}|YutakaHoriguchi{HORIGUCHIYUTAKA}|ShojiKoga{KOGASHOJI}|DivyangiParalkar{PARALKARDIVYANGI}|LorenzoStorinoRamacciotti{RAMACCIOTTILORENZOSTORINO}|DonyaS.Jadvar{JADVARDONYAS.}|GiovanniE.Cacciamani{CACCIAMANIGIOVANNIE.}|MichelleHopstone{HOPSTONEMICHELLE}|DjaladatHooman{HOOMANDJALADAT}|MihirDesai{DESAIMIHIR}|MonishAron{ARONMONISH}|ManjuAron{ARONMANJU}|InderbirS.Gill{GILLINDERBIRS.}|AndreLuisAbreu{ABREUANDRELUIS}|TomoyukiKaneko{KANEKOTOMOYUKI}|HazukiInoue{INOUEHAZUKI}|TeneiOhno{OHNOTENEI}|MasahiroGoto{GOTOMASAHIRO}|NaokiYamamine{YAMAMINENAOKI}|SeitoToyoshi{TOYOSHISEITO}|KazukiYanagida{YANAGIDAKAZUKI}|MichioNoda{NODAMICHIO}|YuumiTokura{TOKURAYUUMI}|ItsukiYoshimura{YOSHIMURAITSUKI}|TaketoKawai{KAWAITAKETO}|TohruNakagawa{NAKAGAWATOHRU}|HisashiMatsushima{MATSUSHIMAHISASHI}|JiroSato{SATOJIRO}|HiyoObikane{OBIKANEHIYO}|ShunjiHasegawa{HASEGAWASHUNJI}|MaiHori{HORIMAI}|MorishigeTakeru{TAKERUMORISHIGE}|TomokoMasuda{MASUDATOMOKO}|HarukiKume{KUMEHARUKI}|MasayaIto{ITOMASAYA}|IchiroYonese{YONESEICHIRO}|HajimeKidou{KIDOUHAJIME}|TsukasaShinoda{SHINODATSUKASA}|TomonoriKanagawa{KANAGAWATOMONORI}|UneMinami{MINAMIUNE}|KenSekiya{SEKIYAKEN}|TakahikoSoma{SOMATAKAHIKO}|FumitakaKoga{KOGAFUMITAKA}|TakumiShiraishi{SHIRAISHITAKUMI}|TakashiUeda{UEDATAKASHI}|NaruhiroKayukawa{KAYUKAWANARUHIRO}|MasatsuguMiyashita{MIYASHITAMASATSUGU}|MasayoshiOkumi{OKUMIMASAYOSHI}|HongoFumiya{FUMIYAHONGO}|BuntaTokuda{TOKUDABUNTA}|KaoriYamada{YAMADAKAORI}|NorihiroAibe{AIBENORIHIRO}|OsamuUkimura{UKIMURAOSAMU}|MinoruKato{KATOMINORU}|ShomaYamamoto{YAMAMOTOSHOMA}|NaoYukimatsu{YUKIMATSUNAO}|TaiyoOtoshi{OTOSHITAIYO}|TakeshiYamasaki{YAMASAKITAKESHI}|KuratsukuriKatsuyuki{KATSUYUKIKURATSUKURI}|JunjiUchida{UCHIDAJUNJI}|MarikoHonda{HONDAMARIKO}|FumihikoUrabe{URABEFUMIHIKO}|ShojiKimura{KIMURASHOJI}|KoichiAikawa{AIKAWAKOICHI}|TakahiroKimura{KIMURATAKAHIRO}|TsuyoshiMajima{MAJIMATSUYOSHI}|TaikiMasumori{MASUMORITAIKI}|ShoichiSato{SATOSHOICHI}|HarukaKurosu{KUROSUHARUKA}|HidejiKawanishi{KAWANISHIHIDEJI}|MuramatsuTomoaki{TOMOAKIMURAMATSU}|IkuoKobayashi{KOBAYASHIIKUO}|KeishiKajikawa{KAJIKAWAKEISHI}|NaotoSassa{SASSANAOTO}|ToyonoriTsuzuki{TSUZUKITOYONORI}|TaigoKato{KATOTAIGO}|HidetatsuOutani{OUTANIHIDETATSU}|NanaeMasunaga{MASUNAGANANAE}|YoheiMiyagi{MIYAGIYOHEI}|ShoheiMyoba{MYOBASHOHEI}|IshizuyaYu{YUISHIZUYA}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|KojiHatano{HATANOKOJI}|AtsunariKawashima{KAWASHIMAATSUNARI}|KenzoShimazu{SHIMAZUKENZO}|MotohideUemura{UEMURAMOTOHIDE}|NorioNonomura{NONOMURANORIO}____ポスターディスカッション 12前立腺腫瘍/診断・マーカー①____Can PSA F/T ratio or PSAD be an aid for prostate cancer diagnosis using MRI?PSA F/T比やPSADはMRIによる前立腺癌の診断の補助になりえるか?|TransPERINEAL vs transrectal MRI/US fusion prostate biopsy: Better characterization of transPERINEAL approach confirmed by a radical prostatectomy specimen経会陰 vs 経直腸MRI/US融合標的化前立腺生検:前立腺全摘標本の評価によりわかった経会陰アプローチの優れた癌サンプリング能|Comparative analysis of MRI-targeted biopsies versus systematic biopsies in prostate biopsy evaluation: a single-center experience当院における前立腺生検の検討:MRI標的生検と系統生検の比較|The efficacy of MRI as a screening modality for detecting clinically significant prostate cancer前立腺癌検診として施行されたbiparametric MRIの有用性の検討|Hematuria-related adverse events after systematic and targeted transperineal prostate biopsy経会陰前立腺針生検後の血尿関連有害事象についての検討|Cancer board for localized prostate cancer当院における限局性前立腺癌に対するCancer board の検討|Bladder cancer detected incidentally by cystoscopy before radical prostatectomy前立腺全摘除術前の膀胱鏡検査で偶然発見された膀胱癌の検討|Initial Experience of Companion Diagnostic Test for Metastatic Castration-Resistant Prostate Cancer当院における転移性去勢抵抗性前立腺癌に対するコンパニオン診断検査の実施経験|BRCA companion diagnosis and olaparib treatment results in metastatic castration-resistant prostate cancer転移性去勢抵抗性前立腺癌におけるBRCA遺伝子検査およびオラパリブの治療成績|Examination of the usefulness of preoperative urine cytology for detecting prostate cancer with IDC-P前立腺癌IDC-P検出を目的とした術前尿細胞診の有用性の検討|GDPP is a novel tumor-agnostic blood biomarker for the diagnosis of bone metastasisGDPPは骨転移診断における癌種横断的な新規血液バイオマーカーとなる

PDA-12

ポスターディスカッション 12
前立腺腫瘍/診断・マーカー①

KaiWuYang{YANGKAIWU}|YukiHoribe{HORIBEYUKI}|－|YoichiFujii{FUJIIYOICHI}|Lien-ChingYu{YULIEN-CHING}|YushiSuhara{SUHARAYUSHI}|Chien-HsiungLo{LOCHIEN-HSIUNG}|YukoShirono{SHIRONOYUKO}|YuIshizuya{ISHIZUYAYU}____JürgenE.Gschwend{GSCHWENDJÜRGENE.}|EijiKikuchi{KIKUCHIEIJI}____Cheng-HuangShen{SHENCHENG-HUANG}|AtsunariKawashima{KAWASHIMAATSUNARI}|MasaruTani{TANIMASARU}|AkihiroYoshimura{YOSHIMURAAKIHIRO}|NesrineSassi{SASSINESRINE}|YoheiOkuda{OKUDAYOHEI}|UemuraToshihiro{TOSHIHIROUEMURA}|AkinaruYamamoto{YAMAMOTOAKINARU}|YuIshizuya{ISHIZUYAYU}|YoshiyukiYamamoto{YAMAMOTOYOSHIYUKI}|TaigoKato{KATOTAIGO}|KojiHatano{HATANOKOJI}|NorioNonomura{NONOMURANORIO}|YusukeSato{SATOYUSUKE}|NobuyukiKakiuchi{KAKIUCHINOBUYUKI}|YuichiShiraishi{SHIRAISHIYUICHI}|JunKamei{KAMEIJUN}|SatoruTaguchi{TAGUCHISATORU}|AkiyamaYoshiyuki{YOSHIYUKIAKIYAMA}|YutaYamada{YAMADAYUTA}|DaisukeYamada{YAMADADAISUKE}|SatoruMiyano{MIYANOSATORU}|SeishiOgawa{OGAWASEISHI}|HarukiKume{KUMEHARUKI}|Che-YuanHu{HUCHE-YUAN}|Wen-HorngYang{YANGWEN-HORNG}|Chien-HuiOu{OUCHIEN-HUI}|Hau-ChernJan{JANHAU-CHERN}|FumihikoUrabe{URABEFUMIHIKO}|WataruFukuokaya{FUKUOKAYAWATARU}|YuImai{IMAIYU}|KosukeIwatani{IWATANIKOSUKE}|KagenoriIto{ITOKAGENORI}|MoriKeiichiro{KEIICHIROMORI}|TakafumiYanagisawa{YANAGISAWATAKAFUMI}|ShunsukeTuzuki{TUZUKISHUNSUKE}|JunMiki{MIKIJUN}|TakahiroKimura{KIMURATAKAHIRO}|VladimirBilim{BILIMVLADIMIR}|TsutomuAnraku{ANRAKUTSUTOMU}|HirooKuroki{KUROKIHIROO}|AkiraKazama{KAZAMAAKIRA}|MasakiMurata{MURATAMASAKI}|HirumaKaede{KAEDEHIRUMA}|YoshihikoTomita{TOMITAYOSHIHIKO}|ToshihiroUemura{UEMURATOSHIHIRO}|YukiHoribe{HORIBEYUKI}|KentaroJingushi{JINGUSHIKENTARO}|LiuYutong{YUTONGLIU}|ToshikiOka{OKATOSHIKI}|KazutakeTsujikawa{TSUJIKAWAKAZUTAKE}____PD Selected 01Urothelial tumor 1____Enhancing bladder cancer immune response through Cyproheptadine-induced Natural Killer cell activation|The incidence of hyper-progressive disease of urothelial carcinoma on second line treatment当院における2次治療中にhyper-progressive diseaseを呈した尿路上皮癌の検討|演題取り下げ|Molecular pathogenesis of multifocal occurrence of upper urinary tract urothelial carcinoma上部尿路上皮癌における多中心性多発のメカニズムについての遺伝学的検討|Tumor burden score stratifies prognosis of patients with upper tract urothelial carcinoma following radical nephrouretectomy|Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from the JIKEI-YAYOI Collaborative GrouppT3上部尿路上皮癌の細分化による予後解析|Increased splenic volume following radical nephroureterectomy for upper tract urothelial carcinoma is associated with adverse post-operatively oncologic outcome|Targeting pro-survival autophagy enhanced GSK-3 beta inhibition-induced apoptosis and retarded proliferation in bladder cancer cells膀胱癌の細胞保護的オートファジーの標的化がGSK-3β阻害のもたらすアポトーシスと増殖遅延を増強する|Clinical significance of cellular fractions and genes that characterize intratumor heterogeneity in upper tract urothelial carcinoma上部尿路上皮癌の腫瘍内不均一性を特徴付ける細胞分画や遺伝子とその臨床的意義|Withdrawn

PDM-01

PD Selected 01
Urothelial tumor 1

KosukeNakano{NAKANOKOSUKE}|－|MasatomoKaneko{KANEKOMASATOMO}|ShenChengHuang{HUANGSHENCHENG}|TomohiroFukui{FUKUITOMOHIRO}|MariaAoki{AOKIMARIA}|YukariBando{BANDOYUKARI}|KazutoItou{ITOUKAZUTO}____RoderickVanDenBergh{BERGHRODERICKVANDEN}|HirojiUemura{UEMURAHIROJI}____DianeCostanzo-Garvey{COSTANZO-GARVEYDIANE}|KabhilanMohan{MOHANKABHILAN}|GrinuMathew{MATHEWGRINU}|LeahCook{COOKLEAH}|YoheiSekino{SEKINOYOHEI}|HongtaoLi{LIHONGTAO}|PhucLoiLuu{LUUPHUCLOI}|XiaojingYang{YANGXIAOJING}|AtsukoFujihara{FUJIHARAATSUKO}|IwataTsuyoshi{TSUYOSHIIWATA}|LorenzoStorinoRamacciotti{RAMACCIOTTLORENZOSTORINO}|GiovanniECacciamani{CACCIAMANIGIOVANNIE}|ManjuAron{ARONMANJU}|OsamuUkimura{UKIMURAOSAMU}|InderbirS.Gill{GILLINDERBIRS.}|GangningLiang{LIANGGANGNING}|AndreLuisAbreu{ABREUANDRELUIS}|Chiung-YaoFang{FANGCHIUNG-YAO}|Chih-ChiehChou{CHOUCHIH-CHIEH}|MeilinWang{WANGMEILIN}|ChenPei-Lain{PEI-LAINCHEN}|ChangDeching{DECHINGCHANG}|MakiFujiwara{FUJIWARAMAKI}|KensukeHikami{HIKAMIKENSUKE}|ArinobuFukunaga{FUKUNAGAARINOBU}|TakuroSunada{SUNADATAKURO}|TakayukiSumiyoshi{SUMIYOSHITAKAYUKI}|GotoTakayuki{TAKAYUKIGOTO}|RyoichiSaito{SAITORYOICHI}|TakashiKobayashi{KOBAYASHITAKASHI}|ShusukeAkamatsu{AKAMATSUSHUSUKE}|TakuNaiki{NAIKITAKU}|AyaNaiki-Ito{NAIKI-ITOAYA}|NobuhikoShimizu{SHIMIZUNOBUHIKO}|TakashiNagai{NAGAITAKASHI}|KeitaroIida{IIDAKEITARO}|HonmaHideki{HIDEKIHONMA}|NoriyasuKawai{KAWAINORIYASU}|SatoruTakahashi{TAKAHASHISATORU}|TakahiroYasui{YASUITAKAHIRO}|JunTeishima{TEISHIMAJUN}|TakutoHara{HARATAKUTO}|NaotoWakita{WAKITANAOTO}|YasuyoshiOkamura{OKAMURAYASUYOSHI}|KotaroSuzuki{SUZUKIKOTARO}|TerakawaTomoaki{TOMOAKITERAKAWA}|KeiMatsushita{MATSUSHITAKEI}|RaizoYamaguchi{YAMAGUCHIRAIZO}|YuzoNakano{NAKANOYUZO}|MasatoFujisawa{FUJISAWAMASATO}|RyoOki{OKIRYO}|TomohiroMagari{MAGARITOMOHIRO}|YosukeFuruya{FURUYAYOSUKE}|KyokoBaba{BABAKYOKO}|HaruyukiOgura{OGURAHARUYUKI}|KurosawaIsao{ISAOKUROSAWA}|YasushiKaji{KAJIYASUSHI}____PD Selected 02Prostate Cancer 1____Molecular Profiling of Bone Marrow Neutrophil Immune Response to Bone Metastatic Prostate Cancer Cells|演題取り下げ|DNA-Methylation profiles: A Novel Method to Identify Aggressive Prostate Cancer from Needle core Biopsy針生検検体のDNAメチレーション解析による高悪性前立腺癌検出の新規手法|J C Polyomavirus-like Particles Carrying Suicide Genes Effectively Inhibit Orthotopic mCRPC Tumor Growth and Metastasis in Mice|A highly-sensitive screening system to evaluate the reversibility of lineage plasticity in NEPC using a novel NEPC cell line新規NEPC細胞株を用いたNEPCにおける系統的可塑性の可逆性を評価する高感度スクリーニング系|Chemopreventive effects of rutin on prostate carcinogenesis前立腺癌に対するルチンの化学予防効果|Predictive Ability of Lesion Localization Using Real-time 3D MRI/ultrasound Fusion Prostate Biopsy in Robot-assisted Laparoscopic Prostatectomyロボット支援腹腔鏡下前立腺摘除術におけるリアルタイム3D MRI/超音波フュージョン前立腺生検を用いた病変局在の予測能|A diagnostic significance of prostate health index (phi)-MRI sequence flow in patients with PSA below 10 ng/mlPSA10 ng/ml以下におけるprostate health index (phi)-MRIシーケンスフローの診断的意義

PDM-02

PD Selected 02
Prostate Cancer 1

GoAnan{ANANGO}|Wen-ChiChen{CHENWEN-CHI}|AtsushiOkada{OKADAATSUSHI}|PeiHsinLee{LEEPEIHSIN}|ShuzoHamamoto{HAMAMOTOSHUZO}|－|YuujiKatou{KATOUYUUJI}|Shun-LinLiu{LIUSHUN-LIN}|MakotoTaguchi{TAGUCHIMAKOTO}____ClairWhelan{WHELANCLAIR}|ToshiyukiKamoto{KAMOTOTOSHIYUKI}____DaisukeKikuchi{KIKUCHIDAISUKE}|TakuoHirose{HIROSETAKUO}|TakefumiMori{MORITAKEFUMI}|Szu-JuChen{CHENSZU-JU}|Yu-ChiaChen{CHENYU-CHIA}|Chang-HaiTsai{TSAICHANG-HAI}|Fuu-JenTsai{TSAIFUU-JEN}|HiroshiTakase{TAKASEHIROSHI}|ReiUnno{UNNOREI}|KazumiTaguchi{TAGUCHIKAZUMI}|KazuhiroNiimi{NIIMIKAZUHIRO}|ShuzoHamamoto{HAMAMOTOSHUZO}|AndoRyosuke{RYOSUKEANDO}|MasahitoHirose{HIROSEMASAHITO}|TadahiroHashita{HASHITATADAHIRO}|TakahiroIwao{IWAOTAKAHIRO}|TamihideMatsunaga{MATSUNAGATAMIHIDE}|KenjiroKohri{KOHRIKENJIRO}|TakahiroYasui{YASUITAKAHIRO}|CheKangChang{CHANGCHEKANG}|ChanJungLiu{LIUCHANJUNG}|JunichiMatsuzaki{MATSUZAKIJUNICHI}|NoritakaIshito{ISHITONORITAKA}|HiroshiYokoyama{YOKOYAMAHIROSHI}|HideyasuIwamoto{IWAMOTOHIDEYASU}|TakaakiInoue{INOUETAKAAKI}|OkadaShinsuke{SHINSUKEOKADA}|ToshiyukiNakamura{NAKAMURATOSHIYUKI}|MakotoMiyahara{MIYAHARAMAKOTO}|MasahikoIsogai{ISOGAIMASAHIKO}|AtsushiOkada{OKADAATSUSHI}|RyoMatsutani{MATSUTANIRYO}|MasatoshiKumagai{KUMAGAIMASATOSHI}|TakumiSasao{SASAOTAKUMI}|TaijiTsukamoto{TSUKAMOTOTAIJI}|TaketoshiSaka{SAKATAKETOSHI}|YamazakiKiyohito{KIYOHITOYAMAZAKI}|Ryu-SukeIkeda{IKEDARYU-SUKE}|HidekiWada{WADAHIDEKI}|Wen-ChiChen{CHENWEN-CHI}|Chi-PingHuang{HUANGCHI-PING}|Chao-HsiangChang{CHANGCHAO-HSIANG}|Po-JenHsiao{HSIAOPO-JEN}|Yi-HueiChang{CHANGYI-HUEI}|ChenGuan-Heng{GUAN-HENGCHEN}|Li-HsienTsai{TSAILI-HSIEN}|Chin-ChungYeh{YEHCHIN-CHUNG}|Po-FanHsieh{HSIEHPO-FAN}|AkiyoKita{KITAAKIYO}|KazuyoshiNakao{NAKAOKAZUYOSHI}|EriJino{JINOERI}|TomoakiMatsuzaki{MATSUZAKITOMOAKI}|YuyaKoito{KOITOYUYA}|SugiMotohiko{MOTOHIKOSUGI}|TakashiMurota{MUROTATAKASHI}|TakaoMishima{MISHIMATAKAO}____PD Selected 03Stones____Impact of sodium-glucose cotransporter-2 inhibitors on urolithiasis and urinary tract infection - a cross sectional analysis of a nationwide Japanese databaseSGLT2阻害薬と尿路結石症ならびに尿路感染症との関係 - 日本の大規模リアルワールドデータより|Novel GWAS and PRS analyses in Taiwanese Calcium-Containing Stone Patients of Genetic Variations from a Single Medical Center|Drug discovery research using FDA-approved compound library analysis using macrophage crystal phagocytosisマクロファージ結晶貪食を用いたFDA承認化合物ライブラリー解析による創薬研究|Evolution of the renal stone composition over the decades in Taiwan|Nationwide survey on treatment paradigm shift and perioperative complications of percutaneous nephrolithotomy for upper urinary tract calculi in Japan上部尿路結石に対する経皮的尿路結石砕石術の変遷と周術期合併症に関する全国調査|演題取り下げ|Relationship between the development of febrile urinary tract infection after TUL and preoperative obstructive pyelonephritis and drainageTUL後の有熱性尿路感染症と術前の結石性腎盂腎炎・ドレナージとの関連について|Incidence of subcapsular hematoma is lower in patient who received intravenous anesthesia versus analgesics injection for ESWL|Evaluation of ureteral injuries caused by ureteral access sheath insertion during ureteroscopic lithotripsy外径13Frの尿管アクセスシース留置による尿管損傷発生についての検討

PDM-03

PD Selected 03
Stones

ErikaIkezoe{IKEZOEERIKA}|Ya-CheYLee{LEEYA-CHEY}|KentaroMizuno{MIZUNOKENTARO}|ArjunN{NARJUN}|TadashiJinno{JINNOTADASHI}|－|MizukiIzawa{IZAWAMIZUKI}|BoriboonWangkeo{WANGKEOBORIBOON}|TakahitoNegishi{NEGISHITAKAHITO}____AseemR.shukla{R.SHUKLAASEEM}|AkihiroKanematsu{KANEMATSUAKIHIRO}____ShigehiroSoh{SOHSHIGEHIRO}|AkinoriNakayama{NAKAYAMAAKINORI}|ToshiyukiIwahata{IWAHATATOSHIYUKI}|KazutakaSaito{SAITOKAZUTAKA}|HidenoriNishio{NISHIOHIDENORI}|DaisukeMatsumoto{MATSUMOTODAISUKE}|TakuyaSakata{SAKATATAKUYA}|ShoichiroIwatsuki{IWATSUKISHOICHIRO}|YukihiroUmemoto{UMEMOTOYUKIHIRO}|YasuiTakahiro{TAKAHIROYASUI}|YutaroHayashi{HAYASHIYUTARO}|RikuUematsu{UEMATSURIKU}|AkikoHaruna{HARUNAAKIKO}|YoshifumiSugita{SUGITAYOSHIFUMI}|HiroyukiSatoh{SATOHHIROYUKI}|TakashiShimizu{SHIMIZUTAKASHI}|YoshiakiIshizuka{ISHIZUKAYOSHIAKI}|AtsukoSato{SATOATSUKO}|HiroshiAsanuma{ASANUMAHIROSHI}|OyaMototsugu{MOTOTSUGUOYA}|WeerayutWiriyabanditkul{WIRIYABANDITKULWEERAYUT}|NobukiFurubayashi{FURUBAYASHINOBUKI}|YusukeHaraguchi{HARAGUCHIYUSUKE}|ToshikiKoga{KOGATOSHIKI}|MotonobuNakamura{NAKAMURAMOTONOBU}____PD Selected 04Pediatric Urology and Adrenal____Study of nocturnal enuresis beyond adolescence: Can treatment-resistant nocturnal enuresis be cured?思春期以降の夜尿の検討:難治性夜尿は治癒するのか|The prostatic utricle cyst associated with cryptorchidism and hypospadias|Clinical features of hypogonadism detected in boys with cryptorchidism during long-term follow up長期経過観察中の停留精巣に発生した性腺機能低下症の臨床的特徴|Gender Affirmation Surgery - A Urologists Experience|Clinical outcome of voiding function after skin flap vaginoplasty for persistent cloaca総排泄腔遺残に対してSkin flap Vaginoplasty を行った児の排尿機能に関する臨床的検討|Withdrawn|Utility of two-stage surgery for hypospadias with severe chordee高度陰茎腹面屈曲を伴う尿道下裂に対する二期的手術の有用性|Mean and measurement of penile length of newborn infants in Thailand|Retroperitoneal tumor treatment in Kyusyu Cancer Center九州がんセンターにおける後腹膜腫瘍診療

PDM-04

PD Selected 04
Pediatric Urology and Adrenal

北野滋久{きたのしげひさKITANOSHIGEHISA}|菊地栄次{きくちえいじKIKUCHIEIJI}____藤井靖久{ふじいやすひさFUJIIYASUHISA}________ランチョンセミナー 1基礎と臨床から紐解く泌尿器がん治療____泌尿器腫瘍におけるがん免疫療法～基礎から応用まで～|Against mUC, なぜEVなのか?

LS1

ランチョンセミナー 1
基礎と臨床から紐解く泌尿器がん治療

【共催：アステラス製薬株式会社】

北村寛{きたむらひろしKITAMURAHIROSHI}|峯村信嘉{みねむらのぶよしMINEMURANOBUYOSHI}____篠原信雄{しのはらのぶおSHINOHARANOBUO}________ランチョンセミナー 2尿路上皮癌におけるがん免疫療法____尿路上皮癌におけるがん免疫療法|irAEマネジメント

LS2

ランチョンセミナー 2
尿路上皮癌におけるがん免疫療法

【共催：メルクバイオファーマ株式会社 オンコロジーメディカルアフェアーズ部】

横溝晃{よこみぞあきらYOKOMIZOAKIRA}|津村秀康{つむらひでやすTSUMURAHIDEYASU}|木島敏樹{きじまとしきKIJIMATOSHIKI}____木下秀文{きのしたひでふみKINOSHITAHIDEFUMI}|深貝隆志{ふかがいたかしFUKAGAITAKASHI}________ランチョンセミナー 3最新エビデンスから導くｍCSPC治療戦略～アパルタミドの臨床実践～____－

LS3

ランチョンセミナー 3
最新エビデンスから導くｍCSPC治療戦略～アパルタミドの臨床実践～

【共催：ヤンセンファーマ株式会社 / 日本新薬株式会社】

NeilFleshner{FLESHNERNEIL}____MototsuguOya{OYAMOTOTSUGU}________Luncheon Seminar 4Targeting BRCA anomalies in Prostate Cancer: Impact on clinical practice and precision medicine____－

LS4

Luncheon Seminar 4
Targeting BRCA anomalies in Prostate Cancer: Impact on clinical practice and precision medicine

【共催：アストラゼネカ株式会社】

塩田真己{しおたまさきSHIOTAMASAKI}|上村博司{うえむらひろじUEMURAHIROJI}____久米春喜{くめはるきKUMEHARUKI}________ランチョンセミナー 5前立腺癌　診断と治療　up to date____バイオロジーから見た mCRPC治療|mCSPCのupfront治療について

LS5

ランチョンセミナー 5
前立腺癌　診断と治療　up to date

【共催：武田薬品工業株式会社】

野宮正範{のみやまさのりNOMIYAMASANORI}|本田正史{ほんだまさしHONDAMASASHI}____武田正之{たけだまさゆきTAKEDAMASAYUKI}________ランチョンセミナー 6高齢OAB患者の一次治療と二次治療について考える～フレイルを念頭に置きながら～／難治性OABの診断と治療　～高齢者にはどう対応すべきか～____高齢OAB患者の一次治療と二次治療について考える～フレイルを念頭に置きながら～|難治性OABの診断と治療　～高齢者にはどう対応すべきか～

LS6

ランチョンセミナー 6
高齢OAB患者の一次治療と二次治療について考える～フレイルを念頭に置きながら～／難治性OABの診断と治療　～高齢者にはどう対応すべきか～

【共催：ファイザー株式会社】

宮居弘輔{みやいこうすけMIYAIKOSUKE}|三宅牧人{みやけまきとMIYAKEMAKITO}____東治人{あずまはるひとAZUMAHARUHITO}________ランチョンセミナー 7“筋層非浸潤性膀胱癌診療の最前線”　～PathologistとUrologistの立場から～____筋層非浸潤性膀胱癌の病理 ～最近のトピックス～|筋層非浸潤性膀胱癌治療の原点、現状、限界突破～その次へ

LS7

ランチョンセミナー 7
“筋層非浸潤性膀胱癌診療の最前線”　～PathologistとUrologistの立場から～

【共催：MSD株式会社オンコロジーメディカルアフェアーズ部門】

河原崇司{かわはらたかしKAWAHARATAKASHI}____舛森直哉{ますもりなおやMASUMORINAOYA}________ランチョンセミナー 8Upfront ARSI時代におけるゾーフィゴの位置づけ____－

LS8

ランチョンセミナー 8
Upfront ARSI時代におけるゾーフィゴの位置づけ

【共催：バイエル薬品株式会社】

古川順也{ふるかわじゅんやFURUKAWAJUNYA}|山田雄太{やまだゆうたYAMADAYUTA}____武中篤{たけなかあつしTAKENAKAATSUSHI}|雑賀隆史{さいかたかしSAIKATAKASHI}________ランチョンセミナー 9hinotori™手術におけるクリニカルバリューに対する考察____－

LS9

ランチョンセミナー 9
hinotori™手術におけるクリニカルバリューに対する考察

【共催：株式会社メディカロイド / シスメックス株式会社】

清家健作{せいけけんさくSEIKEKENSAKU}|藤田雅一郎{ふじたまさいちろうFUJITAMASAICHIRO}____宮澤克人{みやざわかつひとMIYAZAWAKATSUHITO}________ランチョンセミナー 10MOSES™ Technology for the Stone Management____MOSES™ technologyの期待と導入後の戦略|MOSES™ technologyとHigh Frequencyどう使いこなすか？

LS10

ランチョンセミナー 10
MOSES™ Technology for the Stone Management

【共催：ボストン・サイエンティフィックジャパン株式会社】

阿南剛{あなんごうANANGO}|工藤大輔{くどうだいすけKUDODAISUKE}____藤本直浩{ふじもとなおひろFUJIMOTONAOHIRO}________ランチョンセミナー 11ツリウムファイバーレーザ（TFL)による新たな結石治療の幕開け____ツリウムファイバーレーザは結石治療のgame changerになるのか？|What does TFL change in stone management? ～The super “conductor” for efficiency.

LS11

ランチョンセミナー 11
ツリウムファイバーレーザ（TFL)による新たな結石治療の幕開け

【共催：エダップテクノメド株式会社】

野田祐介{のだゆうすけNODAYUSUKE}|伊藤悠城{いとうひろきITOHIROKI}____高橋悟{たかはしさとるTAKAHASHISATORU}________ランチョンセミナー 12バイポーラ電気メスでここまでできるBPH治療 - BipolEP（核出術）とTUVP（蒸散術） -____BipolEP 核出時間20分を目指せる！経済性・根治性に優れたバイポーラ核出術～新モルセレーションシステムとともに～|TUVP：MISTおよび核出術席巻のこの時代における古き良き選択肢

LS12

ランチョンセミナー 12
バイポーラ電気メスでここまでできるBPH治療 - BipolEP（核出術）とTUVP（蒸散術） -

【共催：カールストルツ・エンドスコピー・ジャパン株式会社 / エム・シー・メディカル株式会社】

松原伸晃{まつばらのぶあきMATSUBARANOBUAKI}____堀江重郎{ほりえしげおHORIESHIGEO}________ランチョンセミナー 13がんゲノム医療におけるリキッドバイオプシーの有用性____前立腺がんではコンパニオン診断のみで満足してはいけません！

LS13

ランチョンセミナー 13
がんゲノム医療におけるリキッドバイオプシーの有用性

【共催：ガーダントヘルスジャパン株式会社】

三宅秀明{みやけひであきMIYAKEHIDEAKI}|加藤琢磨{かとうたくまKATOTAKUMA}|永田政義{ながたまさよしNAGATAMASAYOSHI}|波多野浩士{はたのこうじHATANOKOJI}____野々村祝夫{ののむらのりおNONOMURANORIO}|佐々直人{ささなおとSASANAOTO}________スポンサードセミナー 1変わりゆく前立腺癌治療のARSiの役割～日本人におけるmCSPCの治療選択と求められる患者マネージメント～____－

SS1

スポンサードセミナー 1
変わりゆく前立腺癌治療のARSiの役割～日本人におけるmCSPCの治療選択と求められる患者マネージメント～

【共催：ヤンセンファーマ株式会社 / 日本新薬株式会社】

京田有樹{きょうだゆうきKYODAYUKI}|加藤大貴{かとうだいきKATODAIKI}____羽賀宣博{はがのぶひろHAGANOBUHIRO}________ハンズオンセミナー 1UroLift®を極める。 患者選択から、難症例でのご使用方法まで____－

HS1

ハンズオンセミナー 1
UroLift®を極める。 患者選択から、難症例でのご使用方法まで

【共催：テレフレックスメディカルジャパン株式会社】

宇野裕巳{うのひろみUNOHIROMI}|浮村理{うきむらおさむUKIMURAOSAMU}|秦聡孝{しんとしたかSHINTOSHITAKA}|宍戸俊英{ししどとしひでSHISHIDOTOSHIHIDE}____浮村理{うきむらおさむUKIMURAOSAMU}________ハンズオンセミナー 23D-Realtime OBT Fusion　Biopsyハンズオンセミナー____－

HS2

ハンズオンセミナー 2
3D-Realtime OBT Fusion　Biopsyハンズオンセミナー

【共催：株式会社アムコ】

玉田聡{たまださとしTAMADASATOSHI}____木村剛{きむらごうKIMURAGO}________イブニングセミナー 1シンプルに考える腎癌薬物療法____－

ES1

イブニングセミナー 1
シンプルに考える腎癌薬物療法

【共催：メルクバイオファーマ株式会社】

西村和郎{にしむらかずおNISHIMURAKAZUO}____植村天受{うえむらひろつぐUEMURAHIROTSUGU}________イブニングセミナー 2mCRPCにおけるPARP阻害薬の適正使用____－

ES2

イブニングセミナー 2
mCRPCにおけるPARP阻害薬の適正使用

【共催：ファイザー株式会社 メディカル・アフェアーズ部】

都築豊徳{つづきとよのりTSUZUKITOYONORI}____小原航{おばらわたるOBARAWATARU}________イブニングセミナー 3尿路上皮がんにおける病理診断の必要性____遺伝子時代の尿路上皮がん治療

ES3

イブニングセミナー 3
尿路上皮がんにおける病理診断の必要性

【共催：ヤンセンファーマ株式会社 メディカルアフェアーズ本部】

河嶋厚成{かわしまあつなりKAWASHIMAATSUNARI}|猪口淳一{いのくちじゅんいちINOKUCHIJUNICHI}____榎田英樹{えのきだひできENOKIDAHIDEKI}________イブニングセミナー 4進行性尿路上皮癌の薬物療法____ターニングポイントを迎える進行性・転移性尿路上皮癌治療に対する化学療法|進行性尿路上皮癌　薬物療法 up to date

ES4

イブニングセミナー 4
進行性尿路上皮癌の薬物療法

【共催：MSD株式会社】

水野隆一{みずのりゅういちMIZUNORYUICHI}|田原信{たはらまことTAHARAMAKOTO}____高橋俊二{たかはししゅんじTAKAHASHISYUNJI}________イブニングセミナー 5VEGFR-TKI投与中の蛋白尿を考える____進行性腎細胞癌薬物療法中に出現する蛋白尿と腎機能障害|LenvatinibのAEマネジメント -臨床経験からの考察を踏まえて-

ES5

イブニングセミナー 5
VEGFR-TKI投与中の蛋白尿を考える

【共催：エーザイ株式会社メディカル本部 / MSD株式会社メディカルアフェアーズ部門】

ToshihideMiyauchi{MIYAUCHITOSHIHIDE}|NeilBarber{BARBERNEIL}____RaizoYamaguchi{YAMAGUCHIRAIZO}________Evening Seminar 6Aquablation: Robotic surgery for BPH – Aquablation can be a game changer for BPH treatment based on 100 case experience____－

ES6

Evening Seminar 6
Aquablation: Robotic surgery for BPH – Aquablation can be a game changer for BPH treatment based on 100 case experience

【共催：プロセプト・バイオロボテックス株式会社】

松川宜久{まつかわよしひさMATSUKAWAYOSHIHISA}____柿崎秀宏{かきざきひでひろKAKIZAKIHIDEHIRO}________イブニングセミナー 7前立腺肥大症に潜むPitfall 2024____超高齢化社会におけるMale LUTSに対する治療戦略～pitfallとその対策～

ES7

イブニングセミナー 7
前立腺肥大症に潜むPitfall 2024

【共催：日本新薬株式会社】

吉田宗一郎{よしだそういちろうYOSHIDASOICHIRO}|神宮啓一{じんぐうけいいちJINGUUKEIICHI}____賀本敏行{かもととしゆきKAMOTOTOSHIYUKI}________イブニングセミナー 8前立腺がんの診断と治療____PETが変える前立腺癌診療|前立腺がんに対するMR誘導超寡分割照射の現状

ES8

イブニングセミナー 8
前立腺がんの診断と治療

【共催：ノバルティス ファーマ株式会社】

金尾健人{かなおけんとKANAOKENTO}|中川徹{なかがわとおるNAKAGAWATORU}____古家琢也{こいえたくやKOIETAKUYA}________イブニングセミナー 9今こそ化学療法導入のターニングポイント ～前立腺癌治療を改革する～____－

ES9

イブニングセミナー 9
今こそ化学療法導入のターニングポイント ～前立腺癌治療を改革する～

【共催：サノフィ株式会社】

東武昇平{とうぶしょうへいTOBUSYOHEI}____辻村晃{つじむらあきらTSUJIMURAAKIRA}________イブニングセミナー 10夜間頻尿診療におけるデスモプレシン口腔内崩壊錠はゲームチェンジャーとなったのか？____－

ES10

イブニングセミナー 10
夜間頻尿診療におけるデスモプレシン口腔内崩壊錠はゲームチェンジャーとなったのか？

【共催：フェリング・ファーマ株式会社 / キッセイ薬品工業株式会社】

小路直{しょうじすなおSYOJISUNAO}|吉田崇{よしだたかしYOSHIDATAKASHI}|梶川圭史{かじかわけいしKAJIKAWAKEISHI}____和田耕一郎{わだこういちろうWADAKOICHIRO}________イブニングセミナー 11ハイブリッド・ツリウムヤグレーザーによる泌尿器内視鏡治療のブレークスルー____BPH治療の経験と最新エビデンス|上部尿路腫瘍内視鏡治療における新たな治療モダリティ|結石治療は新時代へ～ハイブリッド・ツリウムヤグレーザーの使用経験～

ES11

イブニングセミナー 11
ハイブリッド・ツリウムヤグレーザーによる泌尿器内視鏡治療のブレークスルー

【共催：タカイ医科工業株式会社】

－____－________開会式____－

NO01

開会式

石山博條{いしやまひろみちISHIYAMAHIROMICHI}____－________卒後教育プログラム[01] 【泌尿器科腫瘍】泌尿器がんに対する定位放射線治療____01【泌尿器科腫瘍】泌尿器がんに対する定位放射線治療

RPG01

卒後教育プログラム
[01] 【泌尿器科腫瘍】泌尿器がんに対する定位放射線治療

佐塚智和{さづかともかずSAZUKATOMOKAZU}____－________卒後教育プログラム[02] 【泌尿器科腫瘍】泌尿器がんにおける周術期薬物療法____02【泌尿器科腫瘍】泌尿器がんにおける周術期薬物療法

RPG02

卒後教育プログラム
[02] 【泌尿器科腫瘍】泌尿器がんにおける周術期薬物療法

柑本康夫{こうじもとやすおKOHJIMOTOYASUO}____－________卒後教育プログラム[03] 【エンドウロロジー・腹腔鏡】腹腔鏡下ならびにロボット支援の腎摘除を安全に施行するために____03【エンドウロロジー・腹腔鏡】腹腔鏡下ならびにロボット支援の腎摘除を安全に施行するために

RPG03

卒後教育プログラム
[03] 【エンドウロロジー・腹腔鏡】腹腔鏡下ならびにロボット支援の腎摘除を安全に施行するために

相馬孝博{そうまたかひろSOUMATAKAHIRO}____－________卒後教育プログラム[04] 【共通講習（必修A）：医療安全】医療安全の最新動向____04【共通講習（必修A）：医療安全】医療安全の最新動向

RPG04

卒後教育プログラム
[04] 【共通講習（必修A）：医療安全】医療安全の最新動向

大日方大亮{おびなただいすけOBINATADAISUKE}____－________卒後教育プログラム[05] 【老年泌尿器科・前立腺肥大症】高齢泌尿器がん患者の治療：適応と注意点____05【老年泌尿器科・前立腺肥大症】高齢泌尿器がん患者の治療：適応と注意点

RPG05

卒後教育プログラム
[05] 【老年泌尿器科・前立腺肥大症】高齢泌尿器がん患者の治療：適応と注意点

安田満{やすだみつるYASUDAMITSURU}____－________卒後教育プログラム[06] 【尿路性器感染症】いまさら聞けない抗菌薬の分類と適正使用____06【尿路性器感染症】いまさら聞けない抗菌薬の分類と適正使用

RPG06

卒後教育プログラム
[06] 【尿路性器感染症】いまさら聞けない抗菌薬の分類と適正使用

望月保志{もちづきやすしMOCHIZUKIYASUSHI}____－________卒後教育プログラム[07] 【腎不全・腎移植】献腎移植における臓器採取手技と周術期管理____07【腎不全・腎移植】献腎移植における臓器採取手技と周術期管理

RPG07

卒後教育プログラム
[07] 【腎不全・腎移植】献腎移植における臓器採取手技と周術期管理

－____－________PD事前確認____－

PREPD10

PD
事前確認

－____－________PD事前確認____－

PREPD20

PD
事前確認

－____－________PD事前確認____－

PREPD30

PD
事前確認

－____－________PD事前確認____－

PREPD40

PD
事前確認

－____－________PD事前確認____－

PREPD05

PD
事前確認

－____－________PD事前確認____－

PREPD06

PD
事前確認

－____－________PD事前確認____－

PREPD07

PD
事前確認

－____－________PD事前確認____－

PREPD08

PD
事前確認

－____－________PD事前確認____－

PREPD09

PD
事前確認

－____－________PD事前確認____－

PREPD11

PD
事前確認

－____－________PD事前確認____－

PREPD12

PD
事前確認

－____－________PDOverview____－

PREPD13

PD
Overview

－____－________PDOverview____－

PREPD14

PD
Overview

－____－________PDOverview____－

PREPD15

PD
Overview

－____－________PDOverview____－

PREPD16

PD
Overview

－____－________PD事前確認____－

PREPD47

PD
事前確認

－____－________International Party＠インターコンチネンタルホテル　3F　パシフィック____－

INTERNATIONALPARTY

International Party
＠インターコンチネンタルホテル　3F　パシフィック